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Leukaemia is a blood/bone marrow cancer caused by malignant immature hematopoietic 
precursors, and quickly becomes a systematic malignancy. The most severe type of leukaemia 
that has the highest number of lethal outcomes is Acute Myeloid Leukaemia (AML) where 
malignant cells escape host immune surveillance by inactivating cytotoxic lymphoid cells. 
We discovered a fundamental biochemical mechanism in AML cells, which includes ligand-
dependent (probably FLRT3) activation of ectopically expressed latrophilin 1 and possible 
other G-protein coupled receptors, leading to upregulated translation and secretion of the 
immune receptor Tim-3 and its ligand galectin-9. This process involved protein kinase C and 
the mammalian target of rapamycin (mTOR). Tim-3 was observed to participate in galectin-9 
secretion, and was also released in a free soluble form. Galectin-9 impaired the anti-cancer 
activities of cytotoxic lymphoid cells including natural killer (NK) cells and soluble Tim-3 
prevented the secretion of interleukin-2 (IL-2), which was required for the activation of 
cytotoxic lymphoid cells. 
These results were validated in ex vivo experiments, using primary samples from AML patients. 
This fundamental pathway provides reliable targets for both highly specific diagnosis and 
immune therapy of AML.  
Furthermore, we demonstrated that the Tim-3/galectin-9 autocrine loop has intracellular 
functions and promotes cell growth and proliferation by directly upregulating translational 
pathway controlled by mTOR. 
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Cancer is a severe disease associated with the transformation of healthy cells at any stage of 
differentiation or maturation. These malignant cells, unlike healthy ones, are non-differentiated 
and are unable to mature into specialised cells with normal biological functions and keep 
proliferating. Also, malignant cells are smaller than healthy ones, they have less cytoplasmic 
space and the cell to cell connection between malignant is weaker. This is due to the lack of 
specialisation of the cells that do not allow the proper development of desmosomes, structure 
responsible by the cell to cell adhesion. These phenomena can result in the breach off of cells 
and the entrance of these in circulation, leading to the formation of metastasis (Figure 1).   
 
Figure 1 Steps of metastasis. The cells migrate from primary tumour and through 
intravasation get into the circulation. They migrate together with the blood until extravasated 





1.1 Epidemiology of cancer  
Cancer is a serious medical burden worldwide, affecting both industrialised and developing 
countries. In 2015, cancer was the second leading cause of death worldwide, being only 
overcome by cardiovascular disease (Wang et al., 2016). There were 17.5 million cancer cases 
worldwide and 8.7 million deaths cancer-related. In 2005, the number of cancer cases was 
much smaller, there were registers of 13 million. This means that between 2005 and 2015 there 
was an increase of 33% in the number of cancer cases. In 2015, 8.7 million people died from 
cancer, which represents 16% of all deaths worldwide. This was an increase of 3% in the 
number of deaths due to cancer, since 2005, where cancer was responsible for 13% of all deaths 
(Fitzmaurice et al., 2016; Bray, 2016). The increase in the number of register cancer cases and 
deaths, not only raises concern in health levels but also in economical levels on a global scale. 
Since 1995, the cost of incident cancer cases suffered a 10-fold increase. And, in 2009, these 
values reached the value of $286 billion (Bray, 2016; Hill et al., 2017). 
In 2015, the type of cancer with the higher number of registered cases was the breast cancer, 
with 2.4 million cases. The type of cancer with the highest number of deaths was the tracheal, 
bronchus and lung cancer with 1.7 million of registered deaths (Fitzmaurice et al., 2016). In 








Table 1 10 Common types of cancer according to the number of cases and 
lethal outcomes. (Fitzmaurice et al., 2016) 
 Registered cases Registered deaths 
Breast cancer 2.4 million 533000 
Tracheal, bronchus and lung cancer 2 million 1.7 million 
Colon and rectum cancer 1.7 million 832000 
Prostate cancer 1.6 million 360000 
Stomach cancer 1.3 million 819000 
Liver Cancer 854000 768000 
Non-Hodgkin lymphoma 666000 231000 
Leukaemia 606000 353000 
Bladder cancer 541000 188000 
Cervical cancer 526000 239000 
 
Among the cancer types present in Table 1, leukaemia is the most poorly studied, and its 
mechanisms are not well understood. Unlike other types of cancer, it affects stem cells 
responsible for tissue (blood) development (haematopoiesis) and thus is considered a severe 
systemic disorder. It affects all the organ systems straight away since blood is required 
everywhere. Leukaemia also develops a strong and highly effective strategy, which allows 
malignant cells to escape immune attack. Therefore, understanding the mechanisms of this type 




Leukaemia is a blood/bone marrow cancer that has origin in self-renewing malignant immature 
precursors, which often becomes a systematic malignancy. 
1.2.1 Epidemiology 
Each year, 250,000 cases of leukaemia are reported worldwide. This is the 3rd most common 
type of cancer among children and young people, and the 8th in general. It represents 2.5% of 
the total number of cancer cases in the world (Fitzmaurice et al., 2016). This type of cancer is 
more common in men (57%) than in women (43%), but in terms of mortality is about the same 
in both genders (75%) (IARC, 2017; World Cancer Research Fund International, n.d.). In 2012, 
Denmark was considered the country with the highest incidence of leukaemia, with 29 cases 
per 100,000 individuals.   
Leukaemia causes are not clear, but several factors have been associated with the increased 
risk of developing it. Some of these factors are age, infection with some virus and exposure 
environmental hazards (like ionising radiation, pollution, benzene, etc.) (Pokharel, 2012; Estey 
and Döhner, 2006). Given the wide use/misuse of nuclear energy and the increase of the 
environmental pollution worldwide, this becomes one of the most serious problems of the 
modern society. That is why timely diagnostics and less aggressive cure against leukaemia are 
an important issues to address. 
The risk of developing leukaemia increases with the age, except in acute lymphoid leukaemia 
(ALL) that has a high number of patients in the group age 2-7 years and then after 40 years. 
Chronic myeloid leukaemia (CML) is more common in patients around 50 years old and 
represents 15 to 20% of leukaemia cases in adult patients, acute myeloid leukaemia (AML) is 
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more common after 70 years old and chronic lymphoid leukaemia (CLL) in the age range 
between 65 to 70 years old (Pokharel, 2012; Chiorazzi et al., 2005; Hehlmann et al., 2007; Pui 
et al., 2008; Estey and Döhner, 2006). 
This risk of developing leukaemia is also related to the ethnic origin of a person. Almost all 
types of leukaemia are most common in white people. The exception is the chronic lymphoid 
leukaemia were white and black people have the same chances of developing it (Pui et al., 
2008; Pokharel, 2012). 
The genetic background of the individual can be also an important risk factor for having 
leukaemia. For example, individuals with Down syndrome have a 20-fold increase chance of 
developing leukaemia. Other syndromes like ataxia-telangiectasia, bloom syndrome, Fanconi 
syndrome, Klinefelter syndrome and neurofibromatosis are known to increase the risk of 
leukaemia (Pokharel, 2012). Also, if there is a familiar history of some types of leukaemia 
(AML and CLL), there is a higher risk of having the disease (Chiorazzi et al., 2005; Estey and 
Döhner, 2006). 
Another factor that is known to increase the chances of developing leukaemia is exposure to 
radiation. Although exposure to high levels of radiation is a known risk factor, exposure to low 
levels of radiation is still not well investigated as a contribute factor for developing leukaemia 
(Pokharel, 2012).  
Exposure to human T-cell lymphotropic virus-1 is linked to T-cell leukaemias/lymphomas 
(ATLL). This is not a common type of leukaemia or infection since the virus is only found in 
some areas of the world, namely the Caribbean Basin, Japan, some parts of south America and 
some parts of Africa (Pokharel, 2012). 
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As any other disease, diagnosis is essential for treating leukaemia. At the moment, the main 
diagnosis methods of leukaemia are physical exam, blood tests, bone marrow aspiration and 
biopsy, and lumbar puncture. In the physical exam, a medical doctor performs palpitation to 
identify any lumps or other abnormalities that can be identified as symptoms of leukaemia. 
There are three blood tests that can be done to diagnose leukaemia, the complete blood count, 
where the amount and quality of all blood cells is measured; the peripheral blood smear, that 
determines presence of blast cells and reveals the type and quantity of white blood cells; and 
the cytogenic analysis, used to identify lymphocytes chromosomes and changes in them. In the 
bone marrow aspiration, a small amount of bone marrow is removed from a bone through a 
needle and this sample is used to check for chromosomes problems and infection signs and the 
bone marrow biopsy, which is normally done after the aspiration, and it consists in removing 
bone with bone marrow for further analysis. Finally, the lumbar puncture consists in the 
removal of a small amount of the spinal fluid from the spaces between the vertebrae in the 
spine and the count of white blood cells is performed in this sample (Pokharel, 2012; Pui et al., 
2008; WebMD, 2005; Pinkel et al., 1986; Baron, 2005). 
After a positive diagnosis, it is important to proceed with treatment. Different treatments for 
leukaemia are available at the moment, such as surgery, where there is removal of the enlarged 
spleen or installation of a venous access device to give medication and withdraw blood. 
Radiotherapy, the use of ionising radiation to kill malignant cells, and chemotherapy, where a 
wide range of drugs (such as antimetabolites, genotoxic drugs, enzyme inhibitors and spindle 
inhibitors) are used to kill malignant cells. There is also immunotherapy, which consist of 
vaccines containing proteins found in or produced by cancer cells. These proteins will stimulate 
the body’s defences against cancer by increasing its response and by stem cell transportation 
(hematopoietic stem cell, multipotent hematopoietic stem cells usually derived from bone 
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marrow, peripheral blood, or umbilical cord blood cells). Prior to stem cell transportation, the 
immune system of the recipient is destroyed with radiation or chemotherapy (Pokharel, 2012). 
1.2.2 Pathophysiology 
Haematopoiesis is the process that leads to the formation of mature blood cells. Mature blood 
cells, mostly, have a short lifetime, therefore stem cells are essential throughout life to restock 
blood cells (Orkin and Zon, 2008). 
Haematopoietic stem cells (HSC) are the stem cells that undergo transformation into mature 
blood cells and are progenitors of all blood cells, due to its capacity of self-renewal and 
differentiation. During the differentiation process, these cells become progressively restricted 
to several or to a single lineage (Orkin and Zon, 2008; Jagannathan-Bogdan and Zon, 2013).  
Haematopoiesis starts with the differentiation of CD14+ HSC into myeloid stem cells or 
lymphoid stem cells. The lymphoid stem cells mature in to B lymphocytes (cells responsible 
for fabricating antibodies), T lymphocytes (help B lymphocytes to fabricate antibodies) and 
natural killer cells (responsible for the attack on cancer cells and viruses). The myeloid stem 
cells become erythrocytes (also known as red blood cells, which carry oxygen and nutrients to 
the body tissues), platelets (responsible for the formation of blood clots) and myeloid 
leukocytes (responsible for fighting pathogens) like basophils, neutrophils, monocytes and 
eosinophils (Orkin and Zon, 2008; Janeway et al., 2001; National Cancer Institute, 2013).  




Figure 2 Normal blood cell development with indication of presence/absence of Kit receptor (stem cell factor receptor). The hematopoietic stem cell 
originates a myeloid stem cell or lymphoid stem cell (beginning of myeloid and lymphoid lineages). These cells will differentiate into the main blood cell 
types. Image adapted from (Wrock, 2011).  
 
 
Figure 3 Representation of haematopoiesis in myeloid leukaemia.   The immature monocyte suffers malignant transformation and origins Myeloid 
Leukeamia cell, it expresses the Kit receptor contrary to what happens in normal haematopoiesis, so it is able to multiply (Wrock, 2011).  
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In leukaemia, the normal process of haematopoiesis is disturbed and malignant transformation 
occurs (Figure 3). It is believed that leukaemia may be initiated by transforming events that 
occur in the hematopoietic stem cells, allowing the cells to keep their self-renewal abilities, 
such as retaining expression of the Kit receptor. Hematopoietic stem cells are a better 
hypothesis for being the precursor of leukaemia cells than more mature cells because they have 
all the machinery for self-renewal so it requires fewer mutations to keep it active than to 
activate it ectopically (Passegue et al., 2003).   
During or after cell division, haematopoietic stem cells must decide their fate, remain HSC, 
differentiate or die by apoptosis. These decisions must be a well-tuned process to maintain a 
steady state level of functional HSC in the bone marrow and a constant source of progenitors 
for the different hematopoietic lineages. Failing in doing these decisions lead to the formation 
of cancer cells. There is evidence showing that leukaemia cells arise from accumulated 
mutations in hematopoietic stem cells that allow them to keep the capacity of indefinite 
proliferation. Both cells have self-renewal ability, extensive proliferative potential and the 
ability to generate new hematopoietic tissues with a combination of heterogeneous cells, with 
different phenotypes and proliferation potentials (Passegue et al., 2003). 
The accumulation of mutations can be potentiated by external factors like ionising radiation 
and chemicals and/or internal factors like chromosomal abnormalities (for example, avoiding 
the telomere shortening trough action of the telomerase complex). Chromosomal 
rearrangements may alter the structure or regulation of cellular oncogenes (Passegue et al., 




This leads to an overproduction of abnormal white blood cells,. These cells, unlike the healthy 
ones, do not die when they become old or damaged. This leads to an increase in the number of 
abnormal cells, overtaking the number of healthy cells. The fact that the number of healthy 
cells decreases makes harder for the body tissues to obtain oxygen, to control bleeding and to 
fight infections (National Cancer Institute, 2013; Spivak, 2017). 
Most of the leukaemia symptoms result from the suppression of normal blood cell formation 
and the organ infiltration, the malignant cells spill into the circulation and infiltration of other 
organs. This infiltration results in enlargement of liver, spleen, and lymph nodes (Spivak, 2017; 
Wu, 2017). 
1.2.2.1 Types of leukaemia 
Leukaemia can be classified into four types, per the type of Leucocytes that are affected 
(myeloid or lymphoid) and according to the characteristics of the disease (acute or chronic). 
These types of leukaemia are acute myeloid leukaemia (AML), chronic myeloid leukaemia 
(CML), acute lymphoid leukaemia (ALL) and chronic lymphoid Leukaemia (CLL). In Table 
2, the main characteristics of these four types of leukaemia are described. 
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Table 2 Schematic information about the four main types of leukaemia. (Cancer Treatment Centers of America, 2017; Chiorazzi et al., 2005; 
Hehlmann et al., 2007; Pui et al., 2008; Dana-Farber cancer institute, 2014; Estey and Döhner, 2006; Pui et al., 2004; Gao et al., 2014) 
 AML CML ALL CLL 
Affected Cells  Myeloid Stem cells  Myeloid stem cells  Lymphoid stem cells  B Lymphocytes 
Epidemiology  > 60 years  > 50 years  2-7 years  65-70 years 
Main Symptoms 
 Pale skin 
 Tiredness 
 Breathlessness 
 Frequent infections 
 Unusual and frequent 
bleeding 
 Tiredness 
 Weight loss 
 Night sweats 
 Tenderness and swelling in the 
left side of the abdomen 
 Pale skin 
 Shortness of breath 
 High temperature 
 Bleeding easily 
 Frequent infections 
 Bone pain 
 Pale skin 
 Tiredness 
 Breathless 
 Frequent infections 
 Unusual and frequent 
bleeding 
 High temperature 
 Night sweats 
 Bone and joint pain 
 Swollen lymph nodes 
 Abdominal pain 
 Weight loss 




 Swollen lymph 
nodes 





 Exposure to very high levels 
of radiation 
 Benzene exposure 
 Underlying blood or genetic 
disorder 
 Genetic disorders 
 
 Previous chemotherapy 
 Smoking 
 Obesity 
 Genetic disorders 
 Weakened immune system 
 Genetic disorders 





 Bone marrow transplant 
 Chemotherapy 
 Chemo-immunotherapy 
 Stem cell transplants 
 Chemotherapy 
 Drugs like glucocorticoid, 
and anthracycline 
 Stem Cell transplant 
 Radiotherapy 
 Chemotherapy 
 Stem cell transplant 
 Immunotherapy 
Survival Rate 
 ≈26%  87%  80% in children 




Acute myeloid leukaemia (AML) is the most common type of leukaemia in adults and the one 
with the highest mortality rate. Although the survival rate improved in younger patients, the 
prognosis in elderly patients continues to be very poor. Approximately, 60% of the patients are 
over 60 years old, which means that elderly patients are the majority (Deschler and Lübbert, 
2006; Lu and Hassan, 2006).  
Elderly patients do not respond well to conventional chemotherapy, due to the intrinsic resistant 
nature of their AML cells and/or their poor tolerance to conventional chemotherapy regimens. 
Untreated AML is uniformly a fatal disease that can kill in 12 to 20 weeks. Despite these facts, 
in the last 30 years, very little progress was made in the treatment of these patients (Lu and 
Hassan, 2006; Deschler and Lübbert, 2006). This shows that finding new treatments, less 
aggressive and more efficient and new diagnosis methods for acute myeloid leukaemia is 
important. In order to do it, understanding the mechanisms of this disease is essential. 
1.3 Acute myeloid leukaemia 
Acute myeloid leukaemia is a heterogeneous, haematological malignant disease that originates 
from the bone marrow and affects hematopoietic progenitor cells (blasts). It is the most 
common myeloid disorder in adults, killing two-thirds of young adults and 90% of older adults 
who have the disease (Lu and Hassan, 2006; Estey and Döhner, 2006; Shafat et al., 2017).  
Even in patients who achieve remission with the available treatment strategies, like 
chemotherapy, there is a 60% chance of relapse. This occurs from minimal residual disease 
sequestered in protective niches in the bone marrow microenvironment (Gao et al., 2014; 
Shafat et al., 2017). 
Acute myeloid leukaemia arises from myeloid haematopoietic progenitors and is characterised 
by the rapid accumulation of abnormal haematopoietic progenitor in the bone marrow. These 
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cells lose the ability to differentiate normally and respond to normal regulators of proliferation. 
This can lead to fatal infection, bleeding, or organ infiltration, normally within one year, in the 
absence of treatment (Estey and Döhner, 2006; Deschler and Lübbert, 2006; Shafat et al., 
2017). Some progress has been made in the treatment of younger patients, but the prospects for 
elderly patients have remained dismal (Estey and Döhner, 2006). 
1.3.1 Epidemiology 
Acute myeloid leukaemia represents 25% of all leukaemias in adults in the Western world and 
therefore is the most common form of leukaemia. Worldwide, its incidence is highest in United 
States, Australia, and Western Europe (Deschler and Lübbert, 2006; Estey and Döhner, 2006). 
AML is primarily a disease of later adulthood, being 60% of the cases in patients over 60 years 
old, being the median age of the newly diagnosed patients 65 years. Acute leukaemias represent 
less than 3% of all cancer, but it constitutes the leading cause of death due to cancer in children 
and people under 39 years old (Deschler and Lübbert, 2006; Gao et al., 2014).  
The incidence of AML varies with gender, being slightly more common in males than in 
females, approximately 3 men for 2 women. The mortality rate is also higher for males (Estey 
and Döhner, 2006; Deschler and Lübbert, 2006). 
The development of AML has been associated with several risk factors. These include age, 
antecedent hematologic disease, genetic disorders (such as Down syndrome or Kinefelter 
syndrome) and exposure to radiation (nontherapeutic or therapeutic), chemicals (such as 
benzene and pesticides) and previous chemotherapy. 10 to 15% of AML patients develop it 
after treatment with cytotoxic chemotherapy for other types of cancer (Deschler and Lübbert, 




The haematopoietic stem cells reside in the bone marrow and remain there until maturation. 
The bone marrow is a soft viscous tissue that is located in the cavities of the bones. It is 
constituted by blood vessels and a heterogeneous population of cells, directly involved in the 
bone marrow's function of haematopoiesis, or act in support of haematopoietic cell function 
(Shafat et al., 2017). 
Leukaemia cells and leukaemia initiating cells (LICs) are a subpopulation of AML cells that 
have long-term repopulation potential, an ability for limitless self-renewal. These cells reside 
in the bone marrow microenvironment and contain one or more oncogenic mutations driving 
tumorigenesis (Shafat et al., 2017; Darwish et al., 2016). 
Acute myeloid leukaemia blasts develop from normal blasts affected by two types of genetic 
damage first (class I) lesion and second (class II) lesion. The first (class I) lesion results in the 
activation of cell surface receptors like tyrosine kinase receptors like FLT3 and Kit. Using 
downstream pathways, it leads to a constitutive activation conferring a survival or proliferative 
advantage, leading to clonal expansion of the affected haematopoietic progenitors. The second 
(class II) lesion can be, for example, the overexpression of HOX genes or formation of fusion 
genes. AML might develop only when both classes of lesion are present (Estey and Döhner, 
2006). 
The genetic reprogramming of AML blasts reduces the capacity in generating mature red blood 
cells, neutrophils, monocytes, and platelets. This is due to the promotion of AML cells survival 
and proliferation by the bone marrow microenvironment (Estey and Döhner, 2006; Shafat et 
al., 2017).  
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AML has diverse biological features have a major impact on the resistance to chemotherapy 
and relapse. AML blast cells have several unfavourable covariates such as high stem cell 
marker CD34 expression; minimally or undifferentiated features; high P-glycoprotein 
expression and bcl-2/bax ratio;; internal tandem duplications (ITDs); mutations of class III 
receptor-type tyrosine kinase for key haematopoietic cytokines (Flt-3 – Flt ligand, 25-35% of 
patients; Kit – SCF ligand, 10-20% of patients; fms – M-CSF ligand, 5-20% of patients) (Lu 
and Hassan, 2006; Gao et al., 2014). 
1.3.2.1 Diagnosis 
The diagnosis of acute myeloid leukaemia is primarily done by the observation of accumulation 
of AML blasts. AML is confirmed when the percentage of blasts in the bone marrow is higher 
than 20% (Estey and Döhner, 2006). 
1.3.2.2 Treatment 
The most common treatment for AML consists in two phases. The first one attempts to produce 
complete remission, defined as bone marrow with less than 5% of blasts, neutrophils over one 
thousand and platelets over one hundred thousand. The complete remission is the only response 
that leads to cure and to an extension in survival. The second phase aims to prolong the 
complete remission. If a patient stays in these stage for 3 years the chances of a relapse decline 
to less than 10% (Estey and Döhner, 2006). Some of the present treatments for AML have as 
their goal the elimination of the affected blasts. This is more efficient on the blasts that are in 
circulation than on the blasts that are in the bone marrow. This is most likely the ones in the 
bone marrow that are protected from the apoptosis induced by the treatment, by the marrow 
stroma (Estey and Döhner, 2006). 
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The most common cause of death in AML patients is bone-marrow failure. The principal sign 
of this failure is infection (Estey and Döhner, 2006). 
1.3.3 Biochemistry of AML 
On the molecular level, acute myeloid leukaemia affects haematopoiesis. Healthy 
haematopoietic stem cells suffer malignant transformation and became leukaemia cells. This 
process is described in section 1.2.2.   
The haematopoiesis requires several cytokines that promote survival, proliferation, and 
differentiation of haematopoietic stem cells. It is the balance of these cytokines within the 
microenvironment surrounding the hematopoietic stem cells that will determine the pathway 
of differentiation (Broudy, 1997; Hauke and Tarantolo, 2000). Cytokines and growth factors 
play a role in haematopoiesis not only by causing differentiation of stem cells toward a cell 
type but also by inducing proliferation of cells and regulating their differentiation (Hauke and 
Tarantolo, 2000). 
The direct contact of leukaemia and stromal cells strongly inhibits apoptosis of leukaemia cells 
and enhances their survival. This may explain how, after chemotherapy, the small number of 
malignant cells remaining are protected in vivo. These stromal cells secret some cytokines and  
growth factors1, including the following proteins (Giles, 2002; Shafat et al., 2017; Waugh and 
Wilson, 2008): 
 
                                                 
1 Growth factors are often confused with cytokines. They are both produce by cells, normally of the immune 
system, but while cytokines will act in the signally of inflammatory response, growth factor will stimulate the 
growth and proliferation of the cells. 
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Table 3 List of growth factors and cytokines secreted by stromal cells. 
Designation Description 
Tumour necrosis factor alpha 
(TNFα) 
It is a cytokine that acts during the inflammatory process 
as regulator of immune cells, for example, it can 
stimulate the apoptotic cell death.  
Interleukin 6 (IL-6) 
It is a pro-inflammatory cytokine that stimulates immune 
response during inflammation, which has been shown to 
protect AML cells against programmed cell death. 
Interleukin 8 (IL-8) 
It is a pro-inflammatory chemokine involved in 
chemotaxis, which regulates different stimuli including 
inflammatory signals like TNFα and IL-1β. 
Interleukin 1 beta (IL-1β) 
It is a mediator of inflammatory response that is involved 
in cell proliferation, differentiation, and apoptosis. 
Granulocyte colony-
stimulating factor (G-CSF) 
It is a growth factor responsible for the stimulation of the 





It is a growth factor that stimulates stem cells to produce 
granulocytes and monocytes. 
Stem cell factor (SCF) 
It is a haematopoietic growth factor that promotes 
haematopoietic cell proliferation and differentiation, and 





Some of these cytokines and growth factors,  such as SCF, GM-CSF, and TNFα, in serum-free 
medium, produced by leukaemia and stromal cells can achieve a high degree of apoptosis 
inhibition (Giles, 2002). Stromal cells also secrete IL-6, to protect AML cells against 
programmed cell death. IL-8 has also been implicated in bone marrow stromal cell changes 
(Shafat et al., 2017). There is evidence that the secretion of IL-1β by leukaemia cells can 
stimulate the release of G-CSF and GM-CSF from endothelial cells, which, in turn, may affect 
the proliferation of leukaemia blasts. The location of the endothelial cells in the sinusoid of the 
bone, close to other cell types in the bone marrow environment, suggests their role as 
gatekeepers. They may regulate the movement of cells between the bone marrow and the 
circulation (Shafat et al., 2017; Giles, 2002). 
The stem cell factor receptor, Kit was found to be over-expressed in 63% of AML cases, two-
thirds of which are also CD34+. CD34 may play an important role in cell survival and 
maturation because it is expressed mainly on progenitor cells and disappears with cell 
maturation. These are two known factors that lead to a low chance of complete remission and 
to a poor prognosis, thus to a low survival rate (Lu and Hassan, 2006; Darwish et al., 2016). 
It was found that CD34+ cells also express T cell immunoglobulin mucin-3 (Tim-3, section 
1.3.3.3), a cell-surface glycoprotein. Tim-3 overexpression is markedly correlated with poor 
prognosis of AML patients. Also, there is a correlation between the expression of Tim-3 and 





1.3.3.1 Kit receptor 
The Kit receptor, also called CD117, is a member of the type III receptor tyrosine kinase family. 
This family of receptors also contains c-fms receptor, platelet-derived growth factor (PDGF) 
receptors and flk-2/flt3 receptor. It is a transmembrane protein, and its activity is encoded by 
the oncogene Kit (Broudy, 1997; Liang et al., 2013). 
This tyrosine kinase family causes specific expression of certain genes. It regulates cell 
differentiation, proliferation, and resistance to apoptosis. Kit receptor also plays a key role in 
tumour occurrence, development, migration, through activation of downstream molecules 
following interaction with stem cell factor (SCF) (Broudy, 1997; Liang et al., 2013). 
The Kit receptor (Figure 4) is a 145 kDa glycoprotein, with 976 amino acids (aa). 519 aa on 
the extracellular domain, 23 aa on the transmembrane domain and 433 aa at the intracellular 
tail, that consists of a juxta-membrane domain and a tyrosine kinase domain inserted by 
approximately 80 aa residues (Broudy, 1997; Liang et al., 2013). 
The extracellular domain of Kit receptor has five Ig-like motifs (D1~D5), a single short 
membrane-spanning domain, and a cytoplasmic domain with tyrosine kinase activity. The 
motifs D1~D3 are a key component of binding to SCF, and D4~D5 are the essential region of 
dimerization. This domain is interrupted by a kinase-insert-sequence that divides the kinase 
domain into an ATP (adenosine triphosphate)-binding region and a phosphotransferase region 
(Broudy, 1997; Liang et al., 2013). 
When SCF binds the Kit receptor, it triggers the homodimerization and intermolecular tyrosine 
phosphorylation of the receptor, creating docking sites for a number SH2-containing signal 
transduction molecules (Broudy, 1997). The SCF dimer forms complexes with two molecules 
of the extracellular domain of Kit to activate downstream signal transduction. Then it regulates 
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a variety of cells biological behaviour, such as normal cells proliferation and differentiation 
and tumour occurrence, development, migration, and recurrence (Liang et al., 2013). 
The Kit receptor is broadly distributed within the hierarchy of hematopoietic cells. It is also 
found in germ cells, mast cells, melanoma cells and gastrointestinal tract cajal cells, skin 
appendages, breast epithelial cells and small neurones in the brain. In healthy people, 
approximately 1% to 4% of bone marrow stem cells and 60% to 70% of CD34+ haematopoietic 
cells express Kit receptor. About 85% of B cell progenitors also express Kit receptor, but it 
gradually disappears with the cell differentiation and maturation (Broudy, 1997; Liang et al., 
2013). 
Studies show that Kit receptor is express in 68% of AML and in 80% of CML patients in blast 
phase. Only 2% of acute lymphoid leukaemia patients express it, what suggest that the receptor 
has a more important role in myeloid leukaemias than in lymphoid leukaemias. It was also 
found that AML patients that are Kit positive, survived much shorter time than Kit negative 
AML patients. In patients with low complete remission rate, Kit receptor has, normally, high 
levels of expression (Liang et al., 2013). 
 
Figure 4 Ribbon diagram of the activated form of Kit 
showing the N-termini. Α-helices are illustrated in blue, 
β-strandsin amber and loops in purple. (Roskoski, 2005) 
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This data seems to show that Kit receptor has an important role in AML. It has influence in 
AML complete remission and recurrence, patients that express this receptor have low complete 
remission rate, tend to relapse despite complete remission and they also have a higher mortality 
rate (Liang et al., 2013). 
1.3.3.2 Stem Cell Factor  
Stem cell factor (SCF) or Kit ligand is a hematopoietic cytokine that triggers its biologic effects 
by binding to its receptor (Kit receptor). The constitutive production of SCF by endothelial 
cells and fibroblast is required for the maintenance of normal basal haematopoiesis (Broudy, 
1997). 
SCF is a haematopoietic cytokine, which plays an important role in maintaining the survival of 
haematopoietic cells. It promotes haematopoietic cell proliferation and differentiation and 
regulates growth and development of haematopoietic cells (Liang et al., 2013).  
SCF can be found in two different forms, the soluble form, and the transmembrane form, that 
are generated by alternative splicing that includes or excludes a proteolytic cleavage site. Both 
forms are biologically active. The endothelial cells and the fibroblasts display the 
transmembrane form on its surface and release the soluble form (Broudy, 1997). The soluble 
form of SCF circulates as a non-covalently bonded dimer, it is glycosylated and has 
considerable secondary structure, including region α-helices and β-sheets. It has a molecular 





Enriched populations of human hematopoietic stem cells and progenitor cells (CD34+ Kit 
receptor+) are reported to have SCF mRNA. Some inflammatory stimuli such as interleukin-1 
(IL-1) or tumour necrosis factor (TNF) may modestly enhance SCF protein production by 
marrow stromal cells (Broudy, 1997). SCF can act directly on an enriched population 
containing hematopoietic stem cells to accelerate their entry into cell cycle (Broudy, 1997). 
Recent studies demonstrated that the use of the anti-SCF together with low dosage of 
chemotherapy enhance the effects of the treatment. The anti-SCF enhancing activity was 
associated with a further significant reduction in the expression of the anti-apoptotic gene, bcl-
2 (Lu and Hassan, 2006). 
1.3.3.3 T cell immunoglobulin mucin-3  
T cell immunoglobulin mucin-3 (Tim-3) is a specific surface molecule expressed on leukaemia 
stem cells on most types of AML, thus being a candidate for AML leukaemia cells target 
therapies. It was first discovered in 2002 as a receptor expressed on interferon(IFN)-γ-
producing CD4+ T-helper type 1 (Th1) cells and on CD8+ T cytotoxic type I (Tc1) cells and is 
a type I transmembrane protein. Its discovery led to the discovery of Tim family of genes (Gao 









Figure 5 Structure of the Tim-3 extracellular 
domain created using Swiss pdb viewer. Amino 
acids residues involved in galectin-9-independent 
binding are highlighted in green. Residues, which 
are potential targets for glycosylation, are 
highlighted in red (Gonçalves Silva et al., 2017). 
Human Tim-3 has 302 amino acids residues and belongs to the immunoglobulin superfamily 
(IgSF).  It consists of four domains, the membrane-distal N-terminal immunoglobulin (IgV) 
variable domain, mucin domain, transmembrane domain, and a cytoplasmic tail. The 
membrane-distal N-terminal immunoglobulin (IgV) domain followed by a membrane-
proximal mucin domain, that contains sites for O-linked glycosylation, form an extracellular 
domain. Between the mucin and the transmembrane domain, there is site for N-linked sugars, 
which are followed by the transmembrane domain and a cytoplasmic tail (Figure 5) (Das et al., 
2017; Darwish et al., 2016). 
Tim-3 protein has molecular weight of 33 KDa. It can be subjected to both N- and O- 
glycosylation. In each case the polysaccharide molecule attached has molecular weight of 2 
kDa. Maximum number of glycoside molecules which can be attached to a single Tim-3 
molecule is 11. Minimum – is one. So Molecular weight of this protein can vary from 33 kDa 
up to 55 kDa. In AML cells the WB band normally appears between 35 and 42 kDa also 
depending on the type of MW marker used (Clayton et al., 2015; Gonçalves Silva et al., 2017).  
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Tim-3 plays a key role in inhibiting Th1 responses and the expression of some cytokines like 
TNF and INF-γand non-T cells populations, such as NK cells. This was demonstrated by the 
expression of Tim-3 on tumour-infiltration and suppressing innate antitumour immune 
responses. In this way, Tim-3 is considered a negative regulatory checkpoint molecule 
associated with both T-cell exhaustion and suppression innate immune response (Das et al., 
2017). The analysis of these data leads to believe that Tim-3 may have a function as a signal 
transductor in AML leukaemia cells since it was reported that anti-Tim-3 antibody is able to 
interfere with leukaemia cells’ proliferation (Darwish et al., 2016).  
It is hypothesised, that elevated Tim-3 expression may be a direct consequence of the molecular 
mutations presented in AML cells. Elevated expression levels of Tim-3 showed substantial 
correlation with patients' leukocyte count and a number of treatment cycles to complete 
remission. This seems to indicate Tim-3 as a potential prognostic factor for patients with AML 
(Li et al., 2016). A higher expression of Tim-3 protein was suggested to promote a poor 
response to chemotherapy, which may be closely associated with primary resistance. This 
observation supports the idea that Tim-3 could be considered a potential predictor of 
chemotherapeutic sensitivity and prognosis in AML patients (Li et al., 2016). 
It was reported that Tim-3 also triggers growth factor type responses in AML cells by activating 
a phosphatidylinositol-3 kinase (PI-3K). This includes kinase cascade leading to activation of 
mammalian target of rapamycin (mTOR), a central regulator of cell growth and metabolism, 
via its phosphorylation at S2448. mTOR is known to upregulate glycolysis, proangiogenic 
responses and to induce the non-hypoxic activation of hypoxia-inducible factor 1 (HIF-1), a 
transcription complex essential for cellular adaptation to low oxygen availability (Gibbs et al., 
2015; Prokhorov et al., 2015; Fitzmaurice et al., 2016; Gibbs et al., 2011).  
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HIF-1 is a heterodimeric complex containing two subunits, a constitutively expressed subunit 
hypoxia-inducible factor 1β (HIF-1β) and a hypoxically inducible subunit hypoxia-inducible 
factor 1α (HIF-1α). The non-hypoxic activation of HIF-1 leads to the accumulation of HIF-1α 
that will induce the secretion vascular endothelial growth factor (VEGF). VEGF is the most 
potent endothelial-specific mitogen that directly participates in angiogenesis, recruiting 
endothelial cells into hypoxia and avascular areas and stimulate their proliferation (Gibbs et 
al., 2011; Ke and Costa, 2006). This is an essential process for the survival and proliferation 
of leukaemia cells.   
A natural ligand of this receptor was recently identified, galectin-9. 
1.3.3.4 Galectin-9 
Galectins are a family of lectins that exhibit high affinity for β-galactosides, share conserved 
amino acids sequences in their carbohydrate recognition domains and modulate various 
biological events (Kobayashi et al., 2010).  
Galectin-9 was identified as a Tim-3 ligand. It is expressed as a soluble molecule that is widely 
expressed and upregulated by IFN-γ (Gao et al., 2014). Galectin-9 induces phospholipase C 
(PLC-1) in a Bruton's tyrosine kinase-dependent way, which is required for Ca2+ mobilisation 
and the phosphatidylinositol 3-kinase (PI-3K) pathway. This process leads to mTOR activation 
and to an increase of intracellular mobilisation and upregulation of the transcriptional activity 
of HIF1 complex and its downstream processes, such as glycolysis, VEGF expression and 






Figure 6 Galectin-9 structure created by swiss pdb viewer. 
Sugar located close to a sugar binding site is shown in 
green (Gonçalves Silva et al., 2017). 
Galectin-9 is a soluble protein containing two tandem-repeat type of galectin with two 
carbohydrate recognition domains that specifically recognises the structure of N-linked sugar 
chains in the Tim-3 membrane distal immunoglobulin variable (IgV) domain (Figure 6). There 
normally three splice variants of galectin-9. In all cases sugar binding domains stay unchanged 
but the length of the linker polypeptide fusing them together varies. The one which is secreted 
by AML cells has molecular weight of 31.5 kDa and displays biochemical activity. 
Galectin-9 has been shown to be involved in a variety of cellular functions, such as cell 
adhesion, proliferation and apoptosis  (Darwish et al., 2016; Das et al., 2017; Kobayashi et al., 
2010; Chabot et al., 2002a).  
Galectin-9 is mainly released by the CD34+ fraction of AML cells that contain leukaemia cells 
and primitive blasts (Darwish et al., 2016; Kikushige et al., 2015). It is expressed in various 
tissues involved in the immune system like spleen, thymus and lymphocytes, and in tissues of 




1.3.3.5 Tim-3-galectin-9 interaction  
There is an evidence of correlation between Tim-3 and galectin-9 levels, which is increased in 
AML patients in comparison to the normal individuals (Darwish et al., 2016). The two 
tandemly linked carbohydrate recognition domains of galectin-9, specifically recognise the 
structure of N-linked sugar chains in the Tim-3 IgV domain. It does not recognise the same 
place on other Tim proteins. Also, the interaction between the Tim-3 IgV domain and galectin-
9 has the highest affinity when compared with other galectins. This suggests that the link 
between Galectin-9 and Tim-3 is specific (Das et al., 2017).  
The binding between Tim-3 and galectin-9 induces simultaneous activation of the nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-κB) and β-catenin signalling in 
leukaemic cells. This will trigger marked gene expression changes inducing upregulation of 
Mcl-1, an important survival factor for leukaemia cells, enhancing the pro-survival axis. The 
lack of galectin-9 accelerates apoptosis of leukaemic cells in AML cell lines (Darwish et al., 
2016; Kikushige et al., 2015). This binding also triggers death in effector Th1 cells, dampening 
tissue inflammation and increases the Tim-3-mediated IFN-γ production in an NK cell line 
(NK92) (Das et al., 2017; Kikushige et al., 2015). The binding between Tim-3 and galectin-9, 
also, phosphorylates tyrosine residues of the cytoplasmic tail of Tim-3 and activates Src family 
of kinases through its Src homology 2 (SH2) binding motif in T-cells and monocytes 
(Kikushige et al., 2015). 
In AML cells, galectin-9 was found to be bound to Tim-3 on the cell surface, suggesting that 
AML cells may secrete galectin-9. The levels of intracellular galectin-9 in AML cells are higher 
than in normal haematopoietic stem cells, but since galectin-9 lacks a sequence essential for 
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secretion through ER-Golgi pathway, this does not mean that the cells will secrete it (Kikushige 
et al., 2015).  
It was found that, prior to secretion, galectin-9 seems to be translocated intermediate through 
the lipid bilayer of cell membraneand that Tim-3+ leukaemic stem cells and blasts cells actively 
secrete galectin-9 while Tim-3- do not. This suggeststhat Tim-3 and galectin-9 may form an 
autocrine loop critical for leukaemia stem cells self-renewal and development of human AML 
(Kikushige et al., 2015). 
Tim-3/galectin-9 autocrine loop activates both NF-κB, and the β-catenin signalling in mist 
leukaemias. NF-κB regulates expression of different but overlapping genes that are involved 
in innate and adaptive immunity, inflammation, anti-apoptosis, proliferation, and cancer 
progression. β-catenin is a key molecule for self-renewing machinery in haematopoietic stem 
cells and leukaemia cells. The signalling of these two molecules is critical in clonal selection, 
where the number of preleukaemic haematopoietic stem cells becomes much higher than the 
number of normal HSC. This autocrine loop is, probably, critical for the survival of leukaemia 
cells since deprivation of Galectin-9 accelerates apoptotic cell death of leukaemia cells 
(Kikushige et al., 2015; Kawai and Akira, 2007). 
Data suggest that the autocrine loop is essential for the secretion of galectin-9 from AML cells, 
and secretion of Galectin-9 is essential for AML cells survival and proliferation. However, the 
mechanism that these cells use, it is unclear. 
It is important to understand the molecular events leading to the secretion of galectin-9. On one 
hand, galectin-9 as all other galectins lacks a signal sequence which is required for transport 
into cellular endoplasmic reticulum (ER) and thus requires a trafficking protein for its secretion 
(Hughes, 1999; Delacour et al., 2009). On the other hand, exocytosis must be provoked to 
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induce not just generation of galectin-9, but its externalisation and secretion into the 
environment. One of the possible candidates is the neuronal G-protein-coupled receptor 
Latrophilin-1 (LPHN1).Its expression could possibly fail to be repressed during 
haematopoiesis in the case of malignant transformation. Importantly, one of the endogenous 
ligands of LPHN1 called fibronectin leucine rich transmembrane protein 3 (FLRT3) is 
expressed in a number of tissues and may function in cell adhesion and cell signalling (Boucard 
et al., 2014). One could therefore hypothesise that FLRT3 and possibly other ligands of LPHN1 
can induce secretion of galectin-9 thus protecting malignant cells against NK cells and 
cytotoxic T cells. Especially, because LPHN1 as a G-protein-coupled receptor acts through 
protein kinase C, which was suggested to be involved in galectin-9 secretion (Chabot et al., 
2002a). However, this hypothesis has not been studied experimentally and thus became the aim 
of the present study. 
Importantly, there is evidence demonstrating that in myeloid leukaemia cell lines Tim-
3/galectin-9 pathway triggers the key translational pathway controlled by the mammalian target 
of rapamycin (mTOR) (Prokhorov et al., 2015). This suggests that the autocrine loop is also 
likely to have a growth/proliferation stimulatory function. 
1.4 Mammalian Target of Rapamycin pathway 
The mammalian target of rapamycin (mTOR) is an enzyme from the serine/threonine kinase 
family, which, like other kinases, phosphorylates substrates using ATP. It is allosterically 
regulated by covalent attachment of H3PO4 in the position S2448 for activation or in the 
position T2446 for inhibition (Yasinska et al., 2014). If mTOR is active, it recruits different 
chaperones. These chaperones determine the structure of mTOR protein, allowing it to 
recognise different substrates. Also, depending on the group of chaperones that mTOR recruits, 
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it forms two types of multiprotein complexes, mTOR1 and mTOR2. These complexes regulate 
translation of different, but essential proteins like transcription factors that will control cell 
survival, differentiation, and death (Wang and Proud, 2006).   
Some of the chaperones are common in both complexes, while others are different. These 
chaperones do not have any specific catalytic function in the complex but they determine the 
shape and conformation of the mTOR recognition site, thus controlling its capacity to recognise 
specific folded different amino acids sequences of its substrates (Laplante and Sabatini, 2009; 
Sabatini, 2006). In Figure 7 is a scheme showing the main components of both complexes. 
These complexes are described with more detail on section “1.4.1 Biochemistry of mTOR as 
an enzyme”. 
 
Figure 7 mTOR1 and mTOR2 complexes with their chaperones. In both complexes mTOR 
is the main constituent recruiting different chaperones according to their function.   
mTOR pathway is activated during various cellular processes such as tumour formation, 
angiogenesis, insulin resistance, adipogenesis and T-lymphocyte activation. In diseases such 
as cancer and type 2 diabetes, mTOR is deregulated (Laplante and Sabatini, 2009). Due to this, 
mTOR inhibitors have been more and more used in the treatment of several diseases such as 
solid tumours, coronary restenosis and rheumatoid arthritis (Laplante and Sabatini, 2009). 
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1.4.1 Biochemistry of mTOR as an enzyme 
The mTOR protein is a 289 kDa serine-therosine kinase that belongs to the phosphoinositide 
3-kinase (PI3K)-related kinase family (Laplante and Sabatini, 2009). As mentioned before, 
mTOR is part of the mammalian target of rapamycin complex 1 and 2 (mTOR1 and mTOR2). 
Two multi-protein complexes responsible for important tasks in the cells (Laplante and 
Sabatini, 2009). 
mTOR1 has five components: mTOR, regulatory-associated protein of mTOR (Raptor), 
mammalian lethal with Sec13 protein 8 (mLST8, also called GβL), proline-rich AKT substrate 
40 kDa (PRAS40), and DEP-domain-containing mTOR-interacting protein (Deptor). The exact 
function of this proteins in mTOR1 signalling remains unclear (Laplante and Sabatini, 2009; 
Sabatini, 2006). 
In this complex mTOR is the catalytic subunit and it is associated with Raptor and LST8 Figure 
7). The Raptor might affect mTOR1 activity by regulating assembly of the complex and by 
recruiting substrates for mTOR. The function of LST8 in mTOR1 function is unclear since its 
deletion does not seem to affect the mTOR1 activity in vivo (Laplante and Sabatini, 2009; 
Sabatini, 2006). 
PRAS40 and Deptor are proposed to be negative regulators of mTOR1. When the activity of 
mTOR1 is reduced these two proteins are recruited to the complex and they promote mTOR1 
inhibition. It is hypothesised that PRAS40 affects mTOR1 kinase activity by acting as a direct 
inhibitor of substrate binding. When mTOR1 is activated, it phosphorylates PRAS40 and 
Deptor, reducing the physical interaction of these with mTOR1 and further activating mTOR1 
signalling (Laplante and Sabatini, 2009).  
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Not much is known about mTOR2. Contrarily to mTOR1 few studies on mTOR2 have been 
done. mTOR2 comprises six different proteins, being three in common with mTOR1. These 
are mTOR, mLST8 and Deptor. In addition to these mTOR2 has the rapamycin-insensitive 
companion of mTOR (Rictor) instead of Raptor, the mammalian stress-activated protein kinase 
interacting protein (mSIN1) and the protein observed with Rictor-1 (Protor-1) (Laplante and 
Sabatini, 2009; Sabatini, 2006).  
Studies seem to show that Rictor and mSIN1 stabilise each other and the structure of the 
mTOR2. Deptor regulates negatively mTOR2 activity, currently it is the only characterised 
endogenous inhibitor. The function of mLST8 is not clear but it is essential for the mTOR2 
activity since its knockout severely reduces the stability and the activity of this complex 
(Laplante and Sabatini, 2009).  
1.4.2 Functions of mTOR1 
mTOR1 has a central role in cell growth and proliferation by promoting several anabolic 
processes like biosynthesis of proteins, lipids and organelles; and limiting catabolic processes 
like autophagy (Laplante and Sabatini, 2009; Sarbassov et al., 2005).  
1.4.2.1 Protein synthesis 
mTOR1 induces protein synthesis used in cell growth, through various downstream effectors. 
This happens by phosphorylation of the eukaryotic initiation factor 4E (eIF4E)-binding protein 
(4E-BP1) and the p70 ribosomal S6 kinase 1 (P70S6K1). This phosphorylation prevents the 
binding of 4E-BP1 to eIF4E and in this way the later promotes cap-dependent translation and 
elongation, and translation of ribosomal proteins through regulation of the activity of many 
proteins such as P70S6K1, programmed cell death 4 (PDCD4), eukaryotic elongation factor 2 
33 
 
kinase (eEF2K) and ribosomal protein S6 (Figure 8) (Laplante and Sabatini, 2009; Sarbassov 
et al., 2005). 
 
Figure 8 Schematic representation of mTOR1 protein synthesis 
(simplified scheme). mTOR1 activates P70S6K1 that will inhibit 
eEF2K (inhibitor of protein elongation) and PDCD4 that supresses cell 
proliferation and activate S6 that is involved in translation. mTOR1 
also inhibits 4EBP1, that is a translation repressor. 
1.4.2.2 Programmed cell death 
There are two types of programmed cell death, apoptosis, and autophagy. mTOR pathway 
participates in the regulation of one of the, autophagy. Autophagy is a self-degradative process 
that leads to cell death. It removes misfolded or aggregated proteins and damaged organelles, 
like mitochondria, endoplasmic reticulum, and peroxisomes, by the formation of vesicles 
(Gozuacik and Kimchi, 2007; Glick et al., 2010).  
These vesicles have double or multiple membrane and appear in the cytoplasm. They engulf 
portions of the cytoplasm, aggregated/misfolded proteins and/or the damaged organelles, and 
then they fuse with lysosomes and deliver their cargo for degradation by lysosomal enzymes 
(Gozuacik and Kimchi, 2007; Glick et al., 2010).  
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mTOR1 has an inhibitory role in autophagy. mTOR1 activation leads to an inhibition of 
autophagy while its activation leads to an increase of autophagy. This regulation is done 
through the regulation of a protein complex composed of unc-S1-like kinase 1 (ULK1), 
autophagy-related gene 13 (ATG13) and focal adhesion kinase family-interacting protein of 
200 kDa (FIP200). mTOR1 promotes ULK1 and ATG13 phosphorylation and by consequence 
its repression. Repression of ULK1 and ATG13 leads to repression of autophagy (Figure 9) 
(Laplante and Sabatini, 2009). 
 
Figure 9 Schematic representation of mTOR1 
autophagy (simplified scheme). mTOR1 represses 
ULK1 and ATG13 thus represses autophagy process.  
1.4.2.3 Lipid synthesis 
mTOR participates is a crucial regulator of steroid lipids, which on genomic level control both 
organic and mineral metabolism as well as embryonic development. Steroid lipids also support 
elasticity of cell membrane (cholesterol) and processes of lipid digestion (cholic acids). This 
happens by positive regulation of the activity of sterol regulatory element binding protein 
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(SREBP1) and of peroxisome proliferation-activated receptor-γ (PPARγ) by mTOR1. These 
two transcription factors control the expression of genes encoding proteins involved in lipid 
and cholesterol homoeostasis. Blocking mTOR with rapamycin reduces the expression and the 
transactivation of PPARγ (Figure 10) (Laplante and Sabatini, 2009).  
 
Figure 10 Schematic representation of mTOR1 lipids synthesis (simplified 
scheme). mTOR activates SREBP1 and PPARγ that will activate adipogenic 






1.4.2.4 Mitochondrial metabolism 
Inhibition of mTOR1 by rapamycin lowers mitochondrial membrane potential, consumption 
of oxygen, ATP level and alters mitochondrial phosphoproteome. It reduces the number of 
copies of mitochondrial DNA and expression of genes involved in oxidative metabolism. 
1.4.2.5 mTOR1 signalling 
mTOR1 integrates major signals in the cells: growth factors, energy status, and oxygen levels. 
These signals regulate several processes that are involved in the promotion of cell growth and 
proliferation (Figure 11) (Laplante and Sabatini, 2009). 
 
Figure 11 Schematic representation of mTOR1 (simplified scheme). Main mechanism that 
activates/represses mTOR1 and the ones that mTOR1 activates/inhibits.  
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One of the most important sensors of mTOR1 regulation is the tuberous sclerosis complex 
(TSC). This is a heterodimer that contains TSC1 (also called hamartin) and TSC2 (also called 
tuberin) (Laplante and Sabatini, 2009). TSC1-TSC2 is a GTPase-activating protein (GAP) for 
Ras homologue enriched in brain (Rheb). Rheb is a GTP-binding protein that activates mTOR1, 
by binding to it. TSC1-TC2 inhibits mTOR1 signalling by converting Rheb to its inactive GDP-
bound form. TSC1-TSC2 and Rheb have an important role in the activation of mTOR1 when 
the cell loses the phosphate and tumour suppressors like neurofibromatosis 1 (NF1), serine-
threonine kinase 11 (LKB1) or p53 tumour suppressor (Laplante and Sabatini, 2009; Sabatini, 
2006). 
1.4.2.5.1 Growth factors 
The mTOR1 pathway regulates growth through downstream effectors, such as the regulators 
of translation eukaryotic translation initiation factor 4E binding protein 1 (4EBP1) and P70 
ribosomal S6 kinase 1 (P70S6K1). P70S6K1 promotes protein synthesis and represses the 
phosphatidylinositol3-kinase (PI3K)-protein kinase B (AKT) pathway by inhibiting insulin 
receptor substrate 1 and 2 (IRS1 and IRS2) expression (Sabatini, 2006). P70S6K1 promotes 
the phosphorylation of IRS1 and reduces its stability (Laplante and Sabatini, 2009). 
The activation of mTOR1 can happen when there is the phosphorylation of TSC2 by AKT, by 
extracellular-signal-regulated kinase 1/2 (ERK1/2) and by p90 ribosomal S6 kinase (RSK1). 
This will lead to inactivation of TSC1-TSC2 and by consequence to activation of mTOR1. The 
activation of mTOR1 can also happen in a TSC1-TSC2-independent manner by promoting the 
phosphorylation and dissociation of PRAS40 from mTOR1 (Laplante and Sabatini, 2009). 
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1.4.2.5.2 Energy status 
AMP-activated protein kinase (AMPK), a master sensor of intracellular energy status, is 
responsible for signalling the energy status to mTOR1. When there is lack of energy in the cell 
(low ratio ATP: ADP), AMPK is activated and phosphorylates TSC2 to increase GAP activity 
towards Rheb and decreasing mTOR1 activity. Also, AMPK is able to decrease mTOR1 
activity by phosphorylating Raptor (Laplante and Sabatini, 2009). 
1.4.2.5.3 Oxygen levels 
When the cell is under mild hypoxia the low level of ATP activates AMPK, that will activate 
TSC1-TSC2 and thus inhibit mTOR1 signalling (Laplante and Sabatini, 2009). 
1.4.3 Functions of mTOR2 
Very little is known about mTOR2 since its study has shown to be difficult to perform. 
Nevertheless, it is known that mTOR2 plays key roles in different biological processes like cell 
survival, metabolism, proliferation and cytoskeleton organisation (Laplante and Sabatini, 
2009). 
1.4.3.1 Cell survival, metabolism, and proliferation 
Cell survival, metabolism and proliferation are processes that depend on the activation status 
of AKT. It positively regulates these processes through the phosphorylation of various 
effectors. AKT is active when it is phosphorylated at Ser308 by phosphoinositide-dependent 
kinase 1 (PDK1) and at Ser473 by mTOR2 (Laplante and Sabatini, 2009). 
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1.4.3.2 Cytoskeleton organization 
The molecular mechanism that allows mTOR2 to regulate the cytoskeleton organisation is not 
determinate yet. However, it is known that the knockdown of mTOR2 affects the actin 
polymerization and perturbs cell morphology (Laplante and Sabatini, 2009). It is suggested that 
mTOR2 controls the actin cytoskeleton by promoting protein kinase Cα (PKCα) 
phosphorylation, phosphorylation of paxillin and its relocalization to focal adhesions (Laplante 
and Sabatini, 2009).    
1.4.3.3 mTOR2 signalling 
mTOR2 should be considered part of the PI3K-Akt pathway as it directly phosphorylates Akt 
on one of the two sites that are necessary for Akt activation in response to growth-factor 
signalling. This finding makes mTOR2 essential part of the pathway that activates Akt and, 
like PDK1 (3-phosphoinositide-dependent protein kinase1) and PI3K (Sabatini, 2006). The 
Akt-activation function of mTOR2 sets up the intriguing situation in which mTOR, as part of 





Figure 12 Schematic representation of mTOR2. It is known that mTOR2 is involved in the 
mechanisms of Cell Survival, metabolism and proliferation through Akt activation and 
cytoskeletal organisation through PKCα activation.  
1.4.4 mTOR as a therapeutic target 
mTOR is a master regulator of the main cell pathways and thus there is a crescent interest in 
using it as a therapeutic target. At the moment, drugs are designed to inhibit mTOR. The most 
common mTOR inhibitor is rapamycin. Rapamycin is a macrolide that was originally found as 
an antifungal agent but later recognised as having immunosuppressive and anticancer 
properties (Laplante and Sabatini, 2009; Sabatini, 2006). When rapamycin enters the cell, it 
binds to FKS06-binding protein of 12 kDa (FKBP12). This complex will bind directly to 
mTOR in mTOR1, leading to the inhibition of mTOR1-mediated phosphorylation of the 
substrates S6K1 and 4EBP1. FKBP12-rapamycin cannot bind directly to mTOR in mTOR2, 
suggesting the effects of rapamycin on cellular signalling are just due to inhibition of mTOR1 
(Laplante and Sabatini, 2009; Sabatini, 2006). 
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Recently a new class of mTOR inhibitors have been developed, which are able to inhibit both 
mTOR complexes. These are called dual mTOR1/2 inhibitors, and its aim is to have a better 
effect that the first generation of inhibitors. For example, AZD2014, a dual inhibitor developed 
by AstraZeneca, demonstrates better inhibitory activity against mTOR1 than rapamycin 
(Dienstmann et al., 2014). In Table 4 are some mTOR inhibitors, currently in clinical trials. 
Table 4 New mTOR inhibitors. (Dienstmann et al., 2014) 
Inhibitor Manufacturer Target 
Everolimus Novartis mTOR1 
Temsirolimus Pfizer mTOR1 
AZD2014 AstraZeneca mTOR1/2 
MLN0128 INK128 mTOR1/2 




2. AIMS AND OBJECTIVES 
The aim of this PhD project was to investigate a fundamental molecular mechanism underlying 
the secretion and function of Galectin-9 and soluble Tim-3 in primary human healthy cells and 
AML cells. This aim will allow to figure out the importance of these proteins in the survival of 
AML cells. 
To achieve this aim, the following objectives were considered. 
1. Investigate differential expression and intracellular signalling role of Tim-3 and 
Galectin-9 in primary human healthy cells. 
2. Investigate the role of Tim-3 in trafficking Galectin-9. 
3. Investigate and characterise expression of functional neuronal receptor LPHN1 in 
human AML cells and its involvement in Tim-3/Galectin-9 secretion. 
4. Investigate the intracellular pathways transducing the signal from LPHN1 to Tim-
3/Galectin-9 autocrine loop. 




3. MATERIALS AND METHODS 
3.1 Materials 
All cell culture reagents, were purchased from Sigma (Suffolk, UK). DOPAT transfection 
reagent, primers and galectin-9 silencing RNA (siRNA) and basic laboratory chemicals were 
obtained at the same company. 
Mouse monoclonal antibodies directed against mTOR, HIF-1α and β-actin, and rabbit 
polyclonal antibody against phospho-S2448 mTOR, galectin-9, Tim-3, HRP-labelled rabbit 
anti-mouse secondary antibody were purchased from Abcam (Cambridge, UK). The 
antibodies against phospho-T389 p70S6 kinase 1 (P70 S6K1), total and phospho-S65 
eukaryotic initiation factor 4E binding protein 1 (eIF46E-BP1) antibodies were obtained from 
Cell Signalling Technology (Danvers, MA, USA). Mouse monoclonal antibody against 
FLRT-3 was obtained from Santa Cruz Biotechnology (Heidelberg, Germany). Goat anti-
mouse and goat anti-rabbit Polyclonal rabbit anti-peptide antibody (clone name: PAL1) 
against LPHN1 and polyclonal mouse antibody (clone name; dmAb) against Lasso/teneurin-
2 were previously described (Silva et al., 2011; Davydov et al., 2009). 
Human stem cell factor (SCF) (Wang et al., 2008), anti-Tim-3 monoclonal antibody 
(Prokhorov et al., 2015) and HMGB1 were a kind gift of Dr Luca Varani. 
ELISA-based assay kits were purchased from Bio-Techne (R&D Systems, Abingdon, UK). 
MaxisorpTM microtitre plates were provided by Nunc (Roskilde, Denmark) or Oxley Hughes 
Ltd (London, UK).  
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All other chemicals purchased were of the highest grade of purity and available commercially 
unless otherwise stated.  
3.2 Tissue culture 
3.2.1 THP-1, U937, MCF7, Jurkat T cells, K562, LAD2 and RCC-FG1 
THP-1 human myeloid leukaemia monocytic macrophages, U937 human leukaemia 
monocytes, MCF7, Jurkat T cells, K562 chronic myelogenous leukaemia cells, and RCC-FG1 
(human renal clear cell line) cells were obtained from the European Collection of Cell 
Cultures (Salisbury, UK). LAD2 cells (cell line from the bone marrow of a patient with MC 
sarcoma) were kindly provided by Prof Metcalfe and Dr Kirshenbaum (NAID, NIH, USA; 
(Kirshenbaum et al., 2003)). Cells were cultured in RPMI 1640 media supplemented with 
10% foetal bovine/calf serum, penicillin (50 IV/ml) and streptomycin sulphate (50 µg/ml). 
They were kept at 37°C and 5% CO2. 
3.2.2 Primary NK cells 
Primary NK cells were purified from a buffy coat, prepared from healthy donors. These were 
purchased from the National Health Blood and transfusion Service (NHSBT, UK) following 
ethical approval (REC reference: 16-SS-033). 
3.2.3 Primary healthy leukocytes obtained from healthy donors 
Primary healthy leukocytes were obtained from a buffy coat from human blood, obtained from 
healthy donors. These were purchased from the national health blood and transfusion service 
(NHSBT, UK) following ethical approval (REC reference 16-SS-033). Mononuclear-rich 
leukocytes were obtained by Ficoll-density centrifugation according to the manufacture’s (GE 
Healthcare Life Sciences) protocol and the number of cells was determined using a 
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haemocytometer and diluted accordingly with HEPES-buffered Tyrode’s solution before 
treatment. 
3.2.4 Primary human AML cells 
Primary human mononuclear blasts (AML-PB001F, newly diagnosed/untreated) were 
purchased from All Cells (Alameda, CA, USA) and handled according to manufacturer’s 
instructions following ethical approval (REC reference 16-SS-033). 
3.2.5 Primary human CLL cells 
Primary human bone marrow derived CLL mononuclear cells (CLL-DM001F, newly 
diagnosed/untreated) were purchased from All Cells (Alameda, CA, USA) and handled 
according to manufacturer’s instructions following ethical approval (REC reference 16-SS-
033).  
3.2.6 Primary human blood samples 
Blood serum of healthy donors was obtained from buffy coat blood, originated from healthy 
donors undergoing routine blood donation. It was purchased from the National Health Blood 
and Transfusion Service (NHSBT, UK) following ethical approval (REC reference: 16-SS-
033). Primary human AML serum samples were obtained from the sample bank of University 
Medical centre Hamburg-Eppendorf (UKE).  
3.2.7 Mouse bone narrow extracts  
Femur bones of six-week-old C57 BL16 mice (25 ± 2.5 g, kindly provided by Dr. Gurprit 
Lall, School of Pharmacy, University of Kent) were used for the experiments following 
approval by the Institutional Animal Welfare an Ethics Review Body. Animals were handled 
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by authorised personnel in accordance with the Declaration of Helsinki protocols. Bone 
marrow was isolated from femur bone heads as described before (Swamydas and Lionakis, 
2013) and the whole extract (1 mg protein/ml) of it was then obtained. 
3.3 Cell lysates 
The cells were incubated according to indicate at the results section. After the incubation, the 
cells were centrifuged 5 min at 3000 rpm and re-suspended in lysis buffer (50 mM Tris-HCl, 
5 mM Ethylenediaminetetraacetic acid (EDTA), 150 mM NaCl, 0.5% Nonidet-40, 1 mM 
phenylmethylsulfonyl fluoride (PMSF), pH8.0). The samples incubated on ice and then were 
centrifuge 5 min at 13,200 rpm and used straight after or stored at -80°C until future use. 
3.4 Protein quantification 
This was the method used to quantify the amount of proteins in cell lysates. It was based on 
the method described by (Bradford, 1976), which allows the quantification of the protein due 
to a shift in the absorption maximum of the dye (Coomassie Brilliant Blue G-250) from 465 
nm to 595 nm, from red to blue, upon binding with protein. 
Five µl of cell lysate were mixed with 150 µl of Bradford reagent (0.01% (w/v) Coomassie 
Brilliant Blue G-250, 4.7% (w/v) ethanol and 8.5% (w/v) phosphoric acid) in a microwell 
plate. The optical density at 620 nm was read in the plate reader. 
3.5 Cell viability assay 





In this assay, MTS is converted to aqueous formazan by dehydrogenases in the living cells. 
This conversion is proportional to the amount of living cells and can be by measuring the 
maximum absorbance of the reaction product at 490 nm (Cory et al., 1991).     
To 100 µl of cell and 20 µl of MTS reagent were placed into a microwell plate and mixed. 
The plate was placed on to the incubator at 37°C for 1-2 hours, and the absorbance at 490 nm 
was then measured.  
3.6 Western-blot analysis2 
The cell lysates were mixed with 2X or 4X sample buffer (125 mM Tris-HCL, 2% sodium 
dodecyl sulphate (SDS), 10% glycine, 1 mM dithiothreitol (DTT), 0.002% bromophenol blue, 
pH6.9) and boiled 5 min at 95°C.  
Proteins were resolved on 7.5%, 10% or 12% SDS-polyacrylamide gels, prepared according 
to Table 5, according to the molecular size of the target protein. The gels run at 150-200 V, 
with constant voltage, until the dye front was about 1 cm from the bottom of the gel. 
Filter paper and/or filter pads, together with nitrocellulose membrane were soaked in blotting 
buffer and assemble in the transfer cassette according to Figure 13.  
                                                 




Figure 13 Schematic representation of transfer montage. A. semi-dry transfer B. wet 
transfer. 
The transfer was done in a semi-dry (BioRad system) or wet (Invitrogen system) environment 
at constant voltage and 0.07 Amp (semi-dry transfer) or 0.1 Amp (wet transfer), one to two 
hours, according to the gel and system used. 
The membranes were blocked with blocking buffer (tris-buffered saline, 0.1% Tween 20 
(TBST), 2% bovine serum albumin (BSA)) for at least 1 h under constant agitation at room 
temperature. The antibodies for the target proteins, diluted in blocking buffer, were added to 
the membrane, and incubated for at least 2 h. 
The membranes were washed with TBST for at least 15 min, under constant agitation at room 
temperature. Li-Cor goat secondary antibodies, conjugated with fluorescent dyes, diluted in 
TBST, were used according with the manufacturer’s protocol in order to visualise the proteins 
of interest. This was done using a Li-Cor Odyssey imaging system. Western-blot data were 
subjected to quantitative analysis using Odyssey software and values were normalised against 
respective β-actin bands. 
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Some membranes were stripped using a ReBlotTM Plus Kit (Chemicon International) 
according to the manufacturer’s protocol. Membranes were then blocked and scanned using 
the Li-Cor Odyssey imaging system to make sure that stripping was successfully completed. 
Then the membranes were re-probed to detect new proteins.  
3.7 ELISA 
ELISA is an immunoassay were one of the reagents is immobilized on a solid phase and the 
signal is generated by one enzyme, in this case HRP-Streptavidin.  
3.7.1 Detection of phosphor-S2448 mTOR in cell lysates 
ELISA plates were coated with mouse anti-mTOR antibody and blocked with 2% BSA.  
The cell lysates were added to the plate, and incubated with constant agitation at room 
temperature for at least 2 h.  
The plates were then washed with TBST buffer and anti-phospho-S2448 mTOR antibody was 
added. The plates were incubated with agitation for at least 2 h and once again, washed with 
TBST buffer. 
1:1000 HRP-labelled goat anti-rabbit IgG (Abcam) in TBST buffer was added to the plates 
and it reacted for at least 30 min at room temperature. After washing the plates with TBST, 




3.7.2 Detection of exocytosed IL1-β, IL6, TNFα, VEGF, Galectin-9 and soluble 
Tim-3 
Concentrations of the above proteins released into cell culture media were analysed by ELISA 
(R&D Systems assay kit) according to the manufacturer’s protocol.  
Tim-3 was also detected using a similar approach, but instead of a kit, mouse anti-Tim-3 
(mAnti-Tim-3) was employed as a capture antibody and rabbit anti-Tim-3 (rAnti-Tim-3) as 
detection antibody. HRP-labelled goat anti-rabbit IgG antibody (Abcam) was used to visualise 
the reaction. 
3.7.3 Detection of soluble Tim-3-Galectin-9 complex 
Mouse anti-Tim-3 (mAnti-Tim-3) was added to the ELISA plate and used as capture antibody. 
The cell lysates were added to the plates and incubated for at least 2 h. 
Biotinylated goat anti-galectin-9 (gAnti-Galectin-9, R&D Systems) was used as detection 
antibody. It was added to the plates and reacted with constant agitation for at least 2 h.  
The secondary antibody, HRP-labelled goat anti-rabbit IgG antibody (Abcam), was added to 
the plates and it reacted for at least 2 h with constant agitation. 
The reaction was visualised using HRP-labelled goat anti-rabbit IgG antibody (Abcam). The 
plates were washed with TBST and bound secondary antibodies were visualised by the 




3.8 Characterisation of Tim-3 and galectin-9 interactions in cell lysates 
An ELISA-based analysis was used. ELISA plates were coated with anti-galectin-9 antibody 
and then blocked with 2% BSA. Cell lysates were added to the plates and incubated for at 
least 4 h with constant agitation at room temperature. The plates were washed with TBST and 
a glycine-HCl pH lowering buffer (pH 2) was then applied to extract the bound proteins.  
The extracts were mixed with equal volumes of lysis buffer (50 mM Tris-HCl, 5 mM 
Ethylenediaminetetraacetic acid (EDTA), 150 mM NaCl, 0.5% Nonidet-40, pH8.0) and with 
4X sample buffer (125 mM Tris-HCL, 2% sodium dodecyl sulphate (SDS), 10% glycine, 1 
mM dithiothreitol (DTT), 0.002% bromophenol blue, pH6.9) for SDS-PAGE at the ratio of 
1:3. The samples were analysed through western-blot. 
To confirm that all galectin-9 was extracted, the plate was subjected to analysis with galectin-
9 detection antibody followed by standard ELISA steps. Signals obtained were similar to 
those where PBS was used instead of the sample confirming that all the protein was extracted.  
3.9 In cell Western and in cell assay (also known as on cell assay) 
To analyse the total amount of Tim-3 and galectin-9, a standard Li-Cor in cell Western assay 
was used. The in cell assay was also used to detect the amount of these proteins in the cell 
surface. 
3.9.1 In cell Western 
In this technique, the cells were centrifuged and re-suspended in cold methanol for 10 min at 
-20°C. They were then pelleted, by centrifuging and re-suspended in new media (same used 
in cell culture), at least two times to ensure that no methanol is left.  
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The cells were re-suspended in fresh medium containing anti-Tim-3 or anti-galectin-9, and 
they reacted at least 3 h under constant agitation at room temperature. New centrifugation was 
done and the cells were re-suspended in fresh medium containing Li-Cor goat secondary 
antibodies. They reacted at least 2 h under constant agitation at room temperature.    
The cells were washed and placed in an ELISA plate, where the Li-Cor Odyssey imaging 
system was used to visualise them and the Odyssey software used for quantitative analysis.  
3.9.2 In cell assay 
The protocol used for this technique was the same described for in cell Western, but without 
permeabilisation of the cells with methanol.  
Briefly, cells were re-suspended in medium containing anti-Tim-3 or anti-galectin-9, and the 
reaction was carried out for at least 3 h under constant agitation at room temperature. Cells 
were centrifuged and re-suspended in fresh medium containing Li-Cor goat secondary 
antibodies. The biding was done for at least 2 h under constant agitation at room temperature. 
Cells were then washed and placed in an ELISA plate, where the proteins were visualised 







3.10 Transfer of galectin-9/Tim-3 siRNA into U-937 cells and qRT-PCR 
For the galectin knock-down, a galectin-9-specific siRNA target sequence (uga ggu gga cga 
ugu ggu ucc c) which was previously described (Hsu et al., 2015) was used. For Tim-3 
knockdown, a commercially available siRNA purchased from Santa Cruz Biotechnology, CA, 
USA, was employed. As control, it was used a corresponding random siRNA (uac acc guu 
agc aga cac c dtdt (Wang et al., 2008). Transfection into U-937 cells was performed using 
DOTAP reagent according to the manufacturer’s protocol. 
To monitor galectin-9 and Tim-3 mRNA levels we used qRT-PCR (Moritoki et al., 2013)-
Total RNA was isolated using a GenEluteTM mammalian total RNA preparation kit, followed 
by a target protein mRNA reverse transcriptase-polymerase chain reaction (RT-PCR) 
performed in accordance with the manufacturer’s protocol (Sigma). This was followed by 
quantitative real-time PCR. Primer selection was as follows: Galectin-9, 5’-
CTTTCATCACCACCATTCTG-3’, 5’-ATGTGGAACCTCTGAGCACTG-3’ Tim-3, 5’-
CATGTTTTCACATCTTCCC-3’ actin, 5’-
TGACGGGGTCACCCACACTGTGCCCATCTA-3’, 5’-CTAGAAGCATTTGCGGTCG-
ACGATGGAGGG-3’. Reactions were performed using a LightCycler® 480 real-time PCR 
system and respective SYBR Green I Master kit (Roche, Burgess Hill, UK). Analysis was 
performed according to the manufacturer’s protocol. Values representing galectin-9 and Tim-




3.11 Characterisation of glycolysis and MGO levels 
Glycolytic degradation of glucose was analysed using a colorimetric assay, previously 
described (Porakishvili et al., 2001). This method relies on the fact that cell lysates can be 
used as multi-enzyme preparation, to convert glucose into lactate, in the absence of oxygen 
(Figure 14).  
The cell lysates were incubated, in an anaerobic chamber, for 1 h at 37°C with 1% glucose 
solution, and then proteins were precipitated using a 2% trichloroacetic acid solution. 
Carbohydrate precipitation was performed using CuSO4 solution in combination with 
Ca(OH)2, at a final concentration of 60 mg/ml and lactate was converted into acetic aldehyde 
using concentrated H2SO4 at 90°C for 1 min followed by cooling down on ice. The 
acetaldehyde was then detected using veratrole (1,2-dimethoxybenzene) test. 
Methylglyoxal (MGO) was also detected colorimetrically following biochemical 
modifications (Chaplen et al., 1996a; Chaplen et al., 1996b). It was condensed with reduced 
glutathione (GSH, 1 mM) for 10 min at 37°C. This was converted into lactate by Glyoxalases 





Figure 14 Biochemistry of glycolytic degradation of glucose, generation of methylglyoxal 
(MGO) and MGO-dependent formation of advanced glycation end (AGE) products. 
Additional abbreviations used: HK – hexokinase, PGI – phosphoglucose isomerase, PFK – 
phosphofructokinase, AL – Aldolase, TPI – Triose-phosphate isomerase, GPDH – 
glyceraldehyde-3-phosphate dehydrogenase, PGK – phosphoglycerate kinase, PGM – 
phosphoglycerate mutase, EL – enolase, PK – pyruvate kinase, LDH – lactate dehydrogenase, 
DHAP – dihydroxyacetone phosphate, GA3-P – glyceraldehyde-3-phosphate, 3-PG – 3-
phosphoglycerate, 2-PG – 2-phosphoglycerate, PEP – phosphoenolpyruvate, G-SH – reduced 




3.12 Analysis of phosphatidylinositol-3 kinase (PI-3K) activity and 
phosphate groups 
Activity of PI-3K was measured using a nonradioactive assay based on the ability of the 
enzyme to phosphorylate its substrate as previously described (Abooali et al., 2014).  
Cell lysates were incubated with 0.1 mg/ml substrate (PI-4,5-diphosphate) in kinase assay 
buffer (20 mM Tris pH 7.5, 100 mM NaCl, 0.5 mM EDTA, 8 mM MgCl2, 40 µM ATP). The 
reaction was stopped by adding a mixture of hexane/isopropanol (13:7, v:v) and a mixture of 
2 M KCl/HClconc (8:0.25, v:v). The samples were vortexed and organic phases were washed 
with HCl (0.1 M). Then the detection of phosphates groups was done using molybdenum 
reagent containing 2 parts of 25 mM (MH4)6Mo7O24, 5 parts of 0.3 M ascorbic acid and 1 part 
of 2 mM potassium antimonyl-tartrade.  
Phosphate groups were characterised using colorimetric assay as mention above. 
3.13 Detection of catalytic activity of PKCα 
Catalytic activity of PKCα was measured as described before based on its ability to 
phosphorylate specific substrate (Micol et al., 1999).  
Briefly, the samples were mixed with 20 mM Tris-HCl pH 7.5, 200 µM CaCl2, 5 mM MgCl2 
and added to ELISA plates, previously coated with 0.2 mg/ml Histone_5_III. It reacted 30 
min at 37°C. Glycine-HCl pH lowering buffer (pH 2, at 95°C) was added to the plates 
followed by lysis buffer. 
The samples were then mixed with 4X sample buffer (125 mM Tris-HCL, 2% sodium dodecyl 
sulphate (SDS), 10% glycine, 0.002% bromophenol blue, pH6.9) and resolved using 12% 
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SDS-polyacrylamide gel. The gel was stained with Coomassie Blue and destained with acetic 
acid.  
3.14 Confocal microscopy 
THP-1 cells were cultured in 12 mm cover glasses in 24-well plates. Cells were treated 
overnight with PMA and fixed/permeabilised during 20 min with ice-cold methanol or a 
mixture methanol/acetone. Alternatively, cells were fixed in a freshly prepared 2% 
paraformaldehyde, washed 3 times with PBS and permeabilised with 0.1%TX-100.  
Cover glasses were blocked for 1 hr at room temperature with 10% goat serum in PBS. The 
anti-Tim-3 antibody and anti-galectin-9 antibody both at 1 µg/ml were used as primary 
antibodies and incubated overnight at 4°C. Goat-anti-mouse Alexa Fluor 488 and goat-anti-
rabbit Alexa Fluor 555 were used as secondary antibodies. Cells were incubated with 
secondary antibodies for 45 min at room temperature. The preparations were examined using 
the Olympus laser scanning confocal microscope as described previously (Prokhorov et al., 
2015; Fasler-Kan et al., 2010). Images were collected and analysed using the proprietary 
image acquisition software. 
3.15 Synchrotron radiation circular dichroism spectroscopy 
Human recombinant Tim-3, human recombinant galectin-9 and Tim-3-galectin-9 complex 
were analysed using SRCD spectroscopy at beam line 23 (Figure 15), Diamond Light Source 
(Didcot, UK). SRCD measurements were performed using 0.2 µg/ml of samples in 10 cm 
path length cell, 3 mm aperture diameter and 800 µl capacity using Module B with 1 nm 
increment, 1s integration time, 1.2 nm bandwidth at 23 °C (Hussain et al., 2012). Results 




Figure 15 Beam light 23 at Diamond Light Source Synchrotron and scheme of 
Synchrotron radiation circular dichroism (SRCD) spectroscopy analysis (Gonçalves Silva 





3.16 Leukaemia cell protection assay 
K562 and NK cells were cultured separately or as a 1:2 co-culture (K562: NK) for 16 h, at 
37°C, in the presence or absence of 0.5 - 5 ng/ml of galectin-9. The unfixed cell cultures were 
then imaged under an inverted microscope (TE200, Nikon), using phase-contrast lighting, a 
digital camera and the WinFluor image acquisition software (J. Dempster, University of 
Strathclyde).  
The same camera and microscope settings were used, and images were acquired at several 
different focal planes. The raw images were analysed using the ImageJ software. Due to the 
very large difference in the size of K562 and NK cells, it was possible to identify each cell 
type both in mono-cultures and in co-cultures, by optimising the ranges of particle sizes during 
automatic particle counting. To correct for artefacts of uneven illumination, background was 
subtracted, using a 100-μm window and the Sliding paraboloid algorithm. The images were 
then segmented by automatic thresholding based on manually optimised parameters, which 
were then applied to all images within each experiment. Any overlapping cells were 
subsequently split using the Watershed algorithm. The “Analyze Particles” plugin was used 
to eliminate any artefacts and distorted particles near the edge of the images. The selected 
areas were then applied to the raw image to determine the actual cell numbers. After the 





3.17 Statistical analysis 
Each experiment was performed at least three times and results were statistically validated by 
two-tailed Student’s t-test (when comparing two events at a time). Multiple comparisons were 
performed using one-way ANOVA test. Where applicable, a post-hoc Bonferroni correction 
was used. Statistical probabilities (p) reflecting significant differences between individual 
events were expressed as *, where p<0.05, ** where p<0.01 and *** where p<0.001. 
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4. RESULTS AND DISCUSSION 
4.1 Differential expression and biochemical activity of the immune 
receptor Tim-3 in healthy and malignant human myeloid cells 
Tim-3, as previous mentioned is a plasma membrane-associated receptor that participates in 
several biological responses in human immune cells. It is highly expressed in AML cells, which 
makes it a good possible target for AML therapy, but its biochemical activities are still not well 
understood. In this chapter, we analyse the total expression and externalization of Tim-3 in 
primary AML cells compared to primary leukocytes. 
4.1.1 Results 
4.1.1.1 Tim-3 immune receptor is expressed in AML blasts and healthy 
leukocytes 
The expression and redistribution of Tim-3 in the cells was analysed using in cell Western 
(ICW) and its presence on the cells’ surface using in cell assay (ICA). In this work AML blasts 




Figure 16 Tim-3 expression and Tim-3 surface presence in AML cells and healthy 
leukocytes. A. 3X105 AML-PB001 primary human AML cells per well B. 1.5X106 
healthy PLs per well. Tim-3 expression was done using in cell Western (ICW) and Tim-
3 surface presence using in cell assay (ICA). The fluorescence values were normalized 
to the respective number of cells and use for calculations. Images are from one 
experiment representatives of three which gave similar results. Quantitative data are 
shown as means ± SEM of at least three individual experiments; **p < 0.01 vs. control.  
As shown in Figure 16A it is possible to observe that the majority of Tim-3 is externalised in 
AML cells while in healthy PLs (Figure 16B) this value is approximately 30%. This indicates 
that most Tim-3 protein was stored inside the cells, where the function of Tim-3 is unknown. 
Of note that, for the results in Figure 16 it was used 5 times healthier PLs than AML cells, it is 





4.1.1.2 Tim-3 triggers activation of the mTOR pathway and HIF-1 signalling in 
primary AML cells and primary healthy human leukocytes (PLs) 
In primary AML cells, mTOR S2448 phosphorylation increase after exposure to SCF and anti-
Tim-3 antibody stimulation (approximately half of the SCF-induced effect). LPS shown to be 
a weaker up regulator of the phosphorylation of mTOR S2448. This can be explained by the 
low TLR4 expression levels indicated by the AML-PB001F primary human AML cells 





Figure 17 Anti-Tim-3 agonistic3 antibody induces mTOR activity, HIF-1α accumulation 
and VEGF and TNFα secretion in primary human AML cells. AML-PB001F cells were 
exposed to the indicated concentrations of anti-Tim-3, LPS and SCF for 4 h. A. PI-3K/mTOR 
pathway activity B. HIF-1α accumulation and VEGF and TNF-α release. Images are from 
one experiment representatives of four which gave similar results. Quantitative data are 
shown as means ± SEM of four individual experiments; *p < 0.05; **p < 0.01 vs. control. 
                                                 
3 The biding of this antibody triggers the same activity as a ligand (stimulus) would do.  
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The values obtained for mTOR S2448 phosphorylation and PI-3K activity match the values of 
mTOR activity monitored by the intracellular amounts of phosphor-T389 p70 S6K1 and 
phosphor-S65 eIF4E-BP1 (Figure 17A). Both proteins are phosphorylated at the indicated 
positions by the mTOR kinase complex (Gwinn et al., 2008). 
All the tested stimuli showed the ability to upregulate HIF-1α accumulation, being anti-Tim-3 
antibody the weakest inducer (Figure 17B).. The effect of LPS in HIF-1α accumulation was 
stronger than the one observed when anti-Tim-3 antibody was used, which can be explained 
by the fact that LPS-dependent HIF-1α accumulation trigged by LPS does not depend only on 
mTOR activation, contrarily to what happen to SCF and anti-Tim-3 antibody HIF-1α 
accumulation. LPS-induced TLR4-mediated HIF-1α accumulation is known to be triggered 
through a redox-dependent mechanism, by mTOR and by mitogen-activated protein (MAP) 
kinase signalling cascades. These three pathways together achieved intensities comparable to 
mTOR-dependent processes after exposition to SCF (Figure 17A and Figure 17B).  
None of the tested stimuli affected the levels of total Tim-3 in primary AML cells (Figure 17B). 
Anti-Tim-3 antibody upregulated the secretion of TNFα and VEGF. SCF mostly upregulated 
VEGF secretion but did not had a significant impact in TNFα secretion level (Figure 17B). 
Galectin-9 was able to upregulate mTOR kinase activity and HIF-1α accumulation in primary 
AML cells at levels comparable to the ones observed with anti-Tim-3 antibody. This result 






Figure 18 Anti-Tim-3 and galectin-9 induce similar responses in primary human AML 
cells. AML-PB001F cells were expose to the indicated concentrations of anti-Tim-3 and 
galectin-9 for 4 h. A. PI-3K/mTOR pathway activity B. HIF-1α accumulation Images are from 
one experiment representative of three which gave similar results. Quantitative data are 
shown as means ± SEM of three individual experiments; *p < 0.05; **p < 0.01 vs. control. 
In primary human healthy leukocytes, the effects of anti-Tim-3 antibody were similar to those 
in primary AML cells. However, in these cells, LPS, and not SCF, was the most powerful 
activator (Figure 19A and Figure 19B). This probably happens because the amount of TLR4 




Figure 19 Anti-Tim-3 induces mTOR activity, accumulation of HIF-1α and secretion of 
VEGF and TNF-α in primary human healthy leukocytes. PLs were exposed to the indicated 
concentrations of anti-Tim-3, LPS and SCF for 4 h. A. PI-3K/mTOR pathway activity B. HIP-
1α accumulation, VEGF and TNF-α release. Images are from one experiment representative 
of four which gave similar results. Quantitative data are shown as means ± SEM of four 




The effects of anti-Tim-3 antibody were similar to those of SCF and slightly lower than the 
effects of anti-Tim-3 antibody detected in primary AML cells (Figure 19A and Figure 19B). 
The isotype control (IgG 2a) antibody was tested and it did not induce any effect (data not 
presented). 
Levels of intracellular phospho-S2448 mTOR, HIF-1α and Tim-3 and secreted VEGF were 
significantly higher in AML cells than in healthy PLs, while the secretion level of TNFα was 
slightly higher in primary AML cells. On the other hand, the levels of PI-3K activity were 
higher in healthy PLs than in AML cells. These results suggest that these proteins are used by 





Figure 20 Comparative quantitative analysis of mTOR/HIF-1 pathway components 
and secretion of VEGF and TNF-α in primary human AML cells and healthy human 
PLs. Protein levels were compared based on the indicated type of detection. A. pS2448 
mTOR intracellular levels detected by ELISA, normalised against total cellular protein, 
and compared with the same values. B. C. and D. levels of p70 S6K1, eIF4E-BP1 and 
HIF-1α protein detected by Western-blot (WB), quantitated, and normalised against 
respective actin values before comparison and statistical validation of the results. E. PI-
3K activity levels measured by colorimetric assay (CA). F. intracellular levels of Tim-3 
detected by in cell western (ICW). The fluorescence values obtain for healthy PLs and 
AML cells were divided by the respective cell number (Figure 16) and use for comparison 
(using PLs value as 100%). Similar results were obtained when comparing Tim-3 values 
in AML cells and healthy PLs obtain by western blot and normalised against actin. G. and 
H. TNFα and VEGF measure in the medium by ELISA and amounts per 106 cells were 
compared and statistically validated. Data was obtained from 3 – 6 individual 
experiments, which gave similar results. Quantitative data are shown as means ± SEM; 




It is known that Tim-3 receptor is expressed in healthy human hematopoietic cell but its role is 
not fully understood (Anderson, 2012). Also, it was recently reported that Tim-3 receptor is 
highly expressed and externalised in human AML cells (Kikushige and Miyamoto, 2013; 
Kikushige et al., 2010). In healthy cells, this receptor is not expressed until they reach a mature 
state and lose the expression of the kit receptor. However, malignant cells can express both 
receptors. It is known that these cells use kit receptor for growth and proliferation while Tim-
3 function is not clear. 
Previously, it was reported that Tim-3 mediates activation of the PI-3K/mTOR pathway in 
human AML cell lines (Prokhorov et al., 2015) and in dendritic cells Tim-3 induces TNFα 
production (Anderson et al., 2007; Tang and Lotze, 2012) but it is not clear if the same happens 
in primary human AML cells, since activation of mTOR pathway and TNFα production use 
growth factors and inflammatory mediator-like responses.  
Our results show that primary AML cells express more Tim-3 than primary healthy leukocytes 
even on the surface. While in PHLs approximately 30% of Tim-3 is expressed on the surface, 
in AML cells almost all Tim-3 is externalized. This difference probably has impact on Tim-3 
activity in its ability to mediate ligand-induced activation of mTOR, HIF-1α accumulation and 
cytokine release in these cells. 
Our results suggest that Tim-3 mediates ligand-induced activation of the mTOR pathway, 
which involves upregulation of phosphorylation of S2448 mTOR levels, p70 S6K1(T389) and 
eIF4E-BP-1(S65), accumulation of HIF-1α protein and induced by LPS (classic inflammatory 
mediator) and SCF (classic hematopoietic growth factor). SCF was the strongest inducer in 
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AML cells while in PHLs, LPS had the strongest effect. These differences are due to 
differential expression of TLR4 and kit receptors in healthy and malignant leukocytes. 
SCF is known to trigger IL-6 release in primary cells (MacNeil et al., 2014). IL-6 regulates 
VEGF (Adachi et al., 2006) which is a HIF-1-dependent process (Semenza, 2002). These 
effects may contribute to both HIF-1α accumulation and VEGF release in addition to SCF 
(Figure 19). 
Background levels of pS2448 mTOR, HIF-1α and Tim-3 as well as p70 S6K1 and eIF4E-BP-
1 proteins are much higher in AML cells than in PHLs (Figure 20), especially HIF-1α 
accumulation that is strong in non-treated AML cells and almost undetectable in primary 
healthy leukocytes. These results become more interesting knowing that recently it was 
reported that HIF-1α contributes for Tim-3 expression (Koh et al., 2015). Also, VEGF but not 
TNFα secretions were significantly higher in non-treated AML cells. 
Interestingly, background levels of PI-3K activity were similar in AML cells and PHLs. This 
suggests that increased background levels of pS2448 mTOR in primary AML cells may be due 
to high constitutive phosphorylation, previously reported, for example, in LAD2 mast cell lines 
(Kim et al., 2008; Gibbs et al., 2012). So, mTOR/HIF-1α/VEGF pathway, but not 







In PHLs and primary AML cells, Tim-3 showed moderate properties as inflammatory receptor 
that has activity as growth factor (it leads to mTOR activation) and proangiogenic (promotes 
VEGF release) (Figure 21). Even though mTOR/HIF-1 pathway is triggered by LPS and SCF, 
a significant increase in TNFα and VEGF secretion was only observed after LPS stimulation. 
SCF acted mostly in the VEGF release, without triggering TNFα production. The observed 
high levels of Tim-3 in AML cells compared with PHLs did not result in higher specific 
biochemical activity of the receptor.   
 
Figure 21 Summary scheme of ligand-induced Tim-3-mediated biological responses in 
healthy primary human leukocytes and primary AML cells.
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4.2 The immune receptor Tim-3 acts as a trafficker in a Tim-3/galectin-9 
autocrine loop in human myeloid leukaemia cells 
As previous shown, the receptor Tim-3 is highly expressed in primary AML cells, where it 
seems to act as a growth factor and inflammatory receptor. Recently, it was demonstrated that 
Tim-3 forms an autocrine loop with galectin-9 (its natural ligand) in human AML cells 
(Kikushige et al., 2015). 
In this section, we analysed the involvement of Tim-3 in the secretion of galectin-9 in AML 
cells. 
4.2.1 Results 
4.2.1.1 Galectin-9 is expressed in healthy primary human leukocytes and 
malignant human myeloid cells and forms a complex with Tim-3 in both cell 
types 
To start, we investigated the expression of galectin-9 by healthy primary human leukocytes 
(PL) and malignant myeloid cell lines (THP-1). The results showed that THP-1 cells produce 
more galectin-9 than PLs, but lipopolysaccharide (LPS) and SCF significantly upregulated 
galectin-9 levels in PLS. The effects of LPS are the strongest while in THP-1 only SCF had a 




Figure 22 Effects of LPS and SCF on the expression of galectin-9 in 
THP-1 cells and PLs. Cells were treated for 4 h with SCF or LPS and then 
harvested. Western-blot and human recombinant analysed galectin-9 
levels galectin-9 (R&D Systems) was used as positive control. Images are 
from one experiment representative of three which gave similar results. 
Quantitative data are shown as means ± SEM of three individual 
experiments; *p < 0.05; **p < 0.01 vs. control. 
In PLs, the band correspondent to galectin-9, appears slightly lower on the gel than the one of 
THP-1 cells and the positive control (Figure 22). This seems to suggest differences in the post-
translational processing of the protein in different cells. 
After establishing that these cells produced galectin-9, we proceeded to investigate if galectin-
9 and Tim-3 can form a complex. In Figure 23 is a schematic representation of the method used 





Figure 23 Tim-3 and galectin-9 form a stable complex. Lysates from 3X105 THP-1 cells and 
1.5X106 PLs were loaded in an ELISA plate, pre-coated with rabbit anti-galectin-9 antibody. 
After incubation, the capture proteins were extracted using pH lowering buffer and analysed 
using Western-blot. Images are from one experiment representative of four which gave similar 
results.  
Both galectin-9 and Tim-3 were detected by Western-blot using anti-galectin-9 rabbit antibody 
and anti-Tim-3 mouse antibody. Also in both cells was possible to detect galectin-9 and Tim-
3 (Figure 23). It is possible to see a band slightly above 70 kDa, which corresponds to the sum 
of Tim-3 and galectin-9 molecular weights. We also detected traces of free galectin-9, but free 
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Tim-3 was almost undetectable. Since the complex formed by Tim-3 and galectin-9 was not 
separated during SDS-PAGE, it indicates that the complex is stable. 
The cellular distribution of Tim-3 and galectin-9, comparing the intracellular level with the 
protein surface presence, was also analysed. In this experiment malignant myeloid cell lines 
(THP-1 and U937), primary human leukocytes (PLs) and primary AML cells (AML-PB001F) 
were used (Figure 24).  
 
Figure 24 Comparative analysis of Tim-3 and galectin-9 expression and surface presence 
in human myeloid leukaemia cell lines, PLs and primary human AML cells. The indicated 
number of resting U937, THP-1, PLs and primary human AML cells (AML-PB001F) were 
subjected to ICA or ICW. Images are from one experiment representative of five which gave 
similar results. Quantitative data are shown as means ± SEM of three individual 




Resting THP-1, U937 and PLs cells expressed more Tim-3 and galectin-9 intracellular than on 
the surface, on the other hand primary AML cells expressed more protein on the surface than 
intracellularly. Interestingly, the ratio Tim-3surface/Tim-3total and galectin-9surface/galectin-9total 
was like each other in all studied cell types (Figure 24).  
4.2.1.2 Tim-3 is required for galectin release in human myeloid leukaemia cells 
After the results above described, we hypothesized that Tim-3 is required for galectin-9 release. 
To verify this hypothesis, we did knockdown of galectin-9 and Tim-3, using U937 cells, 
because of their higher siRNA transfection efficiency. Knockdown of galectin-9 expression 
was done in U937 cells and analysis of these cells, plus analysis of non-treated cells and cells 
treated for 4 h with 2 µg/ml of anti-Tim-3 stimulatory antibody was done. 
It was possible to verify the success of the galectin-9 knockdown using Western-blot (Figure 





Figure 25 Effects of galectin-9 knockdown on Tim-3 expression and the mTOR pathway. 
Non-treated normal (wild-type), galectin-9 knockdown U-937 cells and cells treated for 4 h 
with 2 µg/ml anti-Tim-3 stimulatory antibody were analysed. A. Tim-3 and galectin-9 levels 
measured by Western-blot and galectin-9 release measure by ELISA; B. pS2448 mTOR 
intracellular levels, glycolysis, MGO and VEGF secretion. Images are from one experiment 
representative of three to five which gave similar results. Quantitative data are shown as 
means ± SEM of 3-5 individual experiments; *p < 0.05; **p < 0.01 vs. control; ap < 0.05; aap 




Figure 26 qRT-PCR analysis of galectin-9 and Tim-3 mRNA levels in U937 
cells. Non-treated normal (wild type), galectin-9 knockdown, Tim-3 knockdown 
and transfected with random siRNA U937 cells, as well as the same cells which 
underwent 4 h treatment with 2 µg/ml anti-Tim-3, were used. Total RNA was 
isolated and subjected to qRT-PCR analysis of Tim-3 and galectin-9 mRNA 
levels as outlined in Materials and Methods. Data are mean values ± SEM of 
eight independent reactions; * – p < 0.05; ** – p < 0.01 vs. control; a – p < 





Galectin-9 knockdown reduced the levels of Tim-3 and galectin-9 both intracellularly and on 
the media (Figure 25A). It also upregulated stimulatory phosphorylation of mTOR at the 
position S2448. This matches the upregulation of glycolysis and VEGF release, but the levels 
of methylglyoxal (MGO) did not increase significantly (Figure 25B). This indicates that the 
efficiency of glycolysis correlates with the activity of glycolytic enzymes, since MGO is 
spontaneously formed out of dihydroxyacetone phosphate when glycolytic enzymes are 
oversaturated. MGO catalyses glycation followed by generation of advance glycation end 
(AGE) products (Figure 14, pp.55). higher amounts of these products could be produced by 
cancer cells, since they are highly dependent on glycolysis.  
The success of Tim-3 knockdown was confirmed by Western-blot (Figure 27) and qRT-PCR 






Figure 27 Tim-3 is required for galectin-9 secretion in human myeloid leukaemia cells. 
Non-treated normal (wild type), Tim-3 knockdown and transfected with random si-RNA 
U937, as well as the same cells which underwent 4 h of treatment with 2 µg/ml anti-Tim-3 
were used.  A. Tim-3 and galectin-9 levels were measured using Western-blot and galectin-
9 release was measured by ELISA; B.  pS2448 mTOR intracellular levels, glycolysis, MGO 
and VEGF secretion. Images are from one experiment representative of three to five which 
gave similar results. Quantitative data are shown as means ± SEM of 3-5 individual 
experiments; *p < 0.05; **p < 0.01 vs. control; ap < 0.05; aap < 0.01 vs. anti-Tim-3; bp < 
0.05; bbp < 0.01 vs. random RNA. 
There was a significant reduction in Tim-3 levels, but levels of Tim-3/galectin-9 complex and 
intracellular galectin-9 did not became lower. In the meanwhile, levels of galectin-9 secretion 




The level of mTOR phosphorylation in the position S2448 decrease. Also, there was 
downregulation of glycolysis and VEGF release. The levels of MGO remain about the same, 
suggesting that glycolytic efficiency was not affected (Figure 27B) 
4.2.1.3 Tim-3 is a specific trafficker for galectin-9 in certain cell types 
It is known that several cell types are able to produce galectin-9 but not all of these express 
Tim-3. Therefore, we decided to compare the capability of primary human AML cells and 
primary human CLL cells to produce galectin-9. Both, AML and CLL cells, secreted detectable 
amounts of galectin-9. In addition, the amount of secreted galectin-9 significantly increased in 
AML cells, when these were exposed for 4 h to 2 µg/ml anti-Tim-3. This value remained about 




Figure 28 Levels of galectin-9 and Tim-3 in primary AML, CLL and PLs cells and blood plasma. A. Galectin-9 levels, measured by 
ELISA, of non-treated and treated for 4 h with anti-Tim-3 primary human AML and CLL cells. Data represent mean values ±SEM of three 
induvidual experiments; *p < 0.05 vs. control. B. PLs (PHL in the figure), primary human AML and CLL cells analysed by Western-blot 
for Tim-3. Images are from one experiment representative of four which gave similar results. Data are mean values ±SEM of four 
individual experiments. C. Levels of galectin-9, soluble Tim-3 and Tim-3/galectin-9 complex from blood plasma of six healthy donors was 
subjected to ELISA. Data are mean values ±SEM of 3-5 individual experiments.  
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Both PLs (showed as PHL in Figure 28B) and AML cells expressed Tim-3, being the amount 
expressed in AML cells much higher than the one expressed in PLs. On the other hand, CLL 
cells expressed almost undetectable amounts of Tim-3 (Figure 28B). As mention before, 
despite the fact that primary CLL cells express almost no Tim-3, they still release gelctin-9, 
which means that these cells have a different trafficker for galectin-9. 
We also analysed by ELISA the amount of Tim-3 and galectin-9 on blood plasma of healthy 
donors. Both galectin-9 and Tim-3 were detected in these samples (Figure 28C). In these 
samples was even possible to detected galectin-9 when we capture Tim-3 on the ELISA plate, 
but when we added intact culture medium or galectin-9 standards instead of the samples no 
signal was detected. This means that a complex formed by non-cell-associated soluble Tim-3 
and galectin-9 is present in blood plasma of healthy donors.   
4.2.2 Discussion 
It was previously shown that galectin-9 specifically interact with Tim-3, promoting mTOR 
pathway and forming and autocrine loop with Tim-3 in human AML cells (Kikushige et al., 
2015; Prokhorov et al., 2015). Also, galectin-9 specifically interacts with NK and cytotoxic T 
cells, impairing their ability to attack and kill leukaemia cells (Golden-Mason et al., 2013; 
Wang et al., 2007; Khaznadar et al., 2014). 
The results presented in this chapter show that human myeloid leukaemia cells express and 
secrete galectin-9 (Figure 22, Figure 24, Figure 26 and Figure 29), being the production of 




Figure 29 Secretion of galectin-9 in a Tim-3 dependent manner in human AML cells 
potentially can impair anti-leukaemic activity of cytotoxic T cells and NK cells. 
It is possible to see that the secretion of galectin-9 is dependent on Tim-3, since knockdown of 
this receptor in U937 cells, decrease dramatically this process without affecting galectin-9 
intracellular levels (Figure 27A). On the other hand, when we performed galectin-9 
knockdown, Tim-3 level had a non-significant decrease (Figure 25A) but levels of Tim-3 
mRNA were significantly downregulated (Figure 26). This suggests that transcription of Tim-
3 gene depends on intracellular levels of galectin-9. Apparently, galectin-9 levels influence 
Tim-3 expression in a genomic level while Tim-3 protein controls the secretion of galectin-9. 
Recently it was shown that a desintegrin and metaloproteases (ADAM) 10 to 17 controls 
shedding of Tim-3 from the cell surface in HEK-293 cells and human primary CD14+ 
monocytes (Moller-Hackbarth et al., 2013a). This suggests that Tim-3 might be shed when it 
is complexed with galectin-9, being a fragment of Tim-3 shed together with full length galectin-
9 from the membrane. This may explain the fact that LPS reduces Tim-3 surface expression 
(Ma et al., 2013; Moller-Hackbarth et al., 2013a), knowing that our results show LPS-induced 
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upregulation of galectin-9 levels and the results showed on the previous chapter demonstrated 
that Tim-3 production is not reduced by LPS but its surface presence is affected. This may be 
due an increase of intracellular galetin-9 levels leading to increase in galectin-9 secretion 
together with Tim-3. 
The shedding of the complex may be done by ADAM10/17 or other proteolytic enzymes. To 
support the shedding of Tim-3-galectin-9 complex there is evidence that HIV-1 infection leads 
to increase of soluble Tim-3 and galectin-9 in blood plasma (Clayton et al., 2015; Tandon et 
al., 2014) and also PMA upregulates galectin release in Jurkat T cells (Chabot et al., 2002b) 
and the Tim-3 expression/externalisation (Yoon et al., 2011) and proteolytic shedding (Moller-
Hackbarth et al., 2013a). The Matrix metalloproteinase inhibitor BB-94 was able to block the 
PMA-induced galectin-9 release in Jurkat T cells, suggesting that proteolysis is probably 
involved in shedding of Tim-3-galectin-9 complex.  
Our results also show that CLL bone marrow mononuclear cells secrete galectin-9 but have 
low amounts of Tim-3 (Figure 28A and B), suggesting that Tim-3 is a cell type-specific 
trafficker of galectin-9 in AML cells, while other types may use other galectin-9 specific 
proteins that can be externalised. To support this, there is evidence that galectin-9 may cause 
Tim-3 independent effects in lymphoid cells (Golden-Mason et al., 2013; Moritoki et al., 
2013). 
We were able to detect galectin-9and soluble Tim-3 in blood plasma from healthy donors. Also, 
anti-Tim-3 detection antibody originate a positive signal to visualise that product capture by 
anti-galetin-9 antibody, indicating that Tim-3-galectin-9 complex is present in human blood 




Altogether, the results presented in this chapter, indicate that galectin-9 secretion requires Tim-
3 in AML cells and this mechanism may be used to impair anticancer activities of cytotoxic T 
cells and NK cells, allowing malignant blood cells to escape immune attack (Figure 29). The 
decreased of effects like efficient glycolysis and VEGF production (Figure 25A). As shown on 
the previous chapter and previous work of our lab (Prokhorov et al., 2015), in myeloid cell 
lines and PHL, the activity of mTOR pathway is always lower than in primary AML cells. This 
may be due externalisation of the complex in AML cells (Figure 24). 
In this case, the amounts of galectin-9 levels inside that cells are lower, due to the 
externalisation of the Tim-3-galection-9 complex, which can initiate signalling events before 
further modification or proteolytic shedding (Figure 30). 
Tim-3 and galectin-9 seem to be able to be promising therapeutic targets for a possible cure for 
AML. Absence of the autocrine loop form by these two proteins and timely capture and 
inactivation of biological active galectin-9 may decrease the ability of AML cells to escape 
immune attack by impairing anticancer activities of NK and Cytotoxic T cells. This can lead 




Figure 30 Distribution of Tim-3-galectin-9 complex and its effects in healthy and 
malignant human leukocytes. A. intracellular signalling pathways induced by Tim-3-
galectin-9 complex B. Tim-3-galectin-9 complex distribution and its effects in PHL and 
human myeloid leukaemia cell lines (THP-1 and U937). C. Tim-3-galectin-9 complex 
distribution and its effects in primary human AML cells.
89 
 
4.3 Expression of functional neuronal receptor Latrophilin 1 in human 
acute myeloid leukaemia cells 
Recently, latrophilin-1 (LPHN1) was reported to be found in some malignant cells like non-
small cell lung cancer and is implicates in its invasive character (Hsu et al., 2009). LPHN1 is 
an adhesion G-protein-couple receptor that participates in the control of calcium signalling and 
exocytosis in vertebrate neurons and neuroendocrine cells (Silva and Ushkaryov, 2010) and is 
reported as absent from blood. This is the main brain receptor for latrotoxin. 
Latrotoxin is a black widow (Latrodectus sp) spider toxin, which stimulates LPHN responses 
and thus induces neuronal exocytosis in vertebrates (Silva and Ushkaryov, 2010) 
Knowing that exocytosis is an important process in myeloid cell haematopoiesis, especially 
when they undergo malignant transformation and energy resources are very limited, we decided 
to investigate if this receptor can be found in myeloid cells. 
4.3.1 LPHN1 expression and activity in human myeloid leukaemia cell lines 
In order to check the expression of LPHN1 in human myeloid cells, two different cell lines, 
U937 and THP-1, were used. Both cell lines were stimulated with LPS, LTX or a combination 
of both. 
By using Western-blot analysis it was possible to verify that both cell lines, THP-1 and U937, 
expressed LPHN1. The levels of LPHN1 expression significantly increased upon treatment 
with LPS but not with LTX. When a combination of LPS and LTX was used, the same results 





Figure 31 Expression and activity of LPHN1 in U937 cells. U937 cells were exposed to 1 
µg/ml LPS, 500 pM LTX or a combination of both. A. IL-6 release was measured by ELISA 
and LPHN1 proteins levels were analysed by Western-blot using mouse brain extract as 
positive control (PC); B. pS2448 mTOR was detected by ELISA and pT389 p70 S6K1 using 
Western-blot. Western-blot images show one experiment representative of six individual 
experiments, which gave similar results. Quantitative data are shown as means ± SEM; *p 




Figure 32 Expression and activity of LPHN1 in THP-1 cells. THP-1 cells were exposed 
to 1 µg/ml LPS, 500 pM LTX or a combination of both. A. IL-6 release was measured by 
ELISA and LPHN1 proteins levels were analysed by Western-blot using mouse brain 
extract as positive control; B. pS2448 mTOR was detected by ELISA and pT389 p70 S6K1 
using Western-blot. Western-blot images show one experiment representative of six 
individual experiments, which gave similar results. Quantitative data are shown as means 
± SEM; *p < 0.05; **p < 0.01; ***p < 0.01. 
Similar to what happened to the level of LPHN1 expression, LTX did not stimulated the release 
of IL-6 but LPS did. The combination of LTX and LPS increase the release of IL-6 to values 
two times higher than LPS alone (Figure 31A and Figure 32A). LPS, but not LTX, also 
activated the mTOR pathway, increasing the value of mTOR phosphorylation at the position 
S2448 and phosphorylation of its substrate p70 S6K1 at position T389 to values almost two 
times higher (Figure 31B and Figure 32B). 
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It is generally known that mTOR regulates many translational pathways, therefore, we 
hypothesised that this could be responsible for LPS-induced upregulation of LPHN1 
expression. To test this hypothesis, we did 1 h of pre-treatment with two mTOR inhibitors, 
rapamycin and AZD2014, before stimulation with LPS. We also tested different times of 
stimulation with LPS, concluding that the increase in the expression of LPHN1 was higher 
after 24 h of stimulation than after 4 h and that this effect is more pronounce in THP-1 than in 





Figure 33 Expression of LPHN1 in U937 and THP-1 cells depends on mTOR. 
LPHN1 expression was analysed using Western-blot; A. U937 treated with 1 
µg/ml LPS for 4 h with or without 1 h of pre-treatment with 10 µM rapamycin; 
B. THP-1 treated with 1 µg/ml LPS for 4 h with or without 1 h of pre-treatment 
with 10 µM rapamycin; C. U937 treated with 1 µg/ml LPS for 4 h with or without 
1 h of pre-treatment with 10 µM AZD2014; D. THP-1 treated with 1 µg/ml LPS 
for 4 h with or without 1 h of pre-treatment with 10 µM AZD2014. Western-blot 
images show one experiment representative of four individual experiments, 
which gave similar results. Quantitative data are shown as means ± SEM; *p < 
0.05; **p < 0.01; ***p < 0.01. 
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In both cell lines, both rapamycin and AZD2014 were able to fully blocked expression of 
LPHN1 (Figure 33) without affecting viability of the cells. This was verified by MTS cell 
viability test (data not shown). 
4.3.2 Functional LPHN1 is expressed in human primary AML cells, but not in 
healthy leukocytes 
After the obtained results in the AML cell lines, we proceed to test the expression of LPHN1 
in primary human AML cells. These cells were exposed to LPS, LTX or a combination of both 
for 24 h. Similar to what happened in the cell lines, LPS was able to upregulate mTOR 
activation, by increasing phosphorylation of mTOR at the position S2448. It also upregulated 
IL-6 release. On the other hand, LTX did not have any effect on both processes (Figure 34). 
Combination of LPS and LTX was able to increase mTOR activation and IL-6 release more 




Figure 34 Effects of LPS and LTX on IL-6 
exocytosis and mTOR activity in primary 
human AML cells. Cells were exposed to 1 
µg/ml LPS, 500 pM LTX or combination of both 
for 24 h. the release IL-6 and the mTOR 
phosphorylation at position S2448 was 
measured by ELISA. Data are the mean values 
±SEM (n=6), *p < 0.05; **p < 0.01. 
In order to check if LPHN1 expression levels in AML-PB001F cells are control through mTOR 
pathway, cells were exposed to 4 h of LPS, SCF or anti-Tim-3 antibody. All stimuli were able 
to upregulate mTOR activation, being SCF the strongest stimuli (Figure 35A). This is due to 
high expression of kit receptor by these cells, like it was previous mention. Similar to what 
happen to mTOR activation, the levels of LPHN1 expression were significantly increased by 




Figure 35 Primary human AML cells but not healthy primary human 
leukocytes express LPHN1. LPHN1 protein levels were analysed by 
Western-blot using mouse brain extract as positive control and pS2448 
mTOR was quantitated by ELISA. A. Primary AML-PB001F cells 
exposed for 4 h to 1 µg/ml LPS, 0.1 µg/ml SCF or 2 ug/ml anti-Tim-3; 
B. Healthy human primary leukocytes Primary AML-PB001F cells 
exposed for 4 or 24 h to 1 µg/ml LPS, 0.1 µg/ml SCF or 2 ug/ml anti-
Tim-3. Western-blot images show one experiment representative of four 
individual experiments, which gave similar results. Quantitative data 
are mean values ±SEM (n=4) *p < 0.05; **p < 0.01. 
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The same stimuli were tested in primary healthy leukocytes. After 4 h of incubation, no LPHN1 
was detectable. Even increasing the stimuli time for 24 h it was not possible to detect LPHN1 
expression (Figure 35B). These results showed the regulation of LPHN1 expression in human 
AML cells, but not in healthy primary human leukocytes.  
4.3.3 Discussion 
The results obtained, show that human AML cell lines (U937 and THP-1) express detectable 
amounts of functional LPHN1 protein, being its expression dependent on the mTOR pathway. 
LTX, a specific LPHN1 agonist (White et al., 1998), increased LPS-induced exocytosis of IL-
6 in both cell lines. The production of IL-6 depends in mTOR (Schreml et al., 2007), but in 
this case that activity of mTOR was not upregulated by LTX.  
Since it is known that the wild type of LTX used in this experiments forms Ca2+-permeable 
pores in the cell membrane expressing toxin receptors (Volynski et al., 2003), these pores may 
induce LPHN1-independent exocytosis. But LTX on inserts itself into the membrane after 
binding the receptor and this will stimulate LPHN1, leading to exocytosis (Volynski et al., 
2003; Capogna et al., 2003). Our results showed that LTX only stimulates exocytosis in 
LPHN1-expressing cells (Figure 31, Figure 32 and Figure 34). A mutant LTXN4C, that does not 
form pores, was tested and it induced similar results regarding exocytosis of IL-6 in cell lines, 
confirming that LPHN1 has an active role in its secretion. 
Interestingly, when U937 and THP-1 cells were pre-treated with mTOR inhibitors before 
stimulation by LPS, the expression of LPHN1 was totally abolished (Figure 33). This suggests 
that LPHN1 expression is fully dependent in the mTOR pathway (Figure 31B and Figure 32B), 
that is further regulated by LPS. Extra activation of mTOR brings a substantial increase in the 
amount of expresses LPHN1.  
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Since it is known that cell lines and primary cells differ in terms of biological activities and 
protein expression, we checked if the observations made in cell lines can be seen in primary 
cells. The results obtained did not differ from the previous ones regarding detectable LPHN1 
expression and its regulation in response to mTOR stimuli (LPS, SCF and anti-Tim-3). 
As previous seen the stimulation with LTX lead to high increase in the release of LPS-induced 
IL-6. On the other hand, unlike cell lines, LTX upregulates LPS-induce mTOR-activating 
phosphorylation in primary AML cells. This is probably due to low expression of TLR4, LPS 
receptor, in primary AML cells as reported by the supplier. In this case, only some mTOR will 
be activated by LPS while majority will remain phosphorylated creating the possibility of 
phosphorylation through LPHN1-induced signalling. In cell lines where TLR4 expression 
levels are higher, probably there is not a sufficient scope for further mTOR activation by LTX. 
This implies a functional integration of LPHN1 into the AML signalling machinery (Akira and 




Figure 36 Functional integration of LPHN1 into AML cell signalling machinery. LPHN1 
transcription and translation is induced in AML cells. LPS upregulates LPHN1 transcription 
and triggers TLR4-mediated activation of the mTOR pathway, which increases translation of 
LPHN1 and IL-6. In addition, both LPS (through TLR4 and Btk) and LTX (through LPHN1 
and Gq) activate PLC, which produces IP3, leading to release of Ca
2+ from the ER. Increased 
cytosolic Ca2+ triggers exocytosis of IL-6. Abbreviations: Btk, Bruton’s tyrosine kinase; MD, 
myeloid differentiation factor 88; TAP, Toll-like receptor intracellular TIR domain-associated 
protein; PI-3K, phosphatidylinositol 3-kinase; PDK, phosphatidylinositol-3-phosphate-
dependent kinase; IP3, inositol trisphosphate; PLC, phospholipase C; Gq, Gαq subunit of a 
heterotrimeric G protein; TSC1/TSC2, tuberous sclerosis proteins 1 and 2; eIF4E, eukaryotic 
translation initiation factor 4E; p70S6K1, mTOR-dependent S6 kinase 1; ER, endoplasmic 






We also used PHL and observed that these cells do not express ay LPHN1, even after stimuli 
that showed positive effects in AML cells (LPS, SCF and anti-Tim-3). This shows that 
expression of functional LPHN1 is specific in leukaemia cells. 
LPHN1 is important to the survival of malignant leukocytes and also for the release of growth 
factors and cytokines like VEGF and IL-6. This requires efficient exocytotic machinery and 
means of controlling and stimulating exocytosis. According to this results LPHN1 can be 
consider a new biomarker for AML diagnosis, since contrarily to what happens to most existing 
leukaemia biomarkers, it is only expressed by malignant cells. It could also be explored as new 
target for anti-leukaemia therapy and drug delivery. 
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4.4 A fundamental molecular pathway controlling immune escape of 
human acute leukaemia cells 
4.4.1 Tim-3 and Tim-3-galectin-9 complex are differentially shed from the cell 
surface 
It was previously showed that Tim-3 and maybe the complex Tim-3-galectin-9 are shed from 
cell surface (Moller-Hackbarth et al., 2013a; Chabot et al., 2002b). Also, we previously 
demonstrated, in this work, that this complex is present in human blood plasma. 
We investigated medium used to culture THP-1 cells  with or without 16 h of exposure to 100 
nM of PMA, that is known to activated proteolytic shedding of Tim-3 (Moller-Hackbarth et 
al., 2013b), and we immunoprecipitated Tim-3 (as described in Methods and Materials, section 
3.7.3). When the galectin-9 specific antibody was used, we detected a band around 32 kDa, a 
specific galectin-9 band (this is the molecular weight of galectin-9) and another band was 





Figure 37 Free galectin-9-bound Tim-3 is shed differentially from the cell surface. THP-1 cells were pre-treated with 100 mM PMA for 16 h 
and, after medium exchange, they were exposed to GI254023X (ADAM10/17 inhibitor) and BB-94 (matrix metalloproteinase inhibitor) for 4h. 
A. Western-blot characterisation of galectin-9 and Tim-3 variants (20 kDa fragment (Tim-3 (fr)) and 33 kDa (soluble Tim-3)) was done using 
medium from the 4 h of inhibitor treatment. B. Detection of galectin-9, soluble Tim-3 and Tim-3-galectin-9 complex. Images are from one 
experiment representative of six which gave similar results. Quantitative data are mean values ±SEM (n=6) *p < 0.05; **p < 0.01 vs. control. 
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When the anti-Tim-3 antibody was used we detected a specific band at 33 kDa (molecular 
weight of soluble Tim-3) and other at 20 kDa, that probably corresponds to a Tim-3 fragment 
shed together with galectin-9 and it was released from the complex during Western-blot 
procedure and probably is shed at a different cleaved site. With this antibody, a band at 52 kDa 
was also detected. Since the band at 52 kDa is detectable with both antibodies (Tim-3 and 
galectin-9 antibody), this probably corresponds to the Tim-3-galectin-9 complex (Figure 37A). 
It was reported the Tim-3 may be shed from the cell surface by a disintegrin and 
metalloproteinase domain-containing proteins (ADAM) 10/17 (Moller-Hackbarth et al., 
2013a). So, we decided to investigate if this is associated with release of free Tim-3 and/or 
Tim-3-galectin-9 complex. 
THP-1 cells were exposed to 100 nM PMA, protein expression inductor, for 16 h, after which 
the medium was replaced with medium containing 100 µM GI254023X (ADAM 10 and 17 
inhibitor) or 100 µM BB-94, a matrix metalloproteinase inhibitor and incubated for 4 h. Tim-
3 and galectin-9 level in the medium were measure by ELISA and soluble Tim-3-galectin-9 
complex was capture with a single chain anti-Tim-3 antibody and detected using a biotinylated 
anti-gelctin-9 antibody. 
The release of Tim-3, galectin-9 and Tim-3-galectin-9 complex was significantly upregulated 
by PMA (Figure 37B). GI254023X and BB-94 reduced soluble Tim-3 release but had no effect 
in the release of galectin-9 and Tim-3-galectin-9 complex. This indicates that the shedding of 




The lysates from the above described treatment were also analyse by Western-blot. From these 
results, it is possible to see that despite the increased level of soluble Tim-3, galectin-9 and 
Tim-3-galectin-9 complex release upon treatment with PMA, the levels of respective cell-





Figure 38 Tim-3, galectin-9 
and complex Tim-3-galectin-
9’s production and/or release 
is activated by PMA. THP-1 
cells were treated with PMA 
for 16 h. Levels of Galectin-9 
and Tim-3 were analysed by 
Western-blot and ELISA, 
levels of complex Tim-3-
galectin-9 release by ELISA. 
The top bar diagram shows 
comparative analysis (express 
in % of control) of galectin-9 
and complex Tim-3-galectin-9 
levels release by PMA-treated 
and non-treated THP-1 cells. 
Images are from one 
experiment representative of 
three which gave similar 
results. Quantitative data are 
mean values ±SEM (n=3) *p 
< 0.05; **p < 0.01; ***p < 




A band arround 70 kDa was detectable by both anti-Tim-3 and anti-galectin-9 antibodies in all 
the assays (Figure 38). 70 kDa corresponds to the sum of the molecular weight of uncleaved 
Tim-3 and galectin-9, as stated in 4.2.1, and it indicated that a comples between full Tim-3 and 
galectin-9 is firtst formed, then it undergoes sheding and a soluble form of the complex (with 
molecular weight of 52 kDa) is released (Figure 38). 
These results suggest that PMA induces productions an axocytosis of Tim-3-galectin-9 
complex and that the complex and soluble Tim-3 underfo different proteolity sheding. These 
observations were confirm by co-localisation assays using confocal microscopy (Figure 39). 
 
Figure 39 Co-localisation of Tim-3 and galectin-9 in PMA-activated THP-1 cells. Co-
localisation of Tim-3 and galectin 9 was analysed in THP-1 following 24 h of exposure to 
100nM PMA using confocal microscopy. Images are from one experiment representative 
of six which gave similar results. 
The cells for co-localisation were prepared as described in materials and methods. Non 
permeabilised and methanol-permeabilised THP-1 human AML cells were analysed. Both 
galectin-9 and Tim-3 were present on the cell surface and in permeabilised cells there was clear 
evidence of co-localisation of both proteins. In non-permeabilised cells there is sectors full of 
Tim-3 or galectin-9 and no substantial co-localisation (Figure 39). 
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Since galectin-9 is soluble, it can only remain on the cell surface it is bound to its receptor, 
Tim-3. In non-permeabilised cells, no Tim-3 in galectin-9 sectors was detected. This can be 
explained, since its extracellular part is probably occupied by gal-9 and thus does not react with 
the antibodies (Figure 39). This indicates that Tim-3 is externalised on its own or acts as a 
trafficker for galectin-9, that does not have the signal domain required for secretion it requires 
a trafficker. 
To confirm these findings, we analysed blood plasma samples from 98 AML patients and from 
12 healthy donors. The levels of galectin-9 and Tim-3 were measure by ELISA and the obtained 
values were significantly increased in AML patients (Figure 40A, B, E and F). 
 




Figure 40 Levels of galectin-9 and soluble Tim-3 are highly increased in blood plasma of AML patients. A., B., E. and F. Levels of galectin-9 
and Tim-3 in blood obtained from healthy donors and AML patients, measured by ELISA. C. and G. Levels of Tim-3-galectin-9 complex in blood 
plasma of five randomly picked from healthy donors and AML patients measured by ELISA. D. Tim-3 and galectin-9 characterised by Western-blot 
in five randomly picked AML patients. H. and I. Correlation between Tim-3 and galectin-9. J. and K. Correlation between galectin-9 and Tim-3-
galectin-9 complex. Images are from one experiment representative of five which gave similar results. Quantitative data are mean values ±SEM 
(n=3) *p < 0.05; **p < 0.01; ***p < 0.001 vs. control. 
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From the studied groups of samples, we randomly selected five samples from AML patients 
and five from healthy donors and measured levels of Tim-3-galectin-9 complex by ELISA. As 
expected, the levels of Tim-3-galectin-9 complex in AML patients was increased, interestingly 
this increase was similar to the one observed in galectin-9 levels (Figure 40C and G). 
Five blood plasma samples of AML patients were analysed by Western-blot to check levels of 
Tim-3 and galectin-9 (Figure 40D). Both soluble Tim-3 and galectin-9 were detected and also 
a band around 52 kDa (probably representing the soluble form of Tim-3-galectin-9 complex) 
was detectable by both anti-Tim-3 and anti-galectin-9 antibodies. A Tim-3 specific band was 
also detected around 20 kDa (Figure 40D). These results match the ones obtained in THP-1 
cells, confirming that soluble Tim-3 and Tim-3-galectin-9 complex are probably shed from 
plasma membranes of AML cells in a different way. 
These results show a clear evidence of a correlation between Tim-3 and galectin-9 level in the 
plasma of both healthy donors and AML patients and these correlation levels were very similar 
to each other (Figure 40H and I) suggesting a co-release of both proteins in these groups. 
The biophysical properties of Tim-3, galectin-9 and Tim-3-galectin-9 complex were studied 
using synchrotron radiation circular dichroism (SRCD) spectroscopy at Diamond Light Source 
(Figure 15, pp58). In Figure 41A, is a schematic representation of the structural organisation 




Figure 41 Interaction of Tim-3 with galectin-9 leads to major conformational changes 
increasing solubility of the protein complex. A. The schematic structural models of Tim-
3 extracellular domain (on the right) and galectin-9 (on the left). In Tim-3 structure, 
residues involved in galectin-9-independent binding are highlighted in green. Residues, 
which are potential targets for glycosylation, are highlighted in red. In galectin-9, sugar 
is located close to a sugar binding site that is shown in green. B. the SRCD spectroscopy 
of Tim-3, galectin-9 and Tim-3-galectin-9 interaction (both simulated and real curves are 
presented). 
Galectin-9 interacts with non-glycosylated Tim-3 with nanomolar affinity (Kd=2.8x108 M); 
the binding can be further strengthened by interaction of galectin-9 with glycosylated Tim-3 
(Prokhorov et al., 2015). Since the complex is detectable by Western-blot, that means that 
interaction between a lectin and a sugar is taking place. 
SRCD spectroscopy was also done on galectin-9 and Tim-3 mixed at a molar ratio 1:1 (Figure 
41B). In this mixture galectin-9 showed a CD spectrum significantly different from the 
simulated one. This indicates that the interaction of galectin-9 with Tim-3 causes significant 
conformational change of the proteins with a clear increase in β-strand component. This means 
that Tim-3 binding may change galectin-9 conformation, resulting in increased ability to 
interact with receptors in target cells. Since galectin-9 is a tandem protein with two sugar 
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binding domains, one may bind Tim-3 and the other may stay open for interactions with a 
receptor molecule associated with the plasma membrane of a target cell.    
4.4.2 Latrophilin 1, PKC and mTOR-dependent translation play a crucial role in 
Tim-3 and galectin-9 production and secretion 
We exposed THP-1 cells to 100 mM PMA or 250 pM LTX for 16 h, and the lysates were 
analysed by Western-blot. Both stimuli, PMA and LTX, downregulated the levels of 
intracellular Tim-3 and galectin-9, but not on a significant way. In the meanwhile, they 
significantly increase the level of mTOR phosphorylation at the position S2448, as measure by 









Figure 42 LPHN1, PKCα and mTOR pathways are involved in Tim-3 and galectin-9 production and secretion in AML cells. THP-1 cells were treated 
with 100 nM PMA or 250 pM LTX with or without pre-treatment for 1 h Gö6983 (PKCα inhibitor) or AZD2014 (mTOR inhibitor). A., B. and C. Levels of 
Tim-3 and galectin-9 analysed by Western-blot. D. Levels of Tim-3 and galectin-9 analysed by ELISA. Images are from one experiment representative of 
three which gave similar results. Quantitative data are mean values ±SEM (n=3) *p < 0.05; **p < 0.01; ***p < 0.001 vs. control; ap < 0.05; aap < 0.01; aaap 
< 0.001 vs. control and bp < 0.05; bbp < 0.01; bbbp < 0.001 vs. control. 
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When the cells were pre-treated with 70 mM Gö6983 (PKCα inhibitor), prior to treatment with 
PMA or LTX, there was attenuation of the stimulus-induced mTOR phosphorylation and 
downregulation of intracellular levels of Tim-3 and galectin-9. When Gö6983 was used 
without subsequent stimuli, the levels of mTOR phosphorylation and levels of Tim-3 and 
galectin-9 intracellular were the same as the control (Figure 42A and B). 
The levels of release of soluble Tim-3 and galectin -9 were then analysed by ELISA. PMA and 
LTX promote release of soluble Tim-3 and galectin-9, but this was attenuated to basic levels 
by Gö6983. These results suggest that basic release of soluble Tim-3 and galectin-9 does not 
depend on PKCα and both PMA and LTX induce production of Tim-3 and galectin in THP-1 
cells. (Figure 42D). 
We also tested the inhibitor AZD2014 (mTOR inhibitor). THP-1 cells were pre-treated with 10 
µM AZD2014 before exposure to PMA or LTX. This resulted in a reduction of levels of 
intracellular Tim-3 and galectin-9 and in the levels of release of the same proteins (Figure 42C 
and D). These results show that PMA and LTX-induced translation of Tim-3 and galectin-9 
depends on the mTOR pathway.  
To confirm the physiological role of LPHN1 in galectin-9 and Tim-3 release, we exposed THP-
1 cells to FLRT-3 (a physiological LPHN1 ligand (Boucard et al., 2014).  10 nM FLRT-3 
induced a significant upregulation of galectin-9 and soluble Tim-3 release (Figure 43A) and 




Figure 43 FLRT-3, a physiological ligand of LPHN1, induces galectin-9 and Tim-3 secretion. A. THP-1 cells were exposed for 16 h to 10 nM 
human recombinant FLRT-3 followed by measurement of released Tim-3 and galectin-9 by ELISA. B. THP-1 cells were exposed to mouse bone 
marrow (mBM) extracts for 16 h with or without 1 h pre-treatment with 5 µg/ml anti-FLRT3 antibody. The presence of FLRT-3 in mBM extracts was 
confirmed by Western blot analysis. Secreted Tim-3 and galectin-9 were measured by ELISA. C. RCC-FG1 cells (FLRT-3 expression was confirmed 
by Western blot) were co-cultured with THP-1 cells at a ratio of 1 THP-1: 2 RCC-FG1 with or without 1 h pre-treatment with 5 µg/ml FLRT-3 
neutralising antibody. Secreted galectin-9 and Tim-3 were measured by ELISA. Images are from one experiment representative of three which gave 
similar results. Quantitative data depict mean values ± SEM of three independent experiments; *p < 0.05; **p < 0.01; ***p < 0.001 vs. control. 





Figure 44 Activity of PKCα in THP-1 human AML cells. A. Activity 
of PKCα in resting THP-1 cells and THP-1 cells exposed for 16 h to 
100 nM PMA, 250 pM LTX and 10 nM FLRT-3. B. Activity of PKCα 
analysed in resting THP-1 cells and those co-cultured with RCC-FG1 
cells (ratio 1:2) in absence or presence of 5 µg/ml FLRT-3 neutralising 
antibody. Images are from one experiment representative of three 
which gave similar results. Quantitative data are the mean values ± 
SEM of three independent experiments; *p < 0.05; **p < 0.01 vs. 
control. Symbol “bb” means p<0.01 vs. THP-1/RCC-FG1 co-culture. 
To check if this is physiologically relevant, THP-1 cells were exposed 16 h to mouse bone 
marrow (mBM) extracts (10 µg protein/ml, which contains FLRT-3, Figure 43B). These 
treatments were done with or without 1 h of pre-treatment with 5 µg/ml FLRT-3 neutralising 
mouse antibody. FLRT-3 neutralising mouse ab reduced the effects of mBM extracts but did 
not attenuate them (Figure 43B). This means that bone marrow contains several activators of 
galectin-9 secretion in AML cells. 
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THP-1 cells were then co-cultured with RCC-FG1 renal carcinoma cells, highly adherent cells 
that express high levels of FLRT-3 and release almost undetectable amounts of galectin-9, in a 
ratio of 1:2 (Figure 43C). The cells were kept together for 16 h in the absence or presence of 5 
µg/ml FLTR-3 neutralising antibody and secretion of galectin-9 and soluble Tim-3 were 
analysed by ELISA. Presence of RCC-FG1 significantly upregulated PKCα activity, which 
was attenuated by neutralisation of FLRT-3 (Figure 44B). These results suggest that FLRT-3 
(natural ligand of LPHN1) stimulates the release of galectin-9 and soluble Tim-3 from AML 
cells.  
4.4.3 Galectin-9 and soluble Tim-3 attenuate AML cell killing activity of NK cells 
Recently, some results seem to show that galectin-9 (soluble or cell surface associated) is able 
to interact with tim-3 (or maybe other receptors) on cytotoxic lymphoid cells, including NK 
cell and cytotoxic T cells (Gleason et al., 2012). Given our previous results and this 
information, we decided to test if Tim-3-galectin-9 interaction is involved in the creation of 
immunological synapses between target cells and human mast cell sarcoma cells. 
LAD2 cells express both Tim-3 and galectin-9, being both mostly on the cell surface as detected 
by in cell assay and in cell western (Figure 45A). Resting LAD2 cells do not release detectable 
amounts of galectin-9 and stimulation with IgE increased the release of galectin-9 but did not 




Figure 45 LAD2 cells express and externalise Tim-3 and galectin-9. A. Surface-based 
and total Tim-3 and galectin-9 in LAD2 human mast cell sarcoma cells measured by ICA 
and ICW. B. Protein levels of Tim-3 and galectin-9 were measured in resting and IgE-
sensitised LAD2 cells by Western blot. Galectin-9 release was characterised using ELISA. 
Images are from one experiment representative of three which gave similar results. 
Quantitative data show mean values ± SEM of three independent experiments; ***p < 







NK cells isolated from buffy coats of human blood were immobilised in ELISA plates. By 
Western-blot we verified that these cells express Tim-3 with different glycosylation variants 
but not detectable galectin-9 (Figure 46). 
 
Figure 46 Expression of Tim-3 and galectin-9 in primary human NK cells. Expressions of 
both proteins were analysed in whole cell extracts by Western-blot. Human recombinant 
galectin-9 was used as a positive control. Images are from one experiment representative (two 
donors in each) of three which gave similar results. 
We applied IgE-sensitised LAD2 cells (Sumbayev et al., 2012) to the NK cells at a ratio of 1:1, 
with or without 15 min of pre-incubation with galectin-9neutralising antibody or with isotype 
control antibody to rule out the IgG effect. LAD2 cells were flagged using mouse IgM anti-
IgE. The results showed that LAD2 cells bind to NK cells and presence of galectin-9 
neutralising antibody decreased this effect (Figure 47). These results confirm that galectin-9 




Figure 47 Galectin-9 participates in the formation of an “immunological synapse” between 
NK cells and LAD2 cells. Primary human NK cells were immobilised on the surface of 
MaxiSorp plates and then co-incubated for 30 min with LAD2 cells with or without 30 min pre-
treatment of LAD2 cells with 5 µg/ml galectin-9 neutralising antibody (or the same amount of 
isotype control antibody). LAD2 cells were then visualised by ICA. Images are from one 
experiment representative of five which gave similar results. Quantitative data represent mean 
values ± SEM of five independent experiments; *p < 0.05; **p < 0.01. 
We then used K562 chronic myeloid leukaemia cells which do not release detectable amounts 
of galectin-9 (previously confirm by ELISA). These cells were exposed to PMA for 24 h in 
maxisorp plates. The medium was replaced with fresh medium containing isolated primary 
human NK cells at a ratio 1:2 (1 K562 cell for 2 NK cells) in presence or absence of 5 ng/ml 
human recombinant galectin-9. Cells were co-cultured for 16 h and their viability was tested 
by MTS assay. The presence of NK cells significantly reduced the viability of K562 cells but 
presence of galectin-9 attenuated this effect (Figure 48A). During this experiment, the viability 




Figure 48 Galectin-9 protects myeloid leukaemia K562 cells from being killed by primary 
human NK cells. A. K562 cells co-cultured 16 h with primary human NK cells at a 1:2 ratio, 
in the absence or presence of 5 ng/ml galectin-9. Viability of K562 and NK cells was measured 
using MTS test. Images are from one experiment representative of three which gave similar 
results. Quantitative data represent mean values ± SEM (n=3) independent experiments; ***p 
< 0.001 vs. control. B. K562 cells co-cultured 16 h with primary human NK cells, at a 1:2 
ratio, in presence of different concentrations of galectin-9 (0 – 5 ng/ml). Cells were imaged 
using phase-contrast microscopy. The images are from one representative experiment of six (n 
= 6), which gave similar results. Scale bar (the same for all images), 50 μm. C. NK cells-
induced aggregation of K562 cells was quantified as a function of galectin-9 concentration. 
Left, the per cent of cells found in aggregates in individual cultures and in the co-culture. Right, 
the size of cell aggregates in individual cultures and in the co-culture. The data represent the 
mean values ± SD of six independent experiments; *, p < 0.05; **, p < 0.01; ****, p < 0.0001. 
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Not only the cytotoxic attack by NK cells led to a reduction on K562 viability but also it led to 
change in the behaviour of these cells causing their massive aggregation, to determine the effect 
of galectin-9 on K562 cell aggregation in individual or combined K562 and NK cells cultures, 
we used a phase contrast microscopy. 
When there was no galectin-9 present, there was K562 cells aggregation in the presence of NK 
cells, but when we started increasing the dose of galectin-9 there was a decrease in the K562 
cells aggregation by NK cells, in a dose dependent way. When 5 ng/ml galectin-9 were reached 
no aggregation was detected (Figure 48B and C). This shows that galectin-9 protects myeloid 
cells from being killed by NK cells. Galectin-9 on its own had no visible effects in both cell 
types. 
We investigated the interactions between AML THP-1 cells and primary human NK cells. 
These cells were exposed to 100 nM PMA for 16 h and medium was replaced with fresh one 
containing NK cells at a ratio of 2:1 (2 THP-1 cells to 1 NK cell) And it incubated for 6 h, with 
or without 5 µg/ml galectin-9 neutralising antibody. We then measure Tim-3-galectin-9 
complex and galectin-9 in NK cells by Western-blot analysis and viability of THP-1 cells, 
activity of granzyme B and caspase-3 and galectin-9 release were monitored. THP-1 viability 
was reduced when galectin-9 was neutralised (Figure 49A). This is in line with the observed 





Figure 49 Cell-derived galectin-9 attenuates AML cell killing activity of primary human NK 
cells. THP-1 cells were co-incubated with primary human NK cells at 1:2 ratio for 6 h. A. 
Detection of THP-1 cell viability by MTS test; measurement of activities of granzyme B and 
caspase 3 in THP-1 cell lysates and released galectin-9. B. Levels of galectin-9 from NK cells 
measured by Western-blot. Images are from one experiment representative of three which gave 
similar results. Quantitative data show mean values ± SEM of three independent experiments; 
*p < 0.05; **p < 0.01; ***p < 0.001 vs control. 
Resting NK cells did not produce detectable amounts of galectin-9, but it was possible to detect 
galectin-9 and unbroken Tim-3-galectin-9 complex in NK cells co-cultured. The amount of 
both proteins was reduced when galectin-9 neutralising antibody was used (Figure 49B). These 
results suggest that THP-1 cells were the source of galectin-9 that probably bound Tim-3 in the 
surface of NK cells, preventing the delivery of NK cell-derived granzyme B into THP-1 cells, 
resulting in prevention of the caspase-3-dependent apoptotic pathway. 
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 Previously it was reported that there is a possible reciprocal link between levels of soluble 
Tim-3 and IL-2, a cytokine that activates NK and T cells cytotoxic activity (Geng et al., 2006). 
As we previous showed, Tim-3 levels in plasma of healthy donors are significantly lower than 
AML patients (Figure 40), while IL-2 levels were much higher (Figure 50A and B). We 
exposed Jurkat T cells (that produce detectable amounts of IL-2) were exposed to increasing 
concentrations of Tim-3 for 24 h. It is possible to see a clear soluble Tim-3 concentration-
dependent and eventually reduction of IL-2 release from Jurkat T cells (Figure 50C). 
 
Figure 50 Soluble Tim-3 attenuates IL-2 release. A. and B. IL-2 levels measured by ELISA 
in blood serum of healthy donors and AML patients. C. Jurkat T cells were exposed to the 
increasing concentrations of Tim-3 for 24 h and detection of secreted IL-2 was done by ELISA. 
Data show mean values ± SEM of three independent experiments; *p < 0.05; **p < 0.01. 
These results show that Tim-3 is able to bind a target protein and reduce the IL-2 production, 
preventing induction of anti-cancer activity of NK cells and T lymphocytes. All together these 
results show that there is a pathobiochemical pathway in AML cells. It is related with PKCα 
activation by LPHN1 leading to expression and exocytosis of soluble Tim-3 and galectin-9, 





4.4.4 Discussion  
As previously mentioned, Tim-3 is shed by ADAM 10/17 proteolytic enzymes, producing 
soluble Tim-3. Our results showed that this protein can be shed in two different forms, in its 
free from and complexed with galectin-9. We can see a band at 20 kDa corresponding to a 
fragment when Tim-3 is in the complex and a band at 33 kDa when there is soluble Tim-3. 
The analysis of the complex Tim-3-galectin-9 by Synchrotron radiation circular dichroism 
(SRCD) suggests that the interaction between Tim-3 and galectin-9 to interact with target 
proteins. Galectin-9 is a tandem protein that contains two identical covalently fused elements 
(Delacour et al., 2009). One side of this protein may interact with Tim-3, while the other may 
bind a receptor molecule, like Tim-3, in the membrane from the target cell. That explains the 
high efficiency of galectin-9 in triggering Tim-3 on NK cells that do not express galectin-9. 
Because it is possible to see Tim-3/galectin-9 complex on the image of the Western-blot in 
Figure 37, Figure 38 and Figure 40 it is possible that the biding between this proteins is 
strengthened by the interaction of galectin-9 with Tim-3-associated glycosides, 
Previously, it was reported that the release of both Tim-3 and galectin-9 depends on PKCα and 
proteolysis (Chabot et al., 2002b), our results were able to confirm this. PMA treatment was 
able to induce PKCα activation, that then activated exocytosis of Tim-3 and galectin-9, and 
their mTOR-dependent production, in THP-1 AML cells (Figure 42). 
Our results, show evidence of co-localisation of Tim-3 and galectin-9 in these cells after PMA 
exposure (Figure 39). Also, soluble Tim-3 was shown to significantly downregulate IL-2 
production, a cytokine required for activation of NK cells and cytotoxic T lymphocytes. 
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Natural and exogenous LPHN1 ligands activated the PKCα pathway and induced both mTOR-
dependent translation of Tim-3-galectin-9 complex and their exocytosis. PKCα provokes 
agglomeration of SNARE complex, that is responsible for exocytosis (Stöckli et al., 2011; 
Morgan et al., 2005). Constitutively active PKCα in malignant primary AML cells correlates 
with poor prognosis and high mortality rate of patients (Kurinna et al., 2006). 
When THP-1 cells were exposed to mouse bone marrow extracts, there was a high mortality 
and an increase in the galectin-9 release levels. When we used FLRT-3 neutralising antibody 
there was a significant decrease of FLRT-3 induced PKCα-dependent galectin-9 release, this 
means that galectin-9 and Tim-3 are synthetized and exocytosis by AML cells in a 
PKCα/mTOR-dependent manner, using available plasma membrane-associated PKCα 
activating receptors, like LPHN1, to induce the whole pathway. 
Galectin-9 prevents the delivery of granzyme B into AML cells, in a perforin and mannose-6-
phosphate receptor-dependent process (Figure 51). Inside the cells granzyme B cleaves protein 
Bid in to tBid, inducing mitochondrial dysfunction and cytochrome c release and activates 
caspase 3. The proteolytic activation of caspase 3 in addition to the classic pathway may be 
directly catalysed by granzyme B (Lee et al., 2014). This concept is confirmed by our results 




Figure 51 Probable biochemical interactions between AML and NK cells. LPHN1/Tim-
3/galectin-9 pathway leads to externalisation/release of galectin-9, which binds NK cell 
receptor, probably Tim-3. In response, NK cells release IFN-γ which triggers activation of 
IDO1 in AML cells. IDO1 converts tryptophan (Trp) into formyl-kynurenine (FKU), which is 
further degraded into L-kynurenine (KU). KU is released and is capable of attenuating the 
ability of NK cells to deliver granzyme B into AML cells in perforin/mannose-6-phosphate 
receptor (MPR)-dependent manner. If successfully delivered, granzyme B catalyse Bid 
cleavage leading to cytochrome c release from mitochondria. This leads to formation of 
apoptosome and activation of caspase-3. Furthermore, granzyme B is capable of performing 
direct proteolytic activation of caspase-3. These effects lead to AML cell apoptosis. However, 
this process is not taking place due to galectin-9-induced impairing of NK cell activity as 
previously described. 
It was reported that galectin-9 induces IFN-γ release from NK cells (Gleason et al., 2012), this 
interacts with AML cells and induced activity of indoleamine 2,3-dioxygenase (IDO1). IDO1 
converts L-kynurenine and it is released (Corm et al., 2009; Folgiero et al., 2015; Mabuchi et 
al., 2016). L-kynurenine affects the ability of NK cells to kill AML cells. Our experiments 
confirmed this (Figure 51). 
127 
 
Our results show a fundamentally new pathway that leads to production and release of soluble 
Tim-3 and galectin-9, that prevents activation of NK cells, preventing them to kill malignant 
cells (Figure 52).  
 
Figure 52 AML cell-based pathobiochemical pathway showing LPHN1-induced classic 
activation of PKCα, which trigger translation of Tim-3 and galectin-9 as well as their 
secretion required for immune escape.  FLRT-3 (endothelial cell (EC)-based) – LPHN1 
interaction leads to activation of PKCα through classic Gq/PLC/Ca2+ pathway. Ca2+ is 
mobilised by inositol-3-phospate (IP3) released after PLC-dependent PIP2 degradation. IP3 
interacts with ER-associated IP3 receptor (IP3R) leading to Ca2+ mobilisation. PKCα 
activates mTOR translational pathway through downregulation of TSC1/TSC2. mTOR controls 
translation of Tim-3 and galectin-9. PKCα also phosphorylates Munc18 exocytosis protein 
which provokes agglomeration of SNARE complex. This leads to exocytosis of free and 
galectin-9-complexed Tim-3. Both types of Tim-3 are differentially shed from the cell surface 
by proteolytic enzymes. Soluble Tim-3 prevents IL-2 secretion required for activation of NK 





The following conclusions can be made from this work: 
1. Tim-3 and Galectin-9 are highly expressed and externalised in primary human AML 
cells unlike healthy leukocytes, where the expression levels are lower and both proteins 
are mostly located inside the cell. When externalised, Tim-3/Galectin-9 complex 
triggers the mTOR translational pathway thus contributing to cell growth and 
proliferation. 
2. Tim-3 acts as a trafficker in Galectin-9 secretion in human AML cells. 
3. AML cell lines and primary human AML cells express functional neuronal receptor 
LPHN1. Its translation is controlled by the mTOR pathway. LPHN1 is involved in 
induction of Tim-3 and Galectin-9 secretion in human AML cells. It requires 
stimulation with its ligand, for example, FLRT3 to upregulate exocytosis. 
4. Classic Gαq/PLC/PKC pathway is triggering LPHN1-induced exocytosis of Tim-3 and 
Galectin-9, while translation of both proteins is controlled by the mTOR pathway. 
5. Galectin-9 impairs anti-leukaemia activity of primary human NK cells. 
6. Taken together, our PhD programme resulted in a discovery of a fundamental 
biochemical mechanism, which includes ligand-dependent activation of ectopically 
expressed LPHN1 leading to increased translation and exocytosis of the immune 
receptor Tim-3 and its ligand Galectin-9. Physiological relevance of these results was 
validated in ex vivo experiments using primary samples from AML patients. This 
pathway provides reliable targets for both highly specific diagnosis and immune 
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7.1 Electrophoresis solutions 
7.1.1 Resolution gel 
Table 5 Preparation of SDS-polyacrylamide resolution gels. 
 7.5% 10% 12% 
H2O 5.525 ml 4.9 ml 4.4 ml 
1.5 M Tris-HCl (pH 8.8) 2.5 ml 2.5 ml 2.5 ml 
40% Acrylamide/Bis-acrylamide 1.875 ml 2.5 ml 3.0 ml 
10% (w/v) SDS 100 µl 100 µl 100 µl 
10% (w/v) APS 125 µl 125 µl 125 µl 
TEMED 25 µl 25 µl 25 µl 
 
7.1.2 Stacking Gel 
Table 6 Preparation of SDS-polyacrylamide 
stacking gels. 
 4% 
H2O 3.2 ml 
0.5 M Tris-HCl (pH 6.8) 1.25 ml 
40% Acrylamide/Bis-acrylamide 0.5 ml 
10% (w/v) SDS 50 µl 
10% (w/v) APS 100 µl 
TEMED 20 µl 
 
7.1.3 1.5 M Tris-HCL pH 8.8 
Tris 181.5 g 
H2O 1 l 
Adjust pH to 8.8 with HCl. 
7.1.4 0.5 M Tris-HCL pH 6.8 
Tris 60.5 g 
H2O 1 l 
Adjust pH to 6.8 with HCl. 
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7.1.5 10X Running buffer (8.3) 
Tris 30 g 
Glycine 144 g 
SDS 10 g 
Add distilled water until 1 l and check the pH. 
7.1.6 Sample buffer 
Table 7 Sample buffer preparation. 
 2X 
0.5 M Tris-HCl pH 6.8 1.25 ml 
10% SDS 2 ml 
Glycerol 2.5 ml 
Bromophenol 10 mg 
H2O 3.75 ml 
To this solution, 0.05 ml of mercaptoethanol was added prior to use. For 4X sample buffer the 
quantity of chemical compounds was double. 
7.2 Western-blot buffers 
7.2.1 10X Blotting Buffer (pH 8.3) 
Tris 30.3 g 
Glycine 144 g 
H2O 1 l 
Check if the pH is 8.3 but do not adjust it. 
7.2.2 1X Blotting Buffer (with 20% Methanol) 
10X Blotting buffer 100 ml 
Methanol 200 ml 








7.2.3 10X TBS buffer (9% NaCl, 100 mM Tris HCl, pH 7.4) 
Tris 12.11 g 
NaCl 90 g 
H2O 1 l 
Ajust the pH to 7.4, using HCl. 
7.2.4 1X TBST buffer (pH 7.4) 
10X TBS buffer 100 ml 
Tween 20 0.5 ml 
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ABSTRACT
Correction of human myeloid cell function is crucial for the prevention of inflammatory 
and allergic reactions as well as leukaemia progression. Caffeine, a naturally occurring 
food component, is known to display anti-inflammatory effects which have previously 
been ascribed largely to its inhibitory actions on phosphodiesterase. However, more 
recent studies suggest an additional role in affecting the activity of the mammalian target 
of rapamycin (mTOR), a master regulator of myeloid cell translational pathways, although 
detailed molecular events underlying its mode of action have not been elucidated. 
Here, we report the cellular uptake of caffeine, without metabolisation, by healthy and 
malignant hematopoietic myeloid cells including monocytes, basophils and primary 
acute myeloid leukaemia mononuclear blasts. Unmodified caffeine downregulated mTOR 
signalling, which affected glycolysis and the release of pro-inflammatory/pro-angiogenic 
cytokines as well as other inflammatory mediators. In monocytes, the effects of caffeine 
were potentiated by its ability to inhibit xanthine oxidase, an enzyme which plays a 
central role in human purine catabolism by generating uric acid. In basophils, caffeine 
also increased intracellular cyclic adenosine monophosphate (cAMP) levels which further 
enhanced its inhibitory action on mTOR. These results demonstrate an important mode 
of pharmacological action of caffeine with potentially wide-ranging therapeutic impact 
for treating non-infectious disorders of the human immune system, where it could be 
applied directly to inflammatory cells.
INTRODUCTION
Caffeine (1,3,7-trimethylxanthine) is a purine alka-
loid present in the leaves, seeds or nuts of a number of 
plants and is consumed by many people worldwide on a 
daily basis due to its presence in tea or coffee. In humans, 
caffeine is rapidly demethylated by cytochrome P450 
isoform 1A2 and then converted mostly into methylated 
derivatives of uric acid by the enzyme xanthine oxidase 
(XOD) [1]. For a long time caffeine was recognised as 
an isosteric inhibitor of cyclic adenosine monophosphate 
phosphodiesterase (cAMP-PDE) which upregulates intra-
cellular cAMP levels [2]. Caffeine was also found to 
reduce the role of glycolysis in cell energy metabolism 
via upregulation of lipid degradation (lipolysis) [3, 4].
Recent evidence demonstrated that human 
hematopoietic cells do not express the cytochrome P450 
1A2 isoform and thus should not be able to metabolise 
caffeine, resulting in the effects of unmodified caffeine 
[5]. In this case, caffeine could competitively inhibit 
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XOD [6] rather than act as its substrate (most of the other 
methylxanthines can be converted by XOD). Moreover, 
several stable purines including caffeine were recently 
found to inhibit the activity of the mammalian target of 
rapamycin (mTOR) in somatic cells [7, 8]. It was also 
demonstrated that at high concentrations (5 mM), caffeine 
is capable of inhibiting the mTOR pathway in HOS 
osteosarcoma cells [7]. In addition, 10 mM caffeine was 
able to inhibit the PI3K/Akt/mTOR/p70S6K pathway in 
various cell lines including SH-SY5Y neuroblastoma cells 
and HeLa cells [9]. 10 mM caffeine was even capable of 
inhibiting the phosphorylation (Ser473) of Akt in SH-SY5Y 
cells [9]. In myeloid cells mTOR, a highly conserved serine/
threonine kinase, acts as a central regulator of cell growth 
and metabolism and plays crucial pathophysiological roles 
in host immune defence, allergic reactions and leukaemia 
[10]. Importantly, the mTOR pathway plays a pivotal role 
in non-hypoxic activation of the hypoxia-inducible factor 
1 (HIF-1) transcription complex in human myeloid cells. 
HIF-1 controls the expression of over 40 target genes 
responsible for glycolysis, angiogenesis and cell adhe-
sion – physiological processes which form a critical part 
of myeloid cell function in the human immune system. 
This transcription complex, containing an inducible α and a 
constitutive β subunit, is a major component of the myeloid 
cell stress adaptation machinery [11, 12]. Therefore, 
inhibiting the mTOR/HIF-1 metabolic/signalling axis could 
be an excellent therapeutic strategy for treating human 
disorders associated with myeloid cell function – leukaemia, 
autoimmune disease, and allergy. However, existing mTOR 
inhibitors are toxic and can cause major side effects and 
adverse drug reactions. Thus, if the inhibitory activity of 
caffeine on mTOR has indeed been overlooked for decades, 
this agent may be an excellent non-toxic drug candidate for 
the correction of pathophysiological responses of human 
hematopoietic cells of myeloid lineage.
Here we report for the first time that caffeine 
inhibits the activation of mTOR in THP-1 human myeloid 
leukaemia cells, primary human acute myeloid leukaemia 
(AML) cells and primary human basophils. In THP-1 
and primary AML cells caffeine was also found to inhibit 
XOD. In all cases, the caffeine-mediated attenuation of 
the mTOR pathway led to the downregulation of ligand-
induced glycolysis and cytokine/growth factor/mediator 
production. Caffeine is known to upregulate lipolysis 
through activation of hormone sensitive lipase (HSL). 
This upregulates the Krebs’ cycle leading to decreased 
intracellular levels of 2-oxoglutarate (2-OG), thus 
preventing degradation of HIF-1α protein (the inducible 
HIF-1 subunit) by a classical mechanism controlled by 
HIF-1α prolyl hydroxylases (PHDs). This effect was 
observed in all of the myeloid cell types studied except 
for basophils, where HIF-1α accumulation was less 
PHD-dependent and caffeine completely blocked IgE-
induced HIF-1α accumulation. High performance liquid 
chromatography (HPLC) experiments demonstrated that 
caffeine entered all of the above cell types and was not 
metabolised. Taken together, our results reveal novel 
mechanisms for the downregulatory effects of caffeine on 
the biological responses of human myeloid cells.
RESULTS
Caffeine inhibits ligand-induced activation of the 
mTOR pathway and its downstream effects in 
THP-1 human AML cells
We first investigated the effects of caffeine on ligand-
induced mTOR activation through phosphorylation of its 
S2448 residue in THP-1 cells. Cells were exposed for 4 h 
to ligands (see below) with or without 1 h pre-treatment 
with 1 mM caffeine (this concentration corresponds 
to a therapeutic dose of caffeine and is well below the 
toxic dose [13]). In line with our previous observations 
[10], we found that pro-inflammatory ligands of Toll-
like receptors (TLRs) 2 (plasma membrane-associated 
TLR – 1 μg/ml peptidoglycan (PGN) was used as a ligand), 
7/8 (endosomal TLRs recognising viral single-stranded 
RNA – 0.1 μg/ml resiquimod (R848) was employed as a 
ligand) induce activating S2448 phosphorylation of mTOR. 
The same effect was observed for stem cell factor (SCF), 
a major hematopoietic factor which is also known to 
promote growth of leukaemia cells, where caffeine (1 mM) 
attenuated its effect in all cases (Figure 1). Intriguingly, 
caffeine alone did not significantly reduce phospho-S2448 
mTOR in non-stimulated cells but significantly reduced 
background levels of phospho-T389 p70 S6K1 and 
phospho-S65 eIF4E-BP1 (see Figure 1 for details). This 
suggests that caffeine is likely to act directly on mTOR 
as well, which would prevent further phosphorylation but 
not impact on existing activity. The presence of caffeine 
close to the catalytic site (in the active site of mTOR) 
would almost certainly affect its kinase activity. However, 
it is important to stress that phosphorylation of mTOR at 
the inhibitory T2446 site was not increased by caffeine. 
This observation clearly suggests that caffeine is unlikely 
to enhance the activity of this mTOR downregulatory 
pathway and is likely to be a potential direct mTOR 
inhibitor, as some other purine containing compounds (such 
as cAMP) do [8]. Phosphorylation levels of its substrates 
(indicators of mTOR kinase activity) – p70 S6 kinase 1 (p70 
S6K1 – at position T389) and eukaryotic initiation factor 
4E-binding protein 1 (eIF4E-BP1 at position S65) were 
also significantly upregulated by all the employed ligands 
as well as phosphorylation of S2448 mTOR. All these 
processes were attenuated by caffeine (Figure 1).
We next investigated the effects of caffeine on 
mTOR downstream and associated biochemical pathways 
induced by PGN, R848 and SCF. We found that caffeine 
did not downregulate PGN-induced accumulation of 
HIF-1α protein. This was in line with a significant 
decrease in HIF-1α PHD activity in cells treated with PGN 
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Figure 1: Caffeine inhibits the ligand-induced mTOR signalling pathway in THP-1 human acute myeloid leukaemia 
cells. Cells were exposed for 4 h to the indicated concentrations of PGN, R848 or SCF with or without 1 h pre-treatment with 1 mM 
caffeine. Levels of pS2448 and pT2446 phospho-mTOR as well as phosphorylation of its downstream enzymes were analysed as outlined 
in the Materials and Methods. Western blot data show one representative experiment of four that gave similar results and were quantitatively 
analysed. Quantitative data are shown as means ± S.D; * – p < 0.01 vs. control (n = 4), a – p < 0.01 vs. PGN alone, b – p < 0.01 vs. R848 
alone and c – p < 0.01 vs. SCF alone.
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in the presence of caffeine (Figure 2A). ATP levels, which 
are often controlled in a HIF-1-dependent manner, were 
decreased in cells co-stimulated with PGN and caffeine. 
Levels of cAMP did not undergo significant changes, 
probably owing to the fact that receptors involved in 
these events are not G-protein-coupled [14]. They do not 
provoke adenylate cyclase activation/cAMP production 
and thus cAMP-PDE-inhibiting activity of caffeine has 
no effect in this case. AMP levels were also not increased 
by PGN stimulation, which conforms with our previous 
observations (Figure 2B). The presence of caffeine did 
not increase AMP levels despite a significant decrease in 
PGN-induced XOD activity (Figure 2C). This is likely 
to be caused by the inhibition of hypoxanthine-guanine 
phosphoribosyl transferase (HGPRT), an enzyme which 
converts hypoxanthine (accumulated when XOD was 
inhibited) into inosine monophosphate (IMP), which 
is then converted into AMP [15, 16]. However, we 
could not rule out the possibility of caffeine-dependent 
effects on other enzymes involved in the conversion of 
hypoxanthine into AMP. Intracellular reactive oxygen 
species (ROS) levels upregulated by PGN were also 
unaffected by caffeine, possibly because XOD is not the 
main contributor to the intracellular ROS pool (NADPH 
oxidase plays this role [17]) in this case (Figure 2C). 
Glycolysis, which was significantly upregulated by 
PGN, was reduced to its basic level (Figure 2D). This is 
not surprising, since translation of glycolytic enzymes 
is likely to be an mTOR-dependent process in human 
hematopoietic cells [18]. However, intracellular 2-OG 
levels were almost completely abolished by caffeine 
(Figure 2D). This may be due to the caffeine-dependent 
upregulation of lipolysis and, therefore, the Krebs’ cycle 
(which would lead to a reduction of intracellular 2-OG 
levels and a subsequent decrease in 2-OG-dependent 
HIF-1α PHD activity, where 2-OG is used as a cofactor 
[19]; which we observed (Figure 2A)). Furthermore, the 
pro-inflammatory responses of THP-1 cells induced by 
PGN (release of TNF-α and IL-6) were attenuated by 
caffeine (Figure 2E).
The situation with endosomal TLRs 7 and 8 was 
slightly different, where THP-1 cells were exposed to 
0.1 μg/ml R848 with or without 1 h pre-treatment with 
1 mM caffeine. We found that, unlike with PGN, R848-
induced HIF-1α accumulation was significantly reduced 
by caffeine. HIF-1α PHD activity was significantly 
decreased by R848 (as we have reported before [20]), 
but in the presence of caffeine, PHD activity did not 
reduce further and was even slightly elevated compared 
to exposure to R848 alone (Figure 3A). ATP, AMP and 
cAMP levels in the cells were not affected by caffeine 
as in the experiments with PGN (Figure 3B). Caffeine 
inhibited R848-induced XOD activity but also (unlike 
following the exposure of THP-1 cells to PGN) it reduced 
intracellular ROS levels upregulated by R848. In the case 
of endosomal TLRs, XOD contributes to the intracellular 
ROS pool [17] together with NADPH oxidase (Figure 3C). 
This result explains the caffeine-dependent decrease in 
HIF-1α accumulation in THP-1 cells induced by R848, 
since ROS may play a primary role in the process. 
Glycolysis was also significantly upregulated in the 
presence of R848 and this effect was slightly reduced by 
caffeine. 2-OG levels were significantly reduced (by ca. 
50%) by caffeine (Figure 3D). R848-induced production 
of IL-6 and TNF-α were significantly lower in the presence 
of caffeine (Figure 3E).
SCF-induced biological responses of THP-1 cells 
were also affected in a way similar to that observed 
for PGN (see above). THP-1 cells were exposed for 4 
h to 0.1 μg/ml SCF with or without 1 h pre-treatment 
with 1 mM caffeine. We found that SCF-induced HIF-
1α accumulation was not decreased in the presence of 
caffeine which corresponded to a striking decrease in 
HIF-1α PHD activity in the cells (Figure 4A). ATP, cAMP 
and AMP levels were not affected at all (Figure 4B). As 
with TLRs, the Kit receptor, which recognises SCF as a 
ligand, is not a G-protein coupled receptor (it is a typical 
receptor tyrosine kinase), and therefore no changes in 
cAMP levels were observed. SCF-induced XOD activity 
was reduced by caffeine, however intracellular ROS 
levels were slightly upregulated by SCF and remained 
unchanged in the presence of caffeine (Figure 4C). SCF 
also upregulated glycolysis and caffeine attenuated this 
process as well as significantly reduced intracellular 
2-OG levels (Figure 4D). Finally, SCF-induced vascular 
endothelial growth factor (VEGF) production was 
significantly increased upon exposure of the cells to SCF, 
but this process was attenuated by caffeine (Figure 4D).
In order to confirm that caffeine is able to directly 
inhibit XOD and, if so, to characterise this process, 
we studied the kinetics of caffeine effects on purified 
bovine liver XOD activity using the Lineweaver-Burk 
approach [21]. We found that caffeine isosterically (in a 
competitive manner) inhibited XOD (Figure 5). However, 
the Ki was only 4.022 mM suggesting that caffeine is 
a weak inhibitor compared to classic XOD inhibitors 
(for example, allopurinol and sodium tungstate). This 
confirmed our previous studies showing the ability of 
caffeine to inhibit XOD in vitro but not in vivo due to 
demethylation of the drug.
Caffeine affects SCF-induced responses of 
primary human AML cells in an mTOR-
dependent manner
We sought confirmation of our results using primary 
human leukocytes. For this purpose we used primary acute 
myeloid leukaemia cells AML-PB001F purchased from 
AllCells (Alameda, CA, USA). Cells were exposed to 
0.1 μg/ml SCF (these cells express high levels of the Kit 
receptor) for 4 h with or without 1 h pre-treatment with 
1 mM caffeine. We found that SCF induced a significant 
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Figure 2: Effects of caffeine on TLR2-mediated biological responses of THP-1 cells. Cells were exposed for 4 h to PGN with 
or without 1 h pre-treatment with 1 mM caffeine before assessing the indicated biological responses: A. HIF-1α accumulation, B. ATP/
cAMP/AMP levels, C. XOD activity and intracellular ROS pool, D. glycolysis and 2-OG level as well as E. TNF-α/IL-6 release. Western 
blot data show one representative experiment of three that gave similar results. Quantitative data are shown as means ± S.D; * – p < 0.01 
vs. control (n = 3), a – p < 0.01 vs. PGN alone.
Figure 3: Effects of caffeine on TLR7/8-mediated biological responses of THP-1 cells. Cells were exposed for 4 h to R848 with 
or without 1 h pre-treatment with 1 mM caffeine before analysing A. HIF-1α accumulation, B. ATP/cAMP/AMP levels, C. XOD activity 
and intracellular ROS pool, D. glycolysis and 2-OG level as well as E. TNF-α/IL-6 release. Western blot data show one representative 
experiment of three that gave similar results. Quantitative data are shown as means ± S.D; * – p < 0.01 vs. control (n = 3), b – p < 0.01 vs. 
R848 alone.
Figure 4: Effects of caffeine on SCF-induced Kit receptor activation in- THP-1 cells. Cells were exposed for 4 h to SCF with 
or without 1 h pre-treatment with 1 mM caffeine before analysing A. HIF-1α accumulation, B. ATP/cAMP/AMP levels, C. XOD activity 
and intracellular ROS pool, D. glycolysis and 2-OG level as well as VEGF release. Western blot data show one representative experiment 
of three that gave similar results. Quantitative data are shown as means ± S.D; * – p < 0.01 vs. control (n = 3), c – p < 0.01 vs. SCF alone.
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increase in mTOR phosphorylation at position S2448 and 
respectively phosphorylation of its substrates – p70 S6K1 
and eIF4E-BP1 (Figure 6A). These levels were compared 
with those in resting primary human leukocytes (PL) 
obtained from healthy donors (Figure 6A). As in THP-1 
cells, SCF induced significant upregulation of HIF-1α 
accumulation, glycolysis, VEGF release and XOD activity. 
All these effects were attenuated by caffeine (in the case of 
HIF-1α – downregulated; the level was still significantly 
higher than the control) (Figure 6B). Interestingly, 
background levels of HIF-1α, pS2448 mTOR and XOD 
activity were significantly higher in primary AML 
cells compared to primary “healthy” leukocytes (PL) 
suggesting that these factors/pathways are crucial for 
AML cell function. Importantly, resting primary human 
leukocytes obtained from the blood of healthy donors did 
not accumulate detectable amounts of HIF-1α protein.
Given the effects of caffeine on AML cell 
function, we next determined the concentration-
dependent actions of caffeine on these cells following 
exposure to 0.1 μg/ml SCF for 4 h with or without 1 h 
pre-treatment with 0.01, 0.1 and 1 mM caffeine. Levels 
of pS2448 mTOR were monitored as a biochemical 
response. We found that SCF-dependent mTOR 
phosphorylation was significantly affected by 1 and 0.1 
but not 0.01 mM caffeine (Figure 7).
Caffeine downregulates anti-IgE-induced 
activation of human basophils by affecting 
mTOR signalling
We were next interested in investigating the effects 
of caffeine on primary human basophils. These terminally 
differentiated granulocytes display biochemically similar 
but pathophysiologically different responses compared to 
THP-1 and primary AML cells. Furthermore, basophils 
play a crucial role in human allergic reactions since they 
readily respond to IgE-dependent triggering, although 
compared to leukaemic myeloid cells they are relatively 
unresponsive to SCF [22] and TLR2/4 ligands [23]. 
Stimulation of primary human basophils with 1 μg/ml 
anti-IgE led to the activation of mTOR phosphorylation 
at S2448, which was attenuated by caffeine (Figure 8). 
Similar effects were observed regarding the phos-
phorylation of mTOR substrates (Figure 8).
As shown previously [24], HIF-1α accumulation 
was upregulated by anti-IgE. This process was completely 
blocked by caffeine and the process appeared to be 
independent of PHD activity, since no significant 
changes were observed in enzyme activity (Figure 9A). 
Importantly, we could not detect any XOD activity 
in basophils, which is supported by our previous 
observations [21]. Western blot analysis (Figure 9A) 
demonstrated the absence of XOD protein in basophils. 
ATP and AMP levels were not affected by any of the 
treatments; however, cAMP levels were significantly 
upregulated by anti-IgE and were further increased in the 
presence of 1 mM caffeine (Figure 9B). This suggests that 
IgE-induced responses in basophils are indirectly linked 
to G-protein-coupled receptor signalling, possibly due 
to the actions of histamine acting through H2 receptors, 
which may serve as a negative feedback loop limiting 
further basophil degranulation and histamine release. 
Intracellular ROS levels were not affected which confirms 
our previous findings suggesting that IgE-induced 
basophil responses are orchestrated in a redox-independent 
manner (Figure 9C). IgE-dependent histamine release 
was significantly affected by caffeine which is in line 
with the observed caffeine-dependent downregulation 
of IgE-induced glycolysis and 2-OG levels (Figure 9D). 
However, the effect associated with 2-OG levels did not 
impact HIF-1α accumulation or PHD activity, further 
confirming our hypothesis that this process is most likely 
to be PHD-independent in basophils.
Figure 5: Caffeine is a weak competitive inhibitor of XOD. Kinetics of the effects of caffeine on the activity of purified bovine 
liver XOD were analysed as described in the Materials and methods. Each point was analysed in quadruplicate.
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Figure 6: Effects of caffeine on SCF-induced Kit receptor activation in primary human AML cells. AML-PB001F cells 
were exposed for 4 h to SCF with or without 1 h pre-treatment with 1 mM caffeine before analysis of A. mTOR phosphorylation and its 
biological activity and B. HIF-1α accumulation, glycolysis, VEGF release and XOD activity. Western blot data (50,000 cells per well were 
loaded in each case for AML cells and 90,000 for healthy primary leucocytes) show one representative experiment of three-four (using cells 
derived from different donors) that gave similar results. In both panels A and B we also show the results obtained from non-treated healthy 
primary human leukocytes (PL) handled as described in Materials and Methods. Quantitative data are shown as means ± S.D; * – p < 0.01 
vs. control (n = 4 for panel A and n = 3 for panel B), d – p < 0.01 vs. SCF alone.
Figure 7: Dose-dependent effects of caffeine on SCF-induced Kit receptor-mediated intracellular pS2448 mTOR 
levels. AML-PB001F cells were exposed for 4 h to 0.1 μg/ml of SCF with or without 1 h pre-treatment with 0.01, 0.1 or 1 mM caffeine. 
pS2448 mTOR levels were analysed. Quantitative data are shown as means ± S.D of three individual experiments; * – p < 0.01 vs. control.
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Figure 8: Caffeine inhibits ligand-induced mTOR signalling pathway in primary human basophils. Cells were exposed for 2 h to 
0.1 μg/ml anti-IgE with or without 30 min pre-treatment with 1 mM caffeine. pS2448 and pT2446 phospho-mTOR levels as well as phosphorylation 
of its downstream enzymes were analysed as described in Materials and Methods. Western blot data show one representative experiment of four 
that gave similar results. Quantitative data are shown as means ± S.D; * – p < 0.01 vs. control (n = 4), e – p < 0.01 vs. anti-IgE alone.
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We next further verified the differential involvement 
of XOD in the biological responses of myeloid cells 
by assessing whether basophil function could be 
affected by XOD inhibitors/substrate. We studied the 
effects of the XOD inhibitor allopurinol, the XOD sub-
strate hypoxanthine (hypoxanthine – chemically is an 
allopurinol isomer) and the highly specific XOD inhibitor 
sodium tungstate. Neither of these compounds, however, 
was able to significantly affect anti-IgE-stimulated 
basophil histamine release and HIF-1α accumulation 
(Supplementary Figure S1). We also noticed that, while 
0.01 mM caffeine did not significantly inhibit IgE-
induced histamine release, HIF-1α accumulation was 
still markedly reduced at this low caffeine concentra-
tion (Supplementary Figure S1). This provides further 
confirmation of our previous observations [24] suggesting 
that histamine release and HIF-1 activation are controlled 
by biochemically independent pathways.
Caffeine is taken up but not metabolised by 
human myeloid cells
In order to ascertain whether the observed effects 
described above were due to caffeine or a metabolite 
we investigated whether the different myeloid cell 
types employed in the study could metabolised caffeine 
following cellular uptake. We found that neither 
THP-1 cells nor primary human leukocytes nor basophils 
contained the cytochrome P450 1A2 isoform which is 
primarily responsible for caffeine demethylation (data 
not shown since they are at zero levels). We then assessed 
whether caffeine (a) enters the studied cells and (b) is 
metabolised through other pathways. For this purpose we 
used high-performance liquid chromatography (HPLC) in 
order to detect caffeine and its metabolites. As a positive 
control we used urine of healthy volunteers following 
consumption of caffeine by them. In the urine we detected 
six caffeine metabolites as well as unmodified caffeine, 
suggesting that all the metabolites are detectable by our 
method and that caffeine is mostly metabolised in vivo 
in humans (Figure 10). In both THP-1 cells and primary 
human basophils we detected caffeine but none of its 
metabolites, suggesting that caffeine is endocytosed into 
these myeloid cells but is not further metabolised. This 
finding was confirmed by the fact that none of the caffeine 
metabolites was detected in the culture medium; only 
unmodified caffeine was detected (Figure 10). These data 
suggest that the effects of caffeine observed in the study 
were solely caused by unmodified caffeine.
Taken together, our results demonstrate for the first 
time that caffeine affects the biological responses of human 
myeloid cells, including leukaemia cell lines, primary AML 
cells and primary human basophils by downregulating the 
mTOR pathway and differentially inhibiting XOD.
DISCUSSION
Caffeine, a plant-derived purine alkaloid, was 
chemically identified over 100 years ago and its effects 
were observed even before Biochemistry developed 
into an independent field of science [1]. However, due 
to its metabolism and labile properties, the effects of 
caffeine in human hematopoietic cells (where it remains 
unmetabolised) were completely overlooked. Given the fact 
that some purine compounds were found to directly inhibit 
mTOR, we were interested to see whether caffeine displays 
such an activity too. Alternatively, unmodified caffeine was 
found to inhibit XOD, which we recently showed to play 
a major role in myeloid cell responses. We were therefore 
interested in discovering whether caffeine plays a major role 
Figure 9: Effects of caffeine on the anti-IgE-induced biological responses of primary human basophils. Cells were 
exposed for 2 h to 0.1 μg/ml anti-IgE with or without 30 min pre-treatment with 1 mM caffeine before analysis of A. HIF-1α accumulation 
and XOD protein levels, B. ATP/cAMP/AMP levels, C. intracellular ROS pool and histamine release, D. glycolysis and 2-OG level. 
Western blot data show one representative experiment of three that gave similar results. Quantitative data are shown as means ± S.D ; * – p 
< 0.01 vs. control (n = 3), e – p < 0.01 vs. anti-IgE alone.
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in the biological responses of human hematopoietic cells of 
myeloid lineage based on its potential actions on XOD and 
mTOR. These leukocytes determine human innate immune 
responses and are affected during severe human disorders 
such as AML and allergy. Thus, elucidating a potentially 
overlooked mechanism of caffeine may result in additional 
therapeutic uses for this methylxanthine which was rapidly 
taken up by these myeloid cells but not metabolised.
We analysed the effects of caffeine on the pro-
inflammatory and pro-leukaemic responses of human 
AML cells using THP-1 cell line and primary AML cells 
as well as on the pro-allergic reactions of primary human 
basophils. Caffeine was found to downregulate activating 
phosphorylation (S2448 position) of the mTOR protein thus 
affecting its kinase activity. This occurred in both THP-1 
cells (upon exposure to PGN, R848 and SCF) as well as in 
primary AML cells stimulated with SCF (TLR expression 
levels are quite low in these cells). Importantly, caffeine did 
not increase phosphorylation of the T2446 residue of mTOR. 
This shows that caffeine does not activate specific mTOR 
downregulatory cascades, for example the AMPK pathway 
[10]. Intracellular AMP (specific AMP kinase activator) 
levels were also not affected by caffeine. However, caffeine 
inhibited XOD activity in both THP-1 and primary AML 
cells. Our previous studies showed that inhibition of XOD by 
allopurinol or sodium tungstate led to a significant increase 
in intracellular AMP levels and therefore induced AMPK-
dependent downregulatory phosphorylation of mTOR 
at position T2446 [21]. Here, we also observed inhibition 
of XOD but without increases in intracellular AMP 
levels. Recently, it was reported that caffeine is capable 
of inhibiting Akt phosphorylation thus preventing mTOR 
activation (presumably through phosphorylation of its 
S2448 residue). However, other studies demonstrated that, 
in tissues expressing high levels of XOD (for example 
skeletal muscles), high concentrations of caffeine (10 mM) 
activate AMPK [7]. These tissues, however, can metabolise 
caffeine. XOD expression in leukocytes (even in AML cells) 
Figure 10: Determination of caffeine and its metabolites in human urine and myeloid cells. Caffeine and its metabolites 
in human urine (coffee drinkers) and medium/lysates of THP-1 cells (exposed for 4 h to 1 mM caffeine) and human basophils (exposed 
for 2 h to 1 mM caffeine) were detected by HPLC. The caffeine metabolic pathway in humans is also presented indicating how each 
metabolite is obtained biochemically. CYP4501A – cytochrome P450 A2; XOD – xanthine oxidase; NAT2 – N-acetyltransferase 2; 
AAMU – 5 Acetylamino-6-amino-3-methyluracil; AFMU – 5 Acetylamino-6-formylamino-3-methyluracil.
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is relatively low compared to other tissues and in basophils 
where the presence of XOD was even undetectable [21].
Although caffeine is a weak inhibitor of XOD 
compared to allopurinol and especially sodium tungstate, it 
might affect the re-use of purines in myeloid cells (this system 
is quite robust in leukocytes and is not affected by allopurinol 
or tungastates, which are specific XOD inhibitors only – 
especially tungstates, where tungsten replaces molybdenum 
in the catalytic site of the enzyme causing its irreversible 
inhibition). Caffeine is known to inhibit HGPRT, however, in 
myeloid cells its inhibitory effects are more striking since it 
is not metabolised in these cells [25]. This means that, upon 
inhibition of XOD by caffeine, levels of hypoxanthine are 
increased. However, hypoxanthine can’t be converted into 
IMP and further down to AMP [21] (for more details, see 
Supplementary Figure S2). This lack of increase in AMP 
levels prevents the activation of AMP kinase and subsequent 
phosphorylation of mTOR at T2446.
Inhibition of mTOR and XOD by caffeine did 
not lead to the attenuation of HIF-1α accumulation in 
THP-1 and primary AML cells. This was due to a significant 
decrease in HIF-1α PHD activity (resulting from the 
decrease in intracellular 2-OG levels required for this 
reaction in form of a co-factor). Caffeine activates lipolysis 
by upregulating the activity of hormone-sensitive lipase 
(HSL), which is well expressed in myeloid cells [4, 25]. 
This leads to a decrease in glycolysis, which is further 
supported by a decrease in mTOR kinase activity which 
is required for translation of glycolytic enzymes [18, 26]. 
Such an effect results in the upregulation of the Krebs’ 
cycle and thus in a decrease in intracellular 2-OG levels that 
affect HIF-1α PHD activity, thus preventing physiological 
degradation of HIF-1α protein. The effects described above 
are summarised in the scheme presented in the Figure 11.
Caffeine was revealed to inhibit mTOR, thus 
downregulating glycolysis. Previous reports suggested 
a possible influence of caffeine on NF-kB activity and 
calcium-dependent signalling [7, 27]. All these effects 
are likely to be responsible for the decreases in cytokine 
production observed in the present study (e.g. TNF-α and 
IL-6 in the case of TLR ligand stimulation and VEGF 
when the cells were exposed to SCF). These effects took 
place in both THP-1 and primary AML cells.
Despite the well-known fact that caffeine is an 
effective inhibitor of cAMP-PDE [2], no significant changes 
in intracellular cAMP levels were observed in THP-1 or 
AML cells. This could be explained by the fact that neither 
TLRs nor the SCF receptor (Kit) are G-protein coupled 
receptors. Therefore, they do not activate adenylate cyclase, 
the enzyme, which converts ATP into cAMP.
A different picture was observed in primary human 
basophils which did not express detectable amounts of 
XOD. Here, we also observed inhibition of IgE-induced 
mTOR kinase activity and abrogation of the mediator 
(histamine) release. However, HIF-1α accumulation 
did not seem to be PHD dependent in these cells and 
therefore, upon inhibition of mTOR kinase activity, 
IgE-induced HIF-1α accumulation was attenuated by 
caffeine. However, in contrast to AML and THP-1 cells, 
we observed a significant increase in intracellular cAMP 
levels in basophils which were further upregulated by 
caffeine. Basophils release histamine and also express 
H2-type histamine receptors which are G-protein-coupled 
and thus activate adenylate cyclase [15]. The cAMP levels 
induced by the autocrine actions of histamine are therefore 
preserved by caffeine as an inhibitor of cAMP-PDE. In 
this case, it is likely that we observed additional inhibition 
of mTOR activation due to the indirect actions of caffeine 
by increasing cAMP. All the effects reported were studied 
at 1 mM caffeine. However, dose-response investigations 
demonstrated that it displays its activities in primary AML 
cells and basophils at 0.1 mM though not at 0.01 mM.
Taken together, our results demonstrate, for the first 
time, that unmodified caffeine inhibits mTOR function by 
targeting its kinase activity during the biological responses 
of various human myeloid cells. These findings support 
observations made by other groups regarding caffeine effects 
on the mTOR pathway in non-blood cells [7, 8]. Furthermore, 
caffeine inhibits XOD activity but, unlike XOD-specific 
inhibitors, it does not upregulate the re-use of purines in 
AML cells. In contrast, basophils do not express detectable 
amounts of XOD. Since caffeine is a non-toxic drug with 
relatively few side effects at therapeutic concentrations, and 
easily metabolised in non-blood cells, our findings may lead 
to new avenues for therapy of human disorders affecting 
myeloid hematopoietic cells. However, it is obvious that 
high concentrations of caffeine would need to be maintained 
in order to achieve either its anti-inflammatory/anti-allergic 
effects or to affect SCF-induced biological responses. 
Because of this, the therapeutic actions of caffeine would 
more likely be achieved following external applications of 
this drug. For example, caffeine could be applied as a cream 
supplement or through other forms of direct application 
of unmodified caffeine on target myeloid cells with the 
purpose of their inactivation or elimination (previous studies 
have shown the ability of caffeine to induce programmed 
cell death [7, 8]). Alternatively, for internal applications, 
one might consider the recently discovered advantages of 
Nanobiotechnology or other highly specific forms of drug 
delivery in order to supply caffeine directly to myeloid cells.
MATERIALS AND METHODS
Materials
RPMI-1640 medium, foetal calf serum and 
supplements, caffeine, bovine liver XOD, PGN, goat anti-
human-IgE, caffeine metabolites and an ATP luminometric 
detection kit were purchased from Sigma (Suffolk, UK). 
AMP/cAMP detection kits were purchased from Promega 
(Southampton, UK). Maxisorp™ microtitre plates were 
obtained from Nunc (Roskilde, Denmark) as well as from 
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Oxley Hughes Ltd (London, UK). Mouse monoclonal 
antibodies to HIF-1α, mTOR and β-actin as well as rabbit 
polyclonal antibodies against phospho-S2448 mTOR and 
phospho-T2446 mTOR were from Abcam (Cambridge, 
UK). Antibodies against phospho-T389 p70 S6 kinase 1 
(p70 S6K1), total and phospho-S65 eukaryotic initiation 
factor 4E binding protein 1 (eIF4E-BP1) antibodies were 
obtained from Cell Signalling Technology (Danvers, MA 
USA). Goat anti-mouse and goat anti-rabbit fluorescence 
dye-labelled antibodies were obtained from Li-Cor 
(Lincoln, Nebraska USA). ELISA-based assay kits for 
the detection of IL-6, TNF-α and VEGF were purchased 
from R&D Systems (Abingdon, UK). All other chemicals 
were of the highest grade of purity that were commercially 
available (from either Sigma or Fisher Scientific).
THP-1 human myeloid cells
THP-1 human leukaemia monocytic macrophages 
were obtained from the European collection of Cell Cultures 
(Salisbury, UK). Cells were cultured in RPMI 1640 media 
supplemented with 10% foetal calf serum, penicillin (50 IU/
ml) and streptomycin sulfate (50 μg/ml). Cells used in the 
experiments were from the 5–35th passage.
Primary human AML cells
Primary human AML mononuclear cells (AML-
PB001F, newly diagnosed/untreated) were purchased from 
AllCells (Alameda, CA, USA) and handled in accordance 
with manufacturer’s instructions. Cells derived from two 
different patients were used in the experiments.
Primary human leukocytes obtained from 
healthy donors
Primary human leukocytes were obtained from buffy 
coat blood (prepared from healthy donors) purchased from 
the National Health Blood and Transfusion Service (NHSBT, 
UK) following ethical approval (REC reference: 12/
WM/0319). Mononuclear-rich leukocytes were obtained by 
Ficoll-density centrifugation according to the manufacturer’s 
Figure 11: Possible biochemical mechanisms of the effects of caffeine on the mTOR pathway, HIF-1 activity and 
energy metabolism in human myeloid cells (SCF-induced responses are used as the example). Additional abbreviations 
used: HK – hexokinase, PGI – phosphoglucose isomerase, PFK – phosphofructokinase, AL – Aldolase, TPI – Triose-phosphate isomerase, 
GPDH – glyceraldehyde-3-phosphate dehydrogenase, PGK – phosphoglycerate kinase, PGM – phosphoglycerate mutase, EL – enolase, 
PK – pyruvate kinase, LDH – lactate dehydrogenase, DHAP – dihydroxyacetone phosphate, GA3-P – glyceraldehyde-3-phosphate, 3-PG – 
3-phosphoglycerate, 2-PG – 2-phosphoglycerate, PEP – phosphoenolpyruvate, GLT1/3 – glucose transporters 1/3, TSC1/TSC2 – Tuberous 
sclerosis proteins 1 and 2, PDK – P-3-PI-dependent kinase, ADK – adenylate kinase, TK – tyrosine kinase.
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protocol. Cell numbers were determined using a haemocy-
tometer and diluted accordingly with HEPES-buffered 
Tyrode’s solution before treatment as indicated.
Primary human basophils
Primary human basophils were obtained from buffy 
coats and isolated from the leukocyte-rich fraction obtained 
by Ficoll density centrifugation as described above. Basophils 
were then purified by a negative selection procedure to 
90–100% purity (as judged by alcian blue staining) using 
a commercially available kit, as previously described [28]. 
Basophils were pre-incubated for 15 min at 37°C in HEPES-
buffered Tyrode’s solution and then treated as indicated.
Stem cell factor
Human SCF protein was produced in E.Coli and 
purified in accordance with published protocols [29].
Western blot analysis
Expressions of HIF-1α, total and phospho-T389 
p70 S6K1, total and phospho-S65 eIF4E-BP1 as well as 
XOD protein levels were determined by Western blot 
analysis and compared to β-actin in order to determine 
equal protein loading, as previously described [10]. Li-Cor 
goat secondary antibodies, conjugated with fluorescent 
dyes, were used according to the manufacturer’s protocol 
in order to visualise the proteins of interest using a Li-Cor 
Odyssey imaging system. Western blot data were subjected 
to quantitative analysis using Odyssey software and values 
were normalised against respective β-actin bands.
Detection of phospho-S2448 and phospho-T2446 
mTOR in cell lysates by ELISA
Phosphorylation of mTOR was monitored using 
ELISA assays as recently described [10, 21, 30]. Briefly, 
the ELISA plates were coated with mouse anti-mTOR 
antibodies and blocked with 2% BSA. Cell lysates were 
then added to the wells and kept at room temperature for 
at least 2 h (under constant agitation). After extensive 
washing with TBST buffer, anti-phospho-S2448 (or anti-
phospho-T2446) mTOR antibody was added and plates 
were incubated for at least 2 h at room temperature with 
constant agitation. Plates were then washed with TBST 
buffer and incubated with 1:1000 HRP-labelled goat anti-
rabbit IgG in TBST buffer. After extensive washing with 
TBST, bound secondary antibodies were then detected by 
the peroxidase reaction (ortho-phenylenediamine/H2O2).
HIF-1α PHD assay
To detect HIF-1α PHD activity we employed 
a peptide-based assay [31]. HIF-1α-free cell lysates 
were used to avoid the impact of intracellular HIF-1α 
hydroxylation. Lysates of non-treated and treated THP-
1 cells were incubated for one hour in 96-well ELISA 
plates which were coated with HIF-1α capture antibodies 
and blocked with BSA as described previously. Lysates 
were then subjected PHD assay following this incubation 
period.
Detection of intracellular ATP, cAMP, AMP, 
ROS and 2-OG levels, xanthine oxidase activity 
as well as glycolysis intensity
ATP was detected using a commercial luminometric 
kit (Sigma) according to the manufacturer’s protocol. 
AMP and cAMP levels were detected using luminometric 
assay kits in accordance with manufacturer’s protocols. 
Intracellular ROS levels were also monitored by 
luminometric assay as previously described [32]. 2-OG 
levels were analysed using a glutamate dehydrogenase 
spectrophotometric assay [33]. Xanthine oxidase activity 
was measured as described before [21]. The intensity of 
glycolysis was determined based on the ability cell lysate 
enzymes, used as a multienzyme preparation, to convert 
glucose into lactate under anaerobic conditions, which was 
achieved by employing an anaerobic chamber [10].
Detection of IL-6, TNF-α and VEGF release
Concentrations of these cytokines released into the 
cell culture media were analysed by ELISA (R&D Systems 
assay kit) according to the manufacturer’s protocol.
Measurement of histamine release
Histamine releases were assessed using spectro-
fluorometic autoanalysis as previously described [34]. 
Histamine releases were calculated from the histamine 
contents released into the supernatants as a percentage of 
total histamine content present in lysed cell pellets.
High performance liquid chromatography
Caffeine and its metabolites were analysed in urine 
according to a previously described protocol [35, 36] 
with minor modifications. Healthy subjects were asked 
to refrain from all caffeine containing beverages and 
chocolate for 1 day. At 8 a.m. on the test day subjects 
were asked to consume 2 cups of very strong espresso 
(approximately 200 mg of caffeine) and 6 hours later urine 
was collected for analysis.
10 ml of urine were mixed with 200 mg of ascorbic 
acid. The pH was adjusted to 3.5 with 30% acetic acid. 
200 μl of urine were mixed with 140 mg of ammonium 
sulfate, 25 μl of internal standard (137 MU) and vortexed 
at full speed for 1 min. The metabolites were extracted 
with chloroform:isopropanol (95:5) and centrifuged. The 
organic phase was evaporated to dryness using nitrogen or 
Speedvac and the pellet was dissolved in 750 μl of diluent 
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containing MeOH : acetic acid : water (20:0.5:979.5 
vol:vol:vol) and 5 μl of the sample was analysed by 
Agilent HPLC system (the flow rate was 0.5 ml/min) 
with a UV detector using a gradient elution profile. 
Caffeine, caffeine metabolites and the internal standard 
were separated on an Agilent XBD C18 reverse phase 
column (1.8 μm, 4.6 × 50 mm). The solvents used for the 
elution were mobile phase A containing MeOH : acetic 
acid : water (20:0.5:979.5 vol:vol:vol) and mobile phase 
B (MeOH : acetic acid : water 700:0.5:229.5 vol:vol:vol). 
The gradient program was 0% B (0 min), 100% (0.1 to 15 
min) and 0% (15.1 to 18 min). The analytes were detected 
by UV absorbance at 280 nm. Calibration curves were 
developed using known amounts of metabolites.
Analysis of total cytochrome P450 and activity of 
CYP450 1A2
Total CYP450 was analysed by a classic 
spectrophotometric method initially proposed by Omura 
and Sato [37]. CYP450 1A2 activity was analysed based 
on its ability to oxidise caffeine using NADPH as a donor. 
Mouse liver homogenates obtained from commercial 
sources were used as positive control.
Statistical analysis
Each experiment was performed at least three times 
and statistical analysis was conducted using a two-tailed 
Student’s t test. Statistical probabilities (p) were expressed 
as *, where p < 0.01.
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SUPPLEMENTARY figURES
Supplementary figure S1: Effects of allopurinol, hypoxanthine, sodium tungstate and caffeine on anti-igE-induced 
histamine release and HIF-1α accumulation in primary human basophils. Basophils were exposed for 2 h to 0.1 μg/ml 
anti-IgE with or without 30 min pre-treatment with indicated concentrations of inhibitors or hypoxanthine. Western blot data show one 
representative experiment of three that gave similar results. Quantitative data are shown as means ± S.D ; * – p < 0.01 vs. control (n = 3), 
e – p < 0.01 vs. anti-IgE alone.
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Supplementary Figure S2: Possible biochemical mechanisms of the actions of caffeine on hypoxanthine degradation 
and re-use. Additional abbreviations used: ASS – adenylosuccinate synthase; ASL – adenylosuccinate lyase.
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ABSTRACT
The T cell immunoglobulin and mucin domain 3 (Tim-3) is a plasma membrane-
associated receptor which is involved in a variety of biological responses in human 
immune cells. It is highly expressed in most acute myeloid leukaemia (AML) cells and 
therefore may serve as a possible target for AML therapy. However, its biochemical 
activities in primary human AML cells remain unclear. We therefore analysed the 
total expression and surface presence of the Tim-3 receptor in primary human AML 
blasts and healthy primary human leukocytes isolated from human blood. We found 
that Tim-3 expression was significantly higher in primary AML cells compared to 
primary healthy leukocytes. Tim-3 receptor molecules were distributed largely on the 
surface of primary AML cells, whereas in healthy leukocytes Tim-3 protein was mainly 
expressed intracellularly. In primary human AML blasts, both Tim-3 agonistic antibody 
and galectin-9 (a Tim-3 natural ligand) significantly upregulated mTOR pathway 
activity. This was in line with increased accumulation of hypoxia-inducible factor 
1 alpha (HIF-1`) and secretion of VEGF and TNF-`. Similar results were obtained 
in primary human healthy leukocytes. Importantly, in both types of primary cells,  
Tim-3-mediated effects were compared with those induced by lipopolysaccharide 
(LPS) and stem cell factor (SCF). Tim-3 induced comparatively moderate responses 
in both AML cells and healthy leukocytes. However, Tim-3, like LPS, mediated the 
release of both TNF-` and VEGF, while SCF induced mostly VEGF secretion and did 
not upregulate TNF-` release.
INTRODUCTION
The immune receptor T-cell immunoglobulin 
and mucin domain 3 (Tim-3) is involved in a variety 
of leukocyte biological responses [1]. In T cells it 
mainly mediates the inhibition of Th1 responses, while 
in dendritic cells it has a pro-inflammatory effect. In 
monocytes and macrophages Tim-3 is involved in 
phagocytosis [1]. However, in myeloid leukaemia cell 
lines Tim-3 was shown to induce a moderate growth 
factor/pro-inflammatory responses, similar to those 
observed by myeloid cell growth factors (for example 
stem cell factor – SCF) [2, 3].
Interestingly, Tim-3 is highly expressed in leukaemia 
cells, especially in T-cell lymphocytic leukaemia cells as 
well as acute myeloid leukaemia (AML) cells [4–6]. In 
leukaemic T cells Tim-3 agonists induce programmed cell 
death pathways, while in AML cells this does not seem to 
be the case [1, 6]. However, the biochemical mechanisms 
involved in the activation of human myeloid cells and, 
especially, in AML cells, are largely unknown.
Tim-3 is considered as one of the possible AML 
antigens, since malignant AML cells preserve the ability 
to express the SCF receptor (Kit or CD117) as well as 
Tim-3 [5, 7]. In contrast, myeloid stem cells only express 
Kit receptors but not Tim-3 [5]. Conversely, in most cases, 
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mature myeloid cells express Tim-3 but not Kit receptors 
[5, 8]. Despite these differences in cell surface presence, 
total expression levels of Tim-3 in AML cells are also 
significantly increased compared to healthy leukocytes [5].
In myeloid cell lines and primary myeloid 
hematopoietic cells Tim-3 is known to mediate the 
activation of NF-kB transcription factor and TNF-α 
secretion [3]. Furthermore, in AML cell lines, Tim-3 
moderately activates the mammalian target of rapamycin 
(mTOR, a master regulator of myeloid cell translational 
pathways). This results in activation of the hypoxia-
inducible factor 1 (HIF-1) transcription complex, which 
upregulates glycolysis and expression/secretion of the 
pro-angiogenic vascular endothelial growth factor (VEGF) 
[2]. However, the differential effects of Tim-3 in ex vivo 
systems such as primary human AML cells versus healthy 
human leukocytes have not yet been elucidated.
In the present study, we therefore analysed both the 
total and cell surface expressions of the Tim-3 receptor in 
primary human AML blasts and healthy primary human 
leukocytes obtained from peripheral blood (buffy coats). 
We found that, in primary AML cells, Tim-3 expression is 
much higher compared to primary healthy leukocytes. We 
also observed that Tim-3 receptor molecules were mostly 
expressed on the surface of primary AML cells, while the 
majority of Tim-3 protein remained inside primary human 
healthy leukocytes. In primary human AML blasts (AML-
PB001F), Tim-3 agonistic antibody as well as galectin-9 
(one of the natural ligands of Tim-3) induced activation of 
the mTOR pathway (by mTOR-dependent phosphorylation 
of p70 S6 kinase 1 (p70 S6K1) and eIF4E-binding 
protein-1 (eIF4E-BP1)). This was in line with HIF-1 
activation and increased secretion of VEGF and TNF-α. 
Similar results were obtained in primary human leukocytes 
isolated from buffy coats obtained from the blood of 
healthy donors. Importantly, in both types of primary 
cells, the effects were compared with those induced by 
lipopolysaccharide (LPS, a Gram-negative bacteria-derived 
toll-like receptor 4 (TLR4) ligand) and SCF (Kit ligand). 
In primary AML cells SCF induced the strongest biological 
response, whereas LPS displayed comparatively greater 
effects on primary human leukocytes. Tim-3 in both cases 
induced moderate cellular responses. However, although 
Tim-3, like LPS, triggered the release of both TNF-α and 
VEGF, SCF induced mostly VEGF secretion and did not 
significantly impact the TNF-α release.
RESULTS
Primary human AML blasts and healthy 
leukocytes express the Tim-3 immune receptor
Our recent work demonstrated that Tim-3 mediates 
the activation of mTOR via phosphorylation of its S2448 
residue and HIF-1 signalling in human AML cell lines 
[2]. We therefore sought to understand the expression and 
behaviour of this receptor in primary human AML cells 
(AML-PB001F primary mononuclear blasts were used) 
in comparison with healthy whole blood primary human 
leukocytes (PLs).
In order to compare the expression and, more 
importantly, re-distribution of Tim-3 in the cells we 
analysed its total amount and cell surface presence 
using in-cell Western and in-cell assay respectively. We 
found that both primary AML blasts and healthy whole 
blood leukocytes expressed Tim-3 as detected by in-cell 
Western and in-cell assay (Figure 1A and 1B). However, 
in AML cells most of the receptor molecules were 
externalised, whereas in healthy PLs only around 30% 
were present on the surface, clearly indicating that the 
vast majority of Tim-3 protein was stored inside the cell 
(Figure 1A and 1B), where Tim-3 function is unknown. 
These findings confirm that AML cells express more 
Tim-3 protein compared to healthy leukocytes and, 
importantly, AML cells retain almost all Tim-3 receptor 
molecules on their cell surface.
Tim-3 triggers activation of the mTOR pathway 
and HIF-1 signalling in primary AML cells and 
primary healthy human leukocytes (PLs)
Given the high expression/externalisation levels of 
Tim-3 protein in primary human AML cells compared 
to PLs we sought to obtain evidence on differences 
in receptor downstream activities. We found that, in 
primary AML cells, mTOR S2448 phosphorylation was 
substantially increased upon exposure to SCF as well as 
to anti-Tim-3 antibody stimulation (about 50% of SCF-
induced effect), while LPS displayed a weaker ability 
to upregulate the intracellular levels of phospho-S2448 
mTOR. The same pattern was observed for PI-3K activity 
(Figure 2A). Activity of LPS can be explained by the 
low TLR4 expression levels reported by the supplier for 
AML-PB001F primary human AML cells. These results 
were in line with mTOR activity levels monitored based 
on intracellular amounts of phospho-T389 p70 S6 K1 and 
phospho-S65 eIF4E-BP1 (Figure 2A).
Both proteins are phosphorylated at the indicated 
positions by the mTOR kinase complex [9]. All the 
stimuli demonstrated the ability to upregulate HIF-1α 
accumulation; anti-Tim-3 was the weakest inducer 
(Figure 2B) which is consistent with the observations 
made in cell lines. Stronger LPS-induced effects in this 
case were due to the fact that LPS-dependent HIF-1α 
accumulation, unlike the one triggered by both SCF and 
anti-Tim-3, did not solely depend on mTOR activation. 
LPS-induced TLR4-mediated HIF-1α accumulation is 
known to be jointly triggered through a redox-dependent 
mechanism, as well as mTOR and mitogen-activated 
protein (MAP) kinase signalling cascades [10, 11]. 
Therefore, the observed effects were achieved jointly 
via activation of all three pathways, the intensities of 
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which were comparable with mTOR-dependent processes 
following exposure to SCF (Figure 2A and 2B). Total 
Tim-3 levels were not affected by any of the above 
stimuli, while in AML cell lines SCF and Tim-3 receptor 
activation upregulated total Tim-3 expression (Figure 2B). 
Importantly, as with LPS, anti-Tim-3 antibody was able 
to upregulate secretion of both TNF-α and VEGF, while 
SCF mostly upregulated VEGF production and did not 
dramatically change TNF-α secretion level (Figure 2B).
Galectin-9, a natural Tim-3 ligand [2, 5], 
demonstrated the ability to upregulate both mTOR 
kinase activity and HIF-1α accumulation in primary 
AML-PB001F blasts at levels comparable to those seen 
with anti-Tim-3. This suggests similar activities of both 
agonistic ligands (Figure 3A and 3B).
In primary human healthy leukocytes the effects 
of anti-Tim-3 antibody were similar to those observed in 
AML cells. However, in healthy PLs LPS (and not SCF) 
was the most powerful cell activator (Figure 4A and 4B). 
This is probably due to the fact that healthy leukocytes 
contain more cells which express TLR4 than those that 
express Kit receptors. The effects of anti-Tim-3 antibody 
in this case were similar to those of SCF and slightly 
lower than the effects of anti-Tim-3 detected in primary 
human AML blasts (Figure 4A and 4B). Isotype control 
(IgG 2a) antibody [2] was also incubated with all the cell 
types studied and did not induce any effect in cell lines or 
primary leukocytes (data not shown).
Interestingly, background intracellular levels of 
phospho-S2448 mTOR, HIF-1α and Tim-3 proteins as well 
as VEGF, but not PI-3K activity and secreted TNF-α, were 
significantly higher in AML blasts compared to healthy 
PLs (a quantitative breakdown is shown in Figure 5A–5H). 
These findings confirm that the proteins discussed above 
are used by leukaemia cells on a permanent basis more 
than by healthy leukocytes.
DISCUSSION
The immune receptor Tim-3 is expressed in healthy 
human hematopoietic cells and, despite numerous studies, 
its functional role is still a subject for intensive research 
[6]. Recent evidence demonstrated that the Tim-3 receptor 
is highly expressed and externalised in human AML cells 
[5, 7]. Importantly, progenitor hematopoietic cells do not 
express Tim-3 receptors while they produce substantial 
Figure 1: Comparative analysis of Tim-3 expression and surface presence in primary human AML cells and healthy 
leukocytes. 300,000 per well of AML-PB001F primary human AML cells A. and 1,500,000 per well of healthy PLs B. were subjected to 
in-cell Western (ICW) in order to detect total Tim-3 expression. The Tim-3 surface presence was analysed by in-cell assay (ICA). For 
healthy PLs, 1,500,000 cells per well were necessary to properly visualise Tim-3 receptor on the cell surface. Fluorescence values obtained 
for AML cells and healthy PLs were divided by respective cell number (300,000 or 1,500,000) and used for calculations. Images are from 
one experiment representative of three which gave similar results. Quantitative data are shown as means ± SEM of at least three individual 
experiments; **p < 0.01 vs. control.
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amounts of Kit (SCF) receptors. Mature healthy leukocytes 
generally lose their ability to express the Kit receptor 
but start expressing Tim-3 protein. Malignant AML 
cells express both receptors and thus their growth and 
proliferation depend on SCF while the biological activity 
of Tim-3 remains unclear [5]. It was reported that, in 
primary dendritic cells, Tim-3 induces TNF-α production 
through the NF-kB transcription factor [1, 3]. Our recent 
studies demonstrated that Tim-3 mediates activation of 
the PI3K/mTOR pathway in human AML cell lines [2]. 
Figure 2: Anti-Tim-3 agonistic antibody induces mTOR activity, HIF-1α accumulation as well secretion of VEGF and 
TNF-α in primary human AML cells. AML-PB001F cells were exposed for 4 h for the indicated concentrations of anti-Tim-3, LPS 
and SCF, followed by analysis of PI-3K/mTOR pathway activity A. HIF-1α accumulation and release of VEGF and TNF-α B. Images are 
from one experiment representative of four which gave similar results. Quantitative data are shown as means ± SEM of four individual 
experiments; *p < 0.05; **p < 0.01 vs. control.
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However, it was not clear whether similar effects take 
place in primary human AML cells in comparison with 
healthy primary leukocytes, since activating both mTOR 
pathways and TNF-α production utilize both growth factor 
and inflammatory mediator-like responses.
We observed that primary AML cells generate 
more Tim-3 protein compared to healthy leukocytes, 
including cell surface protein expression. Only about 30% 
of Tim-3 molecules were externalised in primary healthy 
leukocytes, while almost all Tim-3 protein was present on 
the cell surface of primary AML cells. This could have 
impact on differences in activity of the protein in terms of 
its ability to mediate ligand-induced activation of mTOR, 
HIF-1α accumulation and cytokine releases. Our results 
suggest that Tim-3 mediates ligand-induced activation 
of the mTOR pathway, which involves upregulation of 
Figure 3: Anti-Tim-3 and galectin-9 induce similar responses in primary human AML cells. AML-PB001F cells were 
exposed for 4 h for the indicated concentrations of anti-Tim-3 and galectin-9 followed by analysis of PI-3K/mTOR pathway activity A. and 
HIF-1α accumulation B. Images are from one experiment representative of three which gave similar results. Quantitative data are shown as 
means ± SEM of three individual experiments; *p < 0.05; **p < 0.01 vs. control.
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phospho-S2448 mTOR levels, phosphorylation of p70 
S6K1(T389) and eIF4E-BP1 (S65), accumulation of 
HIF-1α protein and secretion of TNF-α and VEGF. It is 
however, clear that the effects are moderate and are weaker 
than those induced by LPS or SCF, a classic inflammatory 
mediator and hematopoietic growth factor, respectively.
In AML cells, SCF displayed the highest biological 
activity while LPS effects were stronger in healthy whole 
blood PLs. These differences are due to differential 
expression of TLR4 and Kit receptors in healthy and 
malignant leukocytes. SCF-induced responses in healthy 
PLs are likely to involve both direct and indirect effects. 
Figure 4: Anti-Tim-3 induces mTOR activity, HIF-1α accumulation as well secretion of VEGF and TNF-α in primary 
human healthy leukocytes. PLs were exposed for 4 h for the indicated concentrations of anti-Tim-3, LPS and SCF followed by 
analysis of PI-3K/mTOR pathway activity A. HIF-1α accumulation and release of VEGF and TNF-α B. Images are from one experiment 
representative of four which gave similar results. Quantitative data are shown as means ± SEM of four individual experiments; *p < 0.05; 
**p < 0.01 vs. control.
Oncotarget33829www.impactjournals.com/oncotarget
Figure 5: Comparative quantitative analysis of mTOR/HIF-1 pathway components as well as VEGF/TNF-α secretion 
in primary human AML cells and healthy human PLs. Protein levels were compared based on the indicated type of detection. 
A. pS2448 mTOR intracellular levels were detected by ELISA, normalised against total cellular protein and compared (results were 
statistically validated). B, C. and D. – Levels of p70 S6K1, eIF4E-BP1 and HIF-1α protein were detected by Western blot (WB), quantitated 
and normalised against respective actin values before comparison and statistical validation of the results. E. PI-3K activity levels were 
measured by colorimetric assay (CA), F. – Intracellular levels of Tim-3 were detected by in-cell Westerns (ICW). Fluorescence values 
obtained for healthy PLs and AML cells and were divided by respective cell number (1,500,000 or 300,000, see Figure 1) and used for 
comparison (the value in PLs was considered as 100%). Similar results were obtained when comparing Tim-3 values in AML cells and 
healthy PLs obtained by Western blot and normalised against actin G. TNF-α and H. VEGF levels were measured in the medium by ELISA 
and the amounts per 106 cells were compared and statistically validated. Data was obtained from 3–6 individual experiments, which gave 
similar results. Quantitative data are shown as means ± SEM; *p < 0.05; **p < 0.01; ***p < 0.01 vs. control.
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Several types of leukocytes express Kit receptors. 
This includes hematopoietic stem cells, multipotent 
progenitors, common myeloid progenitors, common 
lymphoid progenitors, megakaryocytes, myeloblasts, 
small lymphocytes, eosinophils, NK cells and dendritic 
cells [8, 12, 13]. Altogether, this amounts to more than 
5–10% of blood leukocytes. SCF is known to trigger 
IL-6 release in primary cells [14] and we have also 
observed a clear increase in IL-6 secretion in healthy 
PLs exposed to 100 ng/ml SCF for 4 h (data not shown). 
IL-6 is known to upregulate VEGF release [15], which 
is a HIF-1-dependent process [16]. These effects could 
contribute to both HIF-1α accumulation and VEGF release 
in addition to SCF (primary stimulus, see Figure 4 for 
more details).
Although Tim-3 ligands are known to trigger 
programmed death of T cells and demonstrate 
downregulatory properties (especially malignant types, 
[1], 55–86% of all leukocytes are myeloid cells. Therefore, 
phenotypically, we observed the response of the vast 
majority of the total cell pool, indicating that the observed 
effects were likely to be derived from myeloid cells.
Intriguingly, the background levels of 
phospho-S2448 mTOR, HIF-1α, Tim-3 as well as p70 
S6K1/eIF4E-BP-1 proteins are significantly higher in 
non-treated AML cells compared to resting healthy PLs 
(see Figure 5 for details). This phenomenon is especially 
applicable to the HIF-1α accumulation which is strong in 
non-treated AML cells and almost undetectable (detectable 
only upon loading around 140,000 cell per well) in 
healthy PLs. This observation becomes more intriguing 
in light of recently reported contribution of HIF-1 to 
Tim-3 expression [17]. Respectively, VEGF but not TNF-α 
secretions were significantly higher in non-treated AML 
cells compared to healthy PLs. Importantly, background 
levels of the PI-3K activity were very similar in AML 
cells and healthy PLs. This suggests that the increased 
background levels of pS2448 mTOR in primary AML cells 
could be due to increased constitutive phosphorylation as 
reported, for example, for the LAD2 mast cell line [18, 
19]. LAD2 mast cells are also derived from the myeloid 
lineage, and were obtained from a 44-year-old male 
patient suffering from mastocytosis. Analysis of bone 
marrow biopsies/aspirates showed results consistent with 
an aggressive form of mast cell leukemia/sarcoma [20]. 
This suggests that the mTOR/HIF-1/VEGF pathway, but 
not inflammatory TNF-α, is used permanently by AML 
cells compared to healthy PLs.
Taken together, our findings indicate that Tim-3 in 
primary leukocytes, both healthy and malignant AML 
cells, displays moderate properties of an inflammatory 
receptor with additional growth factor (mTOR activation) 
and pro-angiogenic (VEGF release) activities (a summary 
of the biochemical activities of Tim-3 in AML cells 
is provided in Figure 6). Although the mTOR/HIF-1 
pathway is triggered by both LPS and SCF, we only 
observed a significant increase in TNF-α/VEGF secretion 
(production of both factors is regulated by mTOR 
[21, 22]) following LPS stimulation. SCF induced mostly 
VEGF release and did not trigger the production of pro-
inflammatory TNF-α. However, highly increased levels of 
Tim-3 protein in AML cells compared to those in healthy 
PLs did not result in higher specific biochemical activity 
of the receptor.
Currently, Tim-3 is being considered as a target 
antigen for anti-leukaemia therapy including T-cell 
leukaemia and AML [5] as well as to reverse T cell 
exhaustion and restore anti-tumour immunity [23]. In 
addition to the current knowledge, our findings suggest 
that Tim-3 is more abundant on the surface of AML cells 
compared to healthy leukocytes. This, together with the 
moderate biochemical activities associated with Tim-3 
activation, is encouraging since it highlights a relatively 




RPMI-1640 medium, foetal calf serum and 
supplements, P. aeruginosa LPS, were purchased from 
Sigma (Suffolk, UK). Maxisorp™ microtitre plates 
were obtained either from Nunc (Roskilde, Denmark) 
or kindly provided by Oxley Hughes Ltd (London, UK). 
Mouse monoclonal antibodies to HIF-1α, mTOR and 
β-actin as well as rabbit polyclonal antibodies against 
phospho-S2448 mTOR were purchased from Abcam 
(Cambridge, UK). Antibodies against phospho-T389 p70 
S6 kinase 1 (p70 S6K1), total and phospho-S65 eukaryotic 
initiation factor 4E binding protein 1 (eIF4E-BP1) 
antibodies were obtained from Cell Signaling Technology 
(Danvers, MA USA). Goat anti-mouse and goat anti-rabbit 
fluorescence dye-labelled antibodies were obtained from 
Li-Cor (Lincoln, Nebraska USA). ELISA-based assay 
kits for the detection of VEGF, TNF-α and IL-6 were 
purchased from Bio-Techne (R&D Systems, Abingdon, 
UK). All other chemicals were of the highest grade of 
purity and available commercially unless otherwise stated.
Primary human AML cells
Primary human AML mononuclear blasts (AML-
PB001F, newly diagnosed/untreated) were purchased from 
AllCells (Alameda, CA, USA) and handled in accordance 
with manufacturer’s instructions. Cells from two different 
patients were analysed.
Primary human leukocytes obtained from 
healthy donors (buffy coats)
Primary human leukocytes were obtained from 
buffy coat blood (which originated from healthy donors 
undergoing routine blood donation). The buffy coat 
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blood was purchased from the National Health Blood 
and Transfusion Service (NHSBT, UK) following 
ethical approval (REC reference: 12/WM/0319). 
Mononuclear-rich leukocytes were obtained by Ficoll-
density centrifugation according to the manufacturer’s 
protocol. Cell numbers were determined using a 
haemocytometer and diluted accordingly with HEPES-
buffered Tyrode’s solution before treatment as indicated 
below.
Stem cell factor
Human SCF protein was produced in E.Coli and 
purified in accordance with published protocols [24].
Western blot analysis
Expressions of HIF-1α, total and phospho-T389 
p70 S6K1, as well as total and phospho-S65 eIF4E-BP1 
were determined by Western blot analysis and compared 
to β-actin in order to determine equal protein loading, 
as previously described [25]. Li-Cor goat secondary 
antibodies, conjugated with fluorescent dyes, were 
employed according to the manufacturer’s protocol 
in order to visualise detected proteins (using a Li-Cor 
Odyssey imaging system). Following Western blot 
detection of phospho-T389 p70S6K1 and phospho-S65-
eIF4E-BP1, membranes were stripped using a ReBlot™ 
Plus Kit (Chemicon International) according to the 
Figure 6: A schematic summary of ligand-induced Tim-3-mediated biological responses in healthy primary human 
leukocytes and primary human AML cells. 
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manufacturer’s protocol. Membranes were then blocked 
and scanned using a Li-Cor Odyssey imaging system to 
make sure that stripping was successfully completed. 
Then membranes were re-probed with antibodies in order 
to detect the total amounts of p70S6K1 and eIF4E-BP1. 
Western blot data were quantitatively analysed using 
Odyssey software and values were normalised against 
respective β-actin bands.
Detection of phospho-S2448 mTOR in cell lysates 
by ELISA
Phosphorylation of mTOR was analysed by ELISA as 
recently described [25]. Briefly, 96-well ELISA plates were 
coated with mouse anti-mTOR antibodies and then blocked 
with 2% BSA. Cell lysates were then added to the wells 
and incubated at room temperature for 2 h under constant 
agitation. After extensive washing with Tris-Buffered 
Saline and Tween 20 (TBST) buffer, anti-phospho-S2448 
mTOR antibodies were added and plates incubated for 2 h 
at room temperature with constant agitation. After washing 
with TBST buffer plates were incubated with HRP-labelled 
goat anti-rabbit IgG (1:1000 dilution in TBST buffer). 
After 1 h incubation, plates were extensively washed using 
TBST and bound secondary antibodies were detected by 
the peroxidase reaction (ortho-phenylenediamine/H2O2).
In-cell western and in-cell assay
We employed a standard Li-Cor in-cell Western 
assay to analyse total Tim-3 expressions in primary 
human AML cells and healthy primary leukocytes (PLs). 
The in-cell assay was also applied to detect Tim-3 protein 
surface presence in the studied cells [2].
Detection of VEGF, TNF-α and IL-6 release
Concentrations of these cytokines released into the 
medium were analysed by ELISA (R&D Systems assay 
kits) according to the manufacturer’s instructions.
Analysis of phosphatidylinositol-3 kinase (PI-3K) 
activity
The activity of PI-3K was measured using a non-
radioactive assay based on the ability of the enzyme to 
phosphorylate its substrate as previously described [26].
Statistical analysis
Each experiment was performed at least three times 
and statistical analysis was conducted using a two-tailed 
Student’s t test. Statistical probabilities (p) were expressed 
as *, where p < 0.05, **, where p < 0.01 and *** when 
p < 0.001.
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INTRODUCTION
Latrophilin-1 (LPHN1) is an adhesion G-protein-
coupled receptor, which participates in control of calcium 
signalling and exocytosis in vertebrate neurons and 
neuroendocrine cells. LPHN1 is highly expressed in the 
brain, detected at low levels in some other tissues, and 
reported as absent from blood [1]. Interestingly, this 
protein and its homologues appear to be upregulated in 
malignant cells: LPHN1 is found in non-small cell lung 
cancer and is implicated in its invasive character [2], while 
LPHN2 and 3 are upregulated or mutated in several types 
of metastatic cancer [3–5]. Stimulation of LPHN1 induces 
intracellular Ca2+ mobilisation and thus triggers significant 
exocytosis of neurotransmitters, which is crucial for 
normal neuronal function [6–7]. LPHN1 also plays an 
important role in cell surface interactions (reviewed in [1]). 
Exocytotic activity is also required for cytokine/growth 
factor release during myeloid cell haematopoiesis [8–11], 
especially when myeloid leukocytes undergo malignant 
transformation. Firstly, the energy resources of leukaemia 
cells are normally very limited [8–12] and lead to oxygen 
starvation. Therefore, the bone marrow vasculature plays 
a pivotal role in the survival of leukaemia cells, which 
induce angiogenesis by releasing vascular endothelial 
growth factor (VEGF) and other pro-angiogenic factors. 
Secondly, leukaemic cells produce and release interleukin 
6 (IL-6), which is necessary to support their own survival 
and proliferation [13]. These processes require efficient 
exocytosis. We therefore hypothesised that myeloid 
leukaemia cells may express LPHN1, a receptor that is 
able to convert cell-surface interactions into intracellular 
signals leading to activation of exocytosis. 
Here we report, for the first time, that LPHN1 
expression is clearly detectable at both RNA and 
protein level in human monocytic leukaemia (ML) 
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ABSTRACT
Acute myeloid leukaemia (AML) is a blood cancer affecting cells of myeloid 
lineage. It is characterised by rapid growth of malignant leukocytes that accumulate 
in the bone marrow and suppress normal haematopoiesis. This systemic disease 
remains a serious medical burden worldwide. Characterisation of protein antigens 
specifically expressed by malignant cells, but not by healthy leukocytes, is vital for 
the diagnostics and targeted treatment of AML. Here we report, for the first time, that 
the neuronal receptor latrophilin-1 is expressed in human monocytic leukaemia cell 
lines and in primary human AML cells. However, it is absent in healthy leukocytes. 
Latrophilin-1 is functional in leukaemia cells tested, and its biosynthesis is controlled 
through the mammalian target of rapamycin (mTOR), a master regulator of myeloid 
cell translational pathways. Our findings demonstrate that latrophilin-1 could be 
considered as a novel biomarker of human AML, which offers potential new avenues 
for AML diagnosis and treatment.
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cell lines (U937 and THP-1) and in primary human 
acute myeloid leukaemia (AML) cells. Treatment of all 
these leukaemia cells with the inflammatory mediator 
lipopolysaccharide (LPS) further upregulates LPHN1 
translation via mammalian target of rapamycin (mTOR, 
a master regulator of myeloid cell translation and growth 
[14]). When LPHN1 is stimulated by its high-affinity 
ligand [7], α-latrotoxin (LTX), this significantly increases 
LPS-induced IL-6 release from leukaemia cell lines and 
primary cells. In contrast, in healthy primary human 
leukocytes, LPHN1 expression is not detectable and is 
not induced by the mTOR activators LPS, SCF or anti-
Tim-3. We therefore conclude that LPHN1 is a novel 
pharmacoproteomic biomarker of human AML that offers 
new approaches to therapeutic targeting of this disease. 
RESULTS
LPHN1 expression and activity in human ML 
cell lines 
In order to investigate the possibility of LPHN1 
expression in human AML cells, we first used human ML 
cell lines, U937 and THP-1. Cells were stimulated for 
24 h with LPS, LTX or a combination of these ligands. 
LPS is a pathogen-associated molecular pattern shared by 
Gram-negative bacteria and is recognised by the Toll-like 
receptor 4 (TLR4), which is expressed by human myeloid 
cells [13]. LPS was chosen to avoid TLR4 activation 
by endogenous ligands (such as proteins released after 
dysfunctionalisation of mitochondria), which themselves 
induce the expression and release of IL-6 and other 
important factors required for leukaemia cell survival 
[15]. Using Western blot analysis, we found that U937 
cells constitutively expressed LPHN1 (Figure 1A) and the 
same pattern was observed in THP-1 cells (Figure 2A). 
In both U937 and THP-1 cells, LPHN1 expression levels 
were significantly increased (4-12-fold) by LPS, but not 
by LTX; when used in combination with LPS, LTX also 
did not significantly change LPHN1 levels compared to 
LPS alone (Figures 1A and 2A). However, whilst LTX 
alone did not stimulate IL-6 release, LTX combined with 
LPS induced the release of IL-6 that was 2 times greater 
than for LPS alone in both U937 and THP-1 human ML 
cells (Figures 1A and 2A). 
We also found that LPS, but not LTX, significantly 
activated the mTOR pathway: LPS augmented by 2-fold 
the activating phosphorylation of mTOR at S2448 and 
increased the phosphorylation of its substrate, p70 S6 
kinase 1 (p70 S6K1) at position T389. This was clearly 
observed in both cell lines (Figures 1B and 2B). 
Figure 1: Expression and activity of LPHN1 in U937 human ML cells. (A) U937 cells were exposed to 1 μg/ml LPS, 500 pM 
LTX or a combination of these two ligands for 24 h. Following cell lysis, IL-6 release was measured by ELISA, whilst LPHN1 protein levels 
were analysed by Western blotting. PC; positive control for LPHN1 (mouse brain extract). (B) Phospho-S2448 mTOR and phospho-T389 
p70 S6K1 were detected using ELISA and Western blotting, respectively. Western blot images show one experiment representative of six, 
all of which gave similar results. Data are the mean values ± SEM (n = 6). *p < 0.05; **p < 0.01; ***p < 0.001.
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Since mTOR is a master regulator of myeloid cell 
translational pathways [14], it could be hypothesised 
that the mTOR pathway is responsible for LPS-induced 
upregulation of LPHN1 protein levels. We therefore 
exposed both U937 and THP-1 cells for 4 h to 1 μg/ml LPS 
with or without 1h pre-treatment with rapamycin (a highly 
specific mTOR inhibitor). We observed that 4-h exposure 
to LPS led to a moderate increase in LPHN1 expression 
in both U937 and THP-1 cells, which was less than the 
increase induced by 24 h stimulation and more pronounced 
in THP-1 versus U937 cells. In both cell lines, rapamycin 
fully blocked the expression of LPHN1 (Figure 3A and 
3B). Importantly, rapamycin did not affect the viability of 
the cells, as verified using MTS cell viability test (data not 
shown). In order to confirm the role of mTOR signalling 
in upregulation of LPHN1, we performed a similar 
experiment using another mTOR inhibitor, AZD2014 
[16]. AZD2014 did not affect cell viability as measured 
by cell viability assay (data not shown); however, in both 
U937 and THP-1 cells, AZD2014 obliterated expression of 
LPHN1 protein (Figure 3C and 3D).
Functional LPHN1 is expressed in human 
primary AML cells, but not in healthy leukocytes
Next, we asked whether functional LPHN1 is 
expressed in primary human AML cells. We exposed 
AML-PB001F primary human mononuclear blasts for 
24 h to LPS, LTX or a combination of these ligands. We 
found that LPS upregulated both mTOR activation and 
IL-6 release by these cells. LTX alone was ineffective, 
but in combination with LPS it significantly increased 
both mTOR activation and IL-6 exocytosis (Figure 4). 
In order to determine whether LPHN1 expression levels 
in AML-PB001F cells were also controlled through the 
mTOR pathway, we exposed these cells for 4 h to different 
mTOR activators: LPS, SCF or anti-Tim-3 antibody. We 
found that each stimulus led to a significant increase in 
the activating phosphorylation of mTOR (on S2448, 
Figure 5A), while the SCF-induced effect was stronger 
due to high levels of Kit receptor expression by these 
cells [17]. The magnitude of mTOR-dependent effects 
provoked by LPS, SCF and anti-Tim-3 in human AML 
cells observed here agrees well with previously published 
data [17]. Interestingly, all stimuli significantly induced 
LPHN1 expression, as shown by Western blot analysis 
(Figure 5A). 
Most importantly, when we tested healthy primary 
human leukocytes, they did not show any LPHN1 
expression (even after overexposure of Western blots). 
Furthermore, LPHN1 was also undetectable following 4 
or 24 h exposures of healthy leukocytes to LPS, SCF or 
anti-Tim-3 antibody (Figure 5B). 
To confirm the results based on protein expression, 
we then conducted quantitative real-time PCR (RT-PCR) 
to detect and quantify LPHN1 mRNA. These experiments 
demonstrated that LPHN1 mRNA is detected in THP-1 
cells and primary AML cells, but not in healthy primary 
human leukocytes (Figure 5C). Furthermore, we noted 
that LPS significantly increased the already high level of 
Figure 2: Effects of LPS and LTX on LPHN1 expression, IL-6 exocytosis and mTOR activity in THP-1 human ML 
cells. (A) THP-1 cells were exposed to 1 μg/ml LPS, 500 pM LTX or a combination of these two ligands for 24 h. Following cell lysis, 
LPHN1 protein levels were analysed by Western blot. IL-6 release was measured by ELISA. (B) Phospho-S2448 mTOR and phospho-T389 
p70 S6K1 were detected using ELISA and Western blot, respectively. Western blot images show one experiment representative of six, 
which gave similar results. Data are mean values ± SEM (n = 6). *p < 0.05; **p < 0.01; ***p < 0.001.
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LPHN1 mRNA in THP-1 cells and primary AML cells. 
In contrast, even a 24 h exposure to LPS did not induce 
LPHN1 mRNA expression in primary healthy human 
leukocytes (Figure 5C).
Taken together, our findings demonstrate the 
regulated expression of the functional neuronal receptor 
LPHN1 in human AML cells, but not in healthy primary 
human leukocytes. This opens a new direction in research 
of malignant transformation and survival of cancerous 
white blood cells and the role of LPHN1 in these 
processes.
DISCUSSION
LPHN1 functions as an exocytosis promoter acting 
through calcium mobilisation/signalling machinery [1, 6, 
7]. The presence of regulated exocytosis is one of the main 
features of neurons and neuroendocrine cells, where this 
receptor is highly abundant. However, the requirement 
of exocytosis in malignant cells, in particular myeloid 
leukocytes, has not yet been investigated and there are no 
reports regarding a possible role of LPHN1 in leukaemia 
and pro-leukaemic haematopoiesis. 
We therefore considered the possibility of LPHN1 
protein expression in human leukaemia cells. Our studies 
demonstrate that resting ML cells from U937 and THP-
1 human cell lines clearly express LPHN1 mRNA and 
possess detectable amounts of functional LPHN1 protein. 
We also show that expression of functional LPHN1 
is dependent on the mTOR pathway. LTX, a specific 
LPHN1 agonist [3], significantly increased LPS-induced 
exocytosis of IL-6 in both cell lines. Since the production 
of IL-6 protein depends on mTOR [18], and the activity of 
the mTOR pathway was not upregulated by LTX in either 
cell line employed, it is evident that LTX triggers IL-6 
exocytosis rather than its biosynthesis. Wild type LTX 
used in our experiments is known to form Ca2+-permeable 
pores in the membrane of cells expressing toxin receptors 
[6], and such pores could potentially induce LPHN1-
independent exocytosis. However, LTX only inserts 
itself into the membrane after binding the receptor [6], 
and this interaction always stimulates LPHN1, leading to 
exocytosis [6, 7]. Indeed, in our experiments, the toxin 
stimulated secretion in LPHN1-expressing cells only 
(Figures 1, 2, 4). Furthermore, mutant LTXN4C, which 
does not form pores [7], induced similar exocytosis of 
Figure 3: Expression of LPHN1 in U-937 and THP-1 cells depends on mTOR. U-937 (A, C) and THP-1 (B, D) cells were 
exposed to 1 μg/ml LPS for 4 h with or without 1 h pre-treatment with 10 µM rapamycin (A, B) or AZD2014 (C, D). LPHN1 expression was 
then measured using Western blot analysis. Western blot images show one experiment representative of four, which gave similar results. 
Data are mean values ± SEM (n = 4). *p < 0.05; **p < 0.01; ***p < 0.001.
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IL-6 in THP-1/U-937 cells (data not shown), confirming 
the active role of LPHN1 in this secretion. Interestingly, 
LPHN1 expression is completely abolished when the cells 
are pre-treated with the mTOR inhibitors (rapamycin or 
AZD2014) before stimulation of U937 or THP-1 cells by 
LPS (Figure 3). This suggests that the process of LPHN1 
expression fully depends on the mTOR pathway. As 
shown in Figures 1B and 2B, both cell lines demonstrate 
a background activity of the mTOR pathway, which 
is further upregulated by LPS, and it is this additional 
activation of mTOR that brings about the substantial 
increase in the amount of expressed LPHN1 at 24 h. 
Clearly, ML cell lines differ from malignant 
leukocytes in vivo both in terms of biological activities 
and protein expression profiles. However, patient-derived 
primary human AML cells (we used primary AML-
PB001F mononuclear blasts obtained from leukaemia 
patients) do not differ from the two ML cell lines in 
respect of the easily detectable LPHN1 expression and 
its upregulation in response to mTOR stimuli (LPS, SCF 
and anti-Tim-3). Similarly, stimulation of the primary 
leukaemia cells with LTX leads to a substantial increase 
in the release of LPS-induced IL-6. On the other hand, 
unlike in the cell lines, LTX also upregulates LPS-induced 
mTOR-activating phosphorylation in the primary AML 
cells. Our observed effect is likely to be the result of low 
expression of the LPS receptor, TLR4, in the primary 
AML cells, as reported by their supplier. As a result of 
the lower TLR4 signalling, only some mTOR will be 
activated by LPS, while the majority of mTOR will still 
remain unphosphorylated and therefore subject to further 
phosphorylation through LPHN1-induced signalling. In 
cell lines, where the TLR4 expression levels are higher, 
there may not be sufficient scope for further activation 
of mTOR by LTX. This finding implies a functional 
integration of LPHN1 into the AML signalling machinery 
[13, 19]. Its possible functions are summarised in Figure 6.
One very important finding of this work is that 
primary healthy human leukocytes do not express any 
LPHN1. Furthermore, LPHN1 expression is not inducible 
by exposure of the healthy cells to any of the stimuli that 
show positive effects in AML cells: LPS, SCF or anti-
Tim-3. This clearly demonstrates that the expression of 
functional LPHN1 occurs specifically in leukaemia cells 
only. Quantitative RT-PCR experiments further confirm 
that healthy primary leukocytes do not possess detectable 
LPHN1 mRNA. This indicates that the change in the 
expression profile of this important receptor only takes 
place in leukocytes during or as a result of malignant 
transformation. The importance of LPHN1 to malignant 
leukocytes is evident: for their survival, these cells release 
certain growth factors and cytokines (for example, VEGF 
Figure 4: Effects of LPS and LTX on IL-6 exocytosis and mTOR activity in primary human AML cells. Primary human 
AML-PB001F cells were exposed to 1 μg/ml LPS, 500 pM LTX or a combination of these two ligands for 24 h. Following cell lysis, IL-6 
release into the medium and mTOR S2448-phosphorylation in cell lysates were measured by ELISA. Data are the mean values ± SEM 
(n = 6). *p < 0.05; **p < 0.01.
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and IL-6). This requires not only the presence of efficient 
exocytotic machinery, but also the means of controlling 
and stimulating exocytosis, for example, in response to 
leukocyte cell-surface interactions.
LPNH1 can, therefore, be further considered as a 
novel biomarker for AML diagnostics. Most existing 
leukaemia biomarkers are relative: they are expressed 
in both healthy and malignant cells, but their levels are 
higher in malignant cells; in contrast, LPHN1 is totally 
absent from healthy leukocytes and is thus an absolute 
biomarker of leukaemic cells. Furthermore, LPHN1 
could now be explored as a potential novel target for anti-
leukaemia therapy and drug delivery. For this purpose, it 
would be essential to identify a ligand that could bind and 
activate LPHN1 in leukaemia cells. Such a ligand would 
not only allow a full characterisation of the malignant 
transformation pathway, but would also provide a potential 
therapeutic target(s) to prevent LPHN1-induced exocytosis 
in leukaemia cells. The ligand of leukaemia LPHN1 could 
be a soluble factor circulating in blood plasma or it could 
be expressed on the surface of certain blood, endothelial 
or bone marrow cells. We previously characterised 
the natural LPHN1 ligand of nervous tissue (Lasso/
teneurin-2) [20]. However, in the current work we were 
unable to detect Lasso by Western blot in ML cell lines 
(THP-1 and U-937), primary healthy leukocytes or blood 
plasma obtained from healthy donors (data not shown). 
Future research will concentrate on the identification and 
isolation of peripheral ligand/s of leukaemic LPHN1. 
MATERIALS AND METHODS
Materials
All cell culture reagents were from Sigma (Suffolk, 
UK). Microtitre plates were obtained from Nunc (Roskilde, 
Denmark). LTX and LTXN4C were purified as previously 
described [6]. Mouse monoclonal antibodies to mTOR 
and β-actin and rabbit polyclonal antibodies against 
phospho-S2448 mTOR were from Abcam (Cambridge, 
Figure 5: Primary human AML cells but not healthy primary human leukocytes express LPHN1. (A, B) Primary AML-
PB001F cells (A) were exposed for 4 h and healthy human leukocytes (B) for 4 h or 24 h to 1 µg/ml LPS, 0.1 µg/ml SCF or 2 µg/ml 
anti-Tim-3. Following cell lysis, LPHN1 protein levels were analysed by Western blotting and phospho-S2448 mTOR was quantitated 
by ELISA. Control, mouse brain extract. (C) Quantitative RT-PCR was used to determine the levels of LPHN1 mRNA in THP-1 cells, 
primary human AML cells and primary healthy human leukocytes (PHL) prior to any treatment (0 h Con), after a 24 h incubation without 
stimulation (24 h Con), or after a 24 h stimulation with 1 μg/ml LPS (24 h LPS). Data are the mean values ± SEM (n = 4). N.d., not 
detectable; *p < 0.05; **p < 0.01. 
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UK). Antibodies against phospho-T389 and total p70 S6 
kinase 1 (p70 S6K1) were obtained from Cell Signalling 
Technology (Danvers, MA USA). Goat anti-mouse and goat 
anti-rabbit fluorescent dye-labelled antibodies were from Li-
Cor (Lincoln, Nebraska USA). ELISA-based assay kits for 
the detection of IL-6, was from R&D Systems (Abingdon, 
UK). The polyclonal rabbit anti-peptide antibody PAL1 
against LPHN1 and polyclonal mouse antibody dmAb 
against Lasso/teneurin-2 were previously described [20, 21]. 
Human SCF [22] and anti-Tim-3 monoclonal antibody [23] 
were a kind gift of Dr. Luca Varani.
THP-1 and U937 human myeloid cells
THP-1 human myeloid leukaemia monocytic 
macrophages and U937 human leukaemia monocytes were 
obtained from the European Collection of Cell Cultures 
(Salisbury, UK). Cells were cultured in RPMI 1640 media 
supplemented with 10% foetal calf serum, penicillin (50 
IU/ml) and streptomycin sulphate (50 µg/ml).
Primary human AML cells 
Primary human AML mononuclear cells (AML-
PB001F, newly diagnosed/untreated) were purchased from 
AllCells (Alameda, CA, USA) and handled in accordance 
with manufacturer’s instructions. Cells from four different 
patients were used in reported experiments.
Primary human leukocytes from healthy donors
Primary human leukocytes were obtained from 
blood buffy coat (prepared from healthy donors) 
purchased from the National Health Blood and 
Transfusion Service (NHSBT, UK) following ethical 
approval (REC reference: 12/WM/0319) [17, 24]. 
Mononuclear-rich leukocytes were obtained by Ficoll-
density centrifugation according to the manufacturer’s 
(GE Healthcare Life Sciences) protocol. Cell numbers 
were determined using a haemocytometer and diluted 
accordingly with HEPES-buffered Tyrode’s solution 
before treatment, as indicated.
Figure 6: Functional integration of LPHN1 into AML cell signalling machinery. LPHN1 transcription and translation 
is induced in AML cells. LPS upregulates LPHN1 transcription and triggers TLR4-mediated activation of the mTOR pathway, which 
increases translation of LPHN1 and IL-6. In addition, both LPS (through TLR4 and Btk) and LTX (through LPHN1 and Gq) activate 
PLC, which produces IP3, leading to release of Ca
2+ from the ER. Increased cytosolic Ca2+ triggers exocytosis of IL-6. Abbreviations: Btk, 
Bruton’s tyrosine kinase; MD, myeloid differentiation factor 88; TAP, Toll-like receptor intracellular TIR domain-associated protein; PI-3K, 
phosphatidylinositol 3-kinase; PDK, phosphatidylinositol-3-phosphate-dependent kinase; IP3, inositol trisphosphate; PLC, phospholipase 
C; Gq, Gαq subunit of a heterotrimeric G protein; TSC1/TSC2, tuberous sclerosis proteins 1 and 2; eIF4E, eukaryotic translation initiation 
factor 4E; p70S6K1, mTOR-dependent S6 kinase 1; ER, endoplasmic reticulum. Symbols: ←activation; ├ inactivation; dotted lines, 
indirect process involving multiple steps.
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Western blot analysis
The levels of LPHN1, total and phospho-T389 p70 
S6K1 as well as Lasso/teneurin 2 were determined by 
Western blot analysis, as previously described [17, 23]. 
Fluorescently labelled antibodies (Li-Cor) were used 
according to the manufacturer’s protocol to visualise the 
proteins of interest using an Odyssey imaging system (Li-
Cor). Western blot data were subjected to quantitative 
analysis using the Odyssey software and values were 
normalised against respective β-actin bands.
Quantitative real-time reverse transcription 
PCR (qRT-PCR)
Total RNA was extracted using the Illustra RNAspin 
Midi RNA isolation kit (GE Healthcare) and quantified 
spectroscopically with a Nanodrop 2000® (Thermo 
Scientific). cDNA was synthesised using Transcriptor 
First Strand cDNA Synthesis Kit (Roche), which was 
performed in accordance with the manufacturer’s protocol. 
Relative quantification of LPHN1 mRNA was performed 
using SYBR Green I Master reaction mix (Roche) and a 
LightCycler 480 (Roche). The house-keeping gene β-actin 
was used as a reference gene. The following primers 
were used at a final concentration of 0.5 µM: LPHN1, 
5′-AGCCGCCCCGAGGCCGGAACCTA-3′ and 5′-AGG 
TTGGCCCCGCTGGCATAGAGGGAGTC-3′; Actin, 5′-T 
TCGCGGGCGACGATGC-3′ and 5′-GGGGCCACACGC 
AGCTCATT-3′.
PCR reactions began with incubation at 95ºC for 3 
min 30 s, then proceeded for 45 cycles of 95ºC for 10 
s, 60ºC for 20 s and 72°C for 10 s. Fluorescence level 
was detected at 80°C in each cycle. A final elongation step 
was held at 72°C for 5 min. Raw fluorescence data were 
analysed using LinRegPCR quantitative PCR data analysis 
programme [25]. Amplified products were examined on 
1.5% agarose gel containing ethidium bromide.
Detection of phospho-S2448 mTOR in cell lysates 
by ELISA
Phosphorylation of mTOR was monitored using 
ELISA assays as recently described [15]. Briefly, ELISA 
plates were coated with mouse anti-mTOR antibodies and 
blocked with 2% BSA. Cell lysates were then added to the 
wells and incubated with agitation at room temperature for 
2 h. After washing with TBST buffer, anti-phospho-S2448 
mTOR antibody was added and plates were incubated 
with agitation for 2 h at room temperature. Plates were 
then washed with TBST buffer and incubated with 1:1000 
HRP-labelled goat anti-rabbit IgG in TBST buffer. 
After washing with TBST, bound secondary antibodies 
were detected by the peroxidase reaction (ortho-
phenylenediamine/H2O2). 
Detection of exocytosed IL-6
Concentrations of IL-6 released into cell culture 
media were analysed by ELISA (R&D Systems assay kit) 
according to the manufacturer’s protocol.
Cell viability assay
Cell viability was analysed using the Promega 
(Southampton, UK) MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) 
assay kit according to the manufacturer’s protocol.
Statistical analysis
Each experiment was performed 3–6 times and 
statistical analysis was conducted using ANOVA test with 
Bonferroni correction.
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ABSTRACT
The immune receptor Tim-3 is often highly expressed in human acute myeloid leukemia (AML) cells
where it acts as a growth factor and inﬂammatory receptor. Recently, it has been demonstrated that
Tim-3 forms an autocrine loop with its natural ligand galectin-9 in human AML cells. However, the
pathophysiological functions of Tim-3 in human AML cells remain unclear. Here, we report for the ﬁrst
time that Tim-3 is required for galectin-9 secretion in human AML cells. However, this effect is
cell-type speciﬁc and was found so far to be applicable only to myeloid (and not, for example,
lymphoid) leukemia cells. We concluded that AML cells might use Tim-3 as a trafﬁcker for the
secretion of galectin-9 which can then be possibly used to impair the anticancer activities of cytotoxic





The T cell immunoglobulin and mucin domain 3 (Tim-3) is a
plasma membrane-associated protein which is highly
expressed in acute myeloid leukemia (AML) cells and is there-
fore considered as a potential target for anti-AML therapy.1,2
Although the biochemical activities of Tim-3 have recently
been elucidated,3-7 the functional role of this protein/receptor
in AML cells remains unclear and the reasons for striking
increases in Tim-3 levels in these cells are also not yet under-
stood. Galectin-9, which was found to be a natural Tim-3
ligand,3,5 was recently suggested to form an autocrine loop,
where newly released galectin-9 interacts with Tim-3
expressed on the cell surface.3 Furthermore, in leukocytes
Tim-3 is known to be shed by proteolytic enzymes including
metalloproteinases.8 This leads to the dissociation of Tim-3
from the plasma membrane as a soluble protein, which then
can be detectable in human blood plasma.8,9 The physiological
role of this shedding remains unclear as well as the functions
of soluble Tim-3. However, it is known that galectin-9 is capa-
ble of impairing the immunological activities of cytotoxic T
cells as well as natural killer (NK) cells1,10,11 In cytotoxic T
cells galectin-9 was found to induce apoptotic death,11 while
in NK cells it mainly affected cytokine production thus
impairing their cytotoxicity function.10 These effects might
therefore help AML cells to escape immune attack by both
cytotoxic T cells and NK cells.1,10,11
Given the above, we hypothesized that Tim-3 might act as a
trafﬁcker for galectin-9 in AML cells. We found that galectin-9
is expressed in the AML cell line THP-1, in primary human
AML cells, and in primary healthy human leukocytes (although
in this case the expression was considerably lower). Galectin-9
is capable of forming a stable complex with Tim-3 in cell
lysates. We also detected that in THP-1 and U-937 cell lines as
well as in primary healthy leukocytes the surface presence of
Tim-3 is much lower compared to primary human AML cells.
The same effect was observed for galectin-9. Galectin-9 knock-
down in U-937 cells reduced their total Tim-3 levels. Further-
more, Tim-3 knockdown in U-937 cells did not show
reductions in intracellular galectin-9 levels but galectin-9 secre-
tion was dramatically reduced. We therefore suggested that
Tim-3 is required for galectin-9 secretion in AML cells. Pri-
mary human chronic lymphoid leukemia (CLL) cells were also
capable of secreting galectin-9 but expressed very low amounts
of Tim-3. These results suggest that Tim-3 might be required
for galectin-9 secretion in AML cells. Using ELISA, we were
able to detect galectin-9 and soluble Tim-3 in human blood
plasma obtained from healthy donors. Furthermore, capturing
soluble Tim-3 on ELISA plates also led to detection of galectin-
9. These results suggest the presence of Tim-3-galectin-9 com-
plexes in human blood plasma but do not indicate whether
they are formed inside secreting cells, on their surface, or con-
stitutively present in blood plasma.
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Galectin-9 is expressed in healthy primary human
leukocytes and malignant human myeloid cells and forms
a complex with Tim-3 in both cell types
We ﬁrst assessed whether healthy primary human leukocytes
(PHL) and malignant human myeloid cell lines express galec-
tin-9 and if its expression could be affected by pro-inﬂamma-
tory stimulation as well as growth factor-induced biological
responses. For this purpose, we used PHL which were isolated
from buffy coat blood obtained from healthy donors and
THP-1 human myeloid leukemia cells which were reported to
express galectin-9.6
We found that THP-1 cells produced more galectin-9 com-
pared to PHL, however, lipopolysaccharide (LPS, ligand of pro-
inﬂammatory Toll-like receptor (TLR) 412) and stem cell
growth factor (SCF—a major haematopoietic cytokine respon-
sible for the promotion of leukemia progression13) signiﬁcantly
upregulated galectin-9 levels in PHL (LPS was however shown,
to be a stronger activator). Interestingly, galectin-9 bands in
PHL cells appeared slightly lower on the gel compared to THP-
1 cells and the positive control (Fig. 1), suggesting potential dif-
ferences in post-translational processing. Only SCF was able to
signiﬁcantly increase galectin-9 levels in THP-1 cells (Fig. 1).
We then asked whether galectin-9 is capable of forming a
complex with Tim-3 in cell lysates. For this purpose, we coated
MaxiSorp ELISA plates with rabbit capture antibody directed
against galectin-9 followed by the addition of cell lysates (see
Materials and Methods). After incubation, galectin-9 was
extracted and detected by Western blot analysis using anti-
galectin-9 rabbit antibody. Tim-3 was also detected using
highly speciﬁc mouse antibody. We found that in both THP-1
and PHL cells Tim-3 and galectin-9 gave positive staining at
above 70 KDa which corresponds to the sum of Tim-3 and
galectin-9 molecular weights detected in these cells by Western
blot analysis (Fig. 2). Traces of free galectin-9 were still detect-
able, while Tim-3 was almost undetectable. The fact that SDS-
PAGE electrophoresis did not separate these proteins indicates
the formation of a stable complex. Since this did not occur with
recombinant proteins expressed in E. Coli (which lack glycosyl-
ation), it is reasonable to surmise that the lectin (galectin-9)
binds to sugar moieties on Tim-3 protein. The fact that both
un-complexed proteins were detected by Western blot in fresh
cell lysates suggests the requirement of both time and the pres-
ence of a surface (a solid phase—ELISA plate bottom in our
case) to form such a steady complex.
Next, we analyzed the cellular distribution of Tim-3 and
galectin-9 comparing intracellular levels with cell-surface
expressions. We used THP-1 and U-937 human myeloid cell
lines, primary human AML cells (AML-PB001F) as well as
PHL. We measured the total amounts of both proteins using
in-cell Western assay in comparison to the amounts present on
the cell surface using in-cell assay (also called on-cell assay; as
described in the Materials and Methods). We observed that
resting THP-1, U-937, and PHL cells expressed substantially
more Tim-3 and galectin-9 intracellularly than on the surface.
In contrast, primary AML cells had comparatively greater sur-
face presence of both proteins (Fig. 3). Interestingly the ratios
of Tim-3surface/Tim-3total and galectin-9surface/galectin-9total
were quite similar to each other in all studied cell types (Fig. 3).
Tim-3 is required for galectin-9 release in human myeloid
leukemia cells
We next asked whether Tim-3 is required for galectin-9
release and used U-937 cells (higher siRNA transfection efﬁ-
ciency could be reached with this cell line using our DOTAP
transfection method) to investigate our hypothesis. We also
studied if galectin-9 is required for Tim-3 production. First,
we knocked down galectin-9 expression in U-937 cells as
outlined in Materials and Methods. Non-treated normal and
galectin-9 knockdown U-937 cells as well as those treated
for 4 h with 2 mg/mL anti-Tim-3 stimulatory antibody5
were analyzed. Successful knockdown of galectin-9 was con-
ﬁrmed by Western blot analysis (Fig. 4A) as well as quanti-
tative real-time reverse transcription PCR (qRT-PCR;
Fig. S1). We found that galectin-9 knockdown reduced cellu-
lar Tim-3 levels as well as affecting galectin-9 levels (both
intracellular and released (Fig. 4A)). Previously, we reported
that Tim-3 activates the mTOR pathway resulting in upregu-
lation of glycolysis and release of pro-angiogenic vascular
endothelial growth factor (VEGF). We found that galectin-9
knockdown upregulated stimulatory phosphorylation of
mTOR (position S2448, Fig. 4B). This result was in line with
the upregulation of glycolysis and VEGF release (Fig. 4B).
Interestingly, we could not observe a signiﬁcant increase in
intracellular levels of methylglyoxal (MGO, Fig. 4B) in either
case, indicating that the efﬁciency of glycolysis correlates
with the activity of glycolytic enzymes, since MGO is
spontaneously formed out of dihydroxyacetone phosphate
when glycolytic enzymes are oversaturated. MGO catalyzes
Figure 1. Effects of LPS and SCF on galectin-9 protein expression in THP-1 cells
and PHL (abbreviated as PL in the ﬁgure). Cells were treated for 4 h with the indi-
cated concentrations of LPS and SCF, then harvested and galectin-9 protein
expression levels were analyzed by Western blot as outlined in Materials and Meth-
ods. Images are from one experiment representatives of three which gave similar
results. Human recombinant galectin-9 (R&D Systems) was used as a positive con-
trol. Data are mean values § SEM of three independent experiments; p < 0.05;
p < 0.01 vs. control.


























glycation followed by generation of advanced glycation end
products (Fig. S2). Higher amounts of these products could
be produced by cancer cells given their dependence on
glycolysis.
In Tim-3 knockdown U-937 cells (successful knockdown
was conﬁrmed by Western blot, Fig. 5A, and qRT-PCR,
Fig. S1), we saw a signiﬁcant reduction in Tim-3 levels. No
reduction in Tim-3/galectin-9 levels and no other effects were
observed when using negative control random siRNA (Fig. 5,
Fig. S1) which conﬁrmed the speciﬁcity of the events observed.
Tim-3 knockdown did not lead to changes in intracellular
galectin-9 levels but dramatically reduced galectin-9 secretion,
suggesting that Tim-3 is required for the release of galectin-9
(Fig. 5A). Reduction in Tim-3-mediated mTOR
phosphorylation at S2448 and respectively downregulation of
glycolysis/VEGF release was also observed in Tim-3 knock-
down U-937 cells. No signiﬁcant changes in MGO levels were
observed suggesting that glycolytic efﬁciency—a key energy
pathway in leukemia cells—was not affected (Fig. 5B).
Tim-3 is a speciﬁc trafﬁcker for galectin-9 in certain
cell types
It is generally known that many cell types, including lymphoid
cells, are capable of producing galectin-9 but not all of them
express Tim-3. We therefore compared the capability of pri-
mary human AML cells and primary human CLL cells to pro-
duce galectin-9. Both cell types secreted detectable amounts of
Figure 2. Galectin-9 and Tim-3 form a stable complex. Lysates obtained from 300,000 THP-1 cells or 1,500,000 PHL (abbreviated as PL in the ﬁgure; expression levels of
both proteins were ca. 5 times lower in PHL compared to THP-1) were loaded onto an ELISA plate pre-coated with rabbit anti-galectin-9 antibody as described in Materials
and Methods). Following incubation, captured proteins were extracted and subjected to Western blot analysis (see Materials and Methods for details). Both Tim-3 (using




























galectin-9. In AML cells, but not in CLL cells, the amount of
secreted galectin-9 was signiﬁcantly increased by 4 h of expo-
sure to 2 mg/mL anti-Tim-3 (Fig. 6A). Both PHL and AML cells
expressed Tim-3 but this expression was much higher in AML
cells compared to PHLs (Tim-3/actin ratios were analyzed,
Fig. 6B). CLL cells expressed almost undetectable amounts of
Tim-3 but still they were capable of releasing galectin-9, indi-
cating that they probably use a different trafﬁcker for this
protein.
Finally, we observed that blood plasma of healthy donors
contained both galectin-9 and soluble Tim-3 as measured by
ELISA. Intriguingly, when capturing Tim-3 on the ELISA plate
and applying detection antibody directed against galectin-9 we
were able to detect a clear signal (Fig. 6C) which was not appli-
cable when intact cell culture medium or galectin-9 standards
were used. This means that a complex formed by non-cell-asso-
ciated soluble Tim-3 and galectin-9 is present in the blood
plasma of healthy donors. Our previous experiments demon-
strated that anti-Tim-3 antibody does not compete with
galectin-9.5
Discussion
Galectin-9 is a typical galectin family member which has a
tandem structure.10,14 It has been reported to speciﬁcally
interact with the immune receptor Tim-3 inducing mTOR
pathway activation as well as forming an autocrine loop
with Tim-3 in human AML cells.3,5 Due to very high
expression levels of Tim-3 in AML cells this protein is cur-
rently considered as a target for anti-AML therapy. Further-
more, galectin-9 was reported to speciﬁcally target cytotoxic
T cells and NK cells and impair their ability to attack and
kill leukemia cells.10,11,15
Our present study clearly shows that human myeloid leuke-
mia cells express and secret galectin-9 (Figs. 1, 3, and 7 and
Fig. S1). Importantly, galectin-9 production is upregulated by
pro-inﬂammatory stimulation (LPS) and growth factor (SCF)
action in both healthy human leukocytes and AML cells (THP-
1 cell line). Release of galectin-9 was clearly dependent on the
Tim-3. Tim-3 knockdown in U-937 cells led to signiﬁcant
reductions in galectin-9 secretion compared to normal (wild
type) U-937 cells (Fig. 5A). Tim-3 protein levels were also
reduced (but not signiﬁcantly) in galectin-9 knockdown U-937
cells compared to wild type cells (Fig. 4A). However, Tim-3
mRNA levels were signiﬁcantly downregulated in galectin-9
knockdown U-937 cells ( Fig. S1) suggesting that transcription
of the Tim-3 gene depends on intracellular levels of galectin-9.
Interestingly, Tim-3 knockdown did not affect intracellular
galectin-9 levels in U-937 cells, as measured by Western blot
analysis, but dramatically reduced the capability of these cells
to secrete galectin-9. These results suggest that galectin-9 levels
inﬂuence Tim-3 expression at a genomic level, whereas Tim-3
Figure 3. Comparative analysis of total and surface-based Tim-3 and galectin-9 proteins in human myeloid leukemia cell lines, PHL, and primary human AML cells. The
indicated numbers of resting U-937 and THP-1 cells, PHL and primary human AML cells (AML-PB001F) were subjected to in-cell assay (ICA, detecting surface proteins) or
in-cell Western (ICW, total protein detection) analysis as described in Materials and Methods. Images are from one experiment representative of ﬁve which gave similar
results. Data are mean values § SEM of ﬁve independent experiments; p < 0.05; p < 0.01 vs. control.


























protein controls the capability of myeloid leukemia cells to
secrete galectin-9.
Recent evidence demonstrated that A disintegrin andmetal-
loproteases (ADAM) 10 and 17 control shedding of Tim-3
from the cell surface in HEK-293 cells and human primary
CD14C monocytes.8 This suggests that Tim-3 might undergo
shedding when it is in complex with galectin-9, which allows
dissociation of the Tim-3 fragment together with the full-length
galectin-9 protein. This hypothesis might explain why LPS
reduces cellular Tim-3 surface expression6,8 taking into account
our results demonstrating LPS-induced upregulation of galec-
tin-9 levels. Our previous study demonstrated that Tim-3 pro-
tein production is not reduced by LPS5 while surface presence
is affected.6,8 This might be the result of increased intracellular
galectin-9 levels leading to enhanced galectin-9 secretion
which, as we have described above, requires Tim-3. ADAM10/
17 or other proteolytic enzymes can then possibly shed the
Tim-3/galectin-9 complex. Further evidence also supports the
rapid shedding process such as via ligand-induced Tim-3-
mediated activation of the mTOR pathway.
Although Tim-3 is a weaker signal transducer compared to
Kit (SCF receptor) or TLR4, a moderate level of mTOR activa-
tion could be the result of swift removal of the extracellular
domain which terminates the signal prematurely compared to
those observed for non-cleaved receptors (as TLR4 or Kit).
Furthermore, in support of a Tim-3/galectin-9 complex shed-
ding scenario, other factors, such as HIV-1 infection, lead to
increases in both soluble Tim-3 and galectin-9 levels in blood
plasma.9,16 Also, phorbol 12-myriastate 13-acetate (PMA) was
found to upregulate galectin release in Jurkat T cells,17 where
Figure 4. The effects of galectin-9 knockdown on Tim-3 expression and the mTOR pathway. Non-treated normal (wild type) and galectin-9 knockdown U-937 cells, as well
as those which underwent 4 h treatment with 2 mg/mL anti-Tim-3 stimulatory antibodies, were analyzed for Tim-3 and galectin-9 levels, galectin-9 release (A), pS2448
mTOR intracellular levels, glycolysis, MGO, and VEGF secretion (B). Images are from one experiment representative of three which gave similar results. Data are mean



























it also upregulates Tim-3 expression/externalisation.18 PMA is
also known to promote Tim-3 proteolytic shedding.8 Matrix
metalloproteinase inhibitor BB-94 (ADAM10 was also found
to be sensitive to it19) was able to abolish PMA-induced
galectin-9 release in Jurkat T cells (immortalised T lympho-
cytic cell line derived from T cell leukemia17), suggesting that
proteolysis is probably involved in shedding Tim-3 complexed
with galectin-9.
Our results also demonstrated that CLL bone marrow
mononuclear cells (containing elevated levels of CD4C T cells
with a cytotoxic phenotype20) are capable of secreting galectin-
9 but they only produce very low amounts of Tim-3 (Figs. 6A
and B ). This suggests that Tim-3 is a cell type-speciﬁc trafﬁcker
of galectin-9 in AML cells, while other cell types (such as CLL
bone marrow mononuclear cells) might use other galectin-9-
speciﬁc proteins, which can be externalized. In support of this,
Figure 5. Tim-3 is required for galectin-9 secretion in human myeloid leukemia cells. Non-treated normal (wild type), Tim-3 knockdown and transfected with random
siRNA U-937 cells, as well as the same cells which underwent 4 h treatment with 2 mg/mL anti-Tim-3, were subjected to analysis for Tim-3 and galectin-9 levels, galectin-
9 release (A), pS2448 mTOR intracellular levels, glycolysis, MGO, and VEGF secretion (B). Images are from one experiment representative of three which gave similar
results. Data are mean values § SEM of 3–5 independent experiments; p < 0.05; p < 0.01 vs. control; ap < 0.05; aap < 0.01 vs. anti-Tim-3; bp < 0.05; bbp < 0.01 vs.
random siRNA.


























there is evidence that galectin-9 may cause Tim-3-independent
effects (including apoptosis) in lymphoid cells.10,21
In human blood plasma obtained from healthy donors, we
found that both galectin-9 and soluble Tim-3 are present
(Fig. 6C). However, anti-Tim-3 detection antibodies also gave
rise to a positive signal to visualize the product captured by
anti-galectin-9 antibody (Fig. 6C). This clearly indicates that a
Tim-3/galectin-9 complex is present in human blood plasma.
However, our results do not provide any indication at which
point the complex was formed.
Figure 6. Galectin-9 and Tim-3 levels in primary human AML, CLL, and PHL cells as well as in blood plasma. (A) Non treated primary human AML and CLL cells, as well as
those exposed for 4 h to anti-Tim-3, were precipitated and medium was subjected to measurement of galectin-9 by ELISA. Data represent mean values § SEM of three
independent experiments; p < 0.05 vs. control. (B) PHL, primary human AML, and CLL cells were subjected to Western blot analysis for Tim-3. Images are from one
experiment representative of four which gave similar results. Data are mean values § SEM of four independent experiments. (C) Blood plasma of six healthy donors was
subjected to ELISA assays for galectin-9, soluble Tim-3, and Tim-3-galectin-9 complex (for details, please see Materials and Methods and diagrams underneath the table).
Data are mean values § SEM of 3–5 independent experiments.



























Our results suggest that Tim-3 is required for galectin-9
secretion in AML cells and this mechanism may be then
used to impair the anticancer activity of cytotoxic T cells
and NK cells, which might allow malignant blood cells to
escape immune attack. Our hypothesis is summarized in
the Fig. 7.
Our ﬁndings also demonstrated that decrease in intracellular
galectin-9 level increases mTOR activity and its downstream
effects (efﬁcient glycolysis and VEGF production, Fig. 4A). In
myeloid leukemia cell lines as well as in PHL, the activity of the
mTOR pathway is always lower than in primary AML cells.4,5
One of the reasons for this might be externalisation of the Tim-
3/galectin-9 complex in primary AML cells (conﬁrmed in our
studies—see Fig. 3). In this case, while there are lower amounts
of galectin-9 inside the cells Tim-3/galectin-9 complexes are
externalized on the cell surface, which can initiate signaling
events before further modiﬁcation or proteolytic shedding.
These effects are presented in Fig. 8, which summarizes Tim-3
signal transducing activities in PHL/AML cell lines compared
with primary human AML cells.
Our results also highlight that both Tim-3 and galectin-9 are
promising therapeutic targets for possibly curing AML.
Absence of the Tim-3/galectin-9 autocrine loop or the timely
capture and subsequent inactivation of biologically active galec-
tin-9 may reduce the ability of AML cells to impair the antican-
cer activities of NK cells and cytotoxic T cells. This may
therefore result in the natural eradication of cancer cells by
functional NK cells and cytotoxic T cells.
Figure 8. Distribution of complexes and corresponding effects of Tim-3 and galectin-9 in healthy and malignant human white blood cells. (A) Scheme demonstrating
intracellular signaling pathways induced by Tim-3-galectin-9 complexes. (B) Tim-3/galectin-9 distribution and corresponding effects in PHL and human myeloid leukemia
cell lines (THP-1 and U-937). (C) Tim-3/galectin-9 distribution and corresponding effects in primary human AML cells.




























RPMI-1640 medium, foetal bovine serum and supplements,
LPS (from P. aeruginosa), DOTAP transfection reagent, pri-
mers and galectin-9 silencing RNA (siRNA) were purchased
from Sigma (Suffolk, UK). MaxisorpTM microtitre plates
were provided either by Nunc (Roskilde, Denmark) or were
a kind gift of Oxley Hughes Ltd (London, UK). Mouse
monoclonal antibodies directed against mTOR and b-actin
as well as rabbit polyclonal antibodies against phospho-
S2448 mTOR, galectin-9, Tim-3, and HRP-labeled rabbit
anti-mouse secondary antibody were purchased from Abcam
(Cambridge, UK). Goat anti-mouse and goat anti-rabbit
ﬂuorescence dye-labeled antibodies were obtained from
Li-Cor (Lincoln, Nebraska USA). ELISA-based assay kits for
the detection of VEGF were purchased from Bio-Techne
(R&D Systems, Abingdon, UK). All other chemicals pur-
chased were of the highest grade of purity.
Primary human AML and CLL cells
Primary human AML mononuclear blasts (AML-PB001F,
newly diagnosed/untreated) were purchased from AllCells
(Alameda, CA, USA) and handled in accordance with manu-
facturer’s instructions. Primary human bone marrow derived
CLL mononuclear cells (CLL-BM001F, newly diagnosed/
untreated leukemia) were also obtained from AllCells
(Alameda, CA, USA) and handled in accordance with manu-
facturer’s protocol. Cells from six different patients were ana-
lyzed following ethical approval (REC reference: 16-SS-033).
THP-1 and U937 human myeloid cell lines
THP-1 human myeloid leukemia monocytes and U937
human myeloid monocytes were obtained from the
European Collection of Cell Cultures (Salisbury, UK). Cells
were cultured in RPMI 1640 media supplemented with 10%
foetal bovine serum, penicillin (50 IU/mL) and streptomycin
sulfate (50 mg/mL).
Primary human leukocytes obtained from healthy donors
(buffy coats)
PHL were obtained from buffy coat blood (originated from
healthy donors undergoing routine blood donation) which
was purchased from the National Health Blood and Trans-
fusion Service (NHSBT, UK) following ethical approval
(REC reference: 16-SS-033). Mononuclear-rich leukocytes
were obtained by Ficoll-density centrifugation according to
the manufacturer’s protocol. Cell numbers were counted
using a haemocytometer and diluted accordingly with
HEPES-buffered Tyrode’s solution before the indicated
treatments.4
Stem cell factor
Human SCF protein was produced in E. Coli and puriﬁed in
accordance with previously published protocols.20
Transfer of Galectin-9/Tim-3 siRNA into U-937 cells and
qRT-PCR
We employed a galectin-9-speciﬁc siRNA target sequence (uga
ggu gga agg cga ugu ggu ucc c) which was previously
described.14 For Tim-3 knockdown, we used commercially
available siRNA purchased from Santa Cruz Biotechnology,
CA, USA, as described before.7 As a control, we used corre-
sponding random siRNA (uac acc guu agc aga cac c dtdt22).
Transfection into U-937 cells was performed using DOTAP
reagent according to the manufacturer’s protocol.
To monitor galectin-9 and Tim-3 mRNA levels, we used
qRT-PCR.21 Total RNA was isolated using a GenEluteTM mam-
malian total RNA preparation kit, followed by a target protein
mRNA reverse transcriptase–polymerase chain reaction
(RT-PCR) performed in accordance with the manufacturer’s
protocol (Sigma). This was followed by quantitative real-time
PCR. Primer selection was as follows: Galectin-9, 50-CTTTCAT-
CACCACCATTCTG-30, 50-ATGTGGAACCTCTGAGCACTG-
30 Tim-3, 50-CATGTTTTCACATCTTCCC-30 actin, 50-TGACG
GGGTCACCCACACTGTGCCCATCTA-30, 50-CTAGAAGC
ATTTGCGGTCG-ACGATGGAGGG-30. Reactions were per-
formed using a LightCycler 480 real-time PCR system and
respective SYBR Green I Master kit (obtained from Roche, Burgess
Hill, UK). Analysis was performed according to the manufacturer’s
protocol. Values representing galectin-9 and Tim-3 mRNA levels
were normalized against b-actin.
Western blot analysis
Expressions of Tim-3 and galectin-9 were determined by
Western blot analysis and compared to b-actin in order to
determine equal protein loading, as previously described.4 Li-
Cor goat secondary antibodies, conjugated with ﬂuorescent
dyes, were used in accordance with manufacturer’s protocol to
visualize target proteins (using a Li-Cor Odyssey imaging sys-
tem). Western blot data were quantitatively analyzed using
Odyssey software and values were subsequently normalized
against those of b-actin.
Detection of phospho-S2448 mTOR in cell lysates by ELISA
Phosphorylation of mTOR was analyzed by ELISA as described
before.23 Brieﬂy, 96-well ELISA plates were coated with mouse
anti-mTOR antibodies followed by blocking with 2% BSA. Cell
lysates were then added to the wells and incubated at room
temperature for 2 h (with constant agitation). Plates were then
washed with Tris-Buffered Saline containing Tween 20 (TBST).
Following washing with TBST buffer plates were incubated
with HRP-labeled goat anti-rabbit IgG for 1 h at room temper-
ature. Plates were then washed using TBST and bound second-
ary antibodies were visualized by the peroxidase reaction
(ortho-phenylenediamine/H2O2).
In-cell Western and in-cell (on-cell) assay
We employed a standard Li-Cor in-cell Western assay to ana-
lyze total Tim-3 and galectin-9 expressions in the studied cells.4



























characterized Tim-3 and galectin-9 surface presence in the
studied cells.
Characterization of Tim-3 and galectin-9 interactions in
cell lysates
An ELISA-based analysis was used where plates were ﬁrst
coated with anti-galectin-9 antibody followed by blocking with
2% BSA. Cell lysates were then applied and incubated for at
least 4 h at room temperature after which plates were exten-
sively washed with TBST. A glycine-HCl pH lowering buffer
(pH 2.0) was then applied to extract the bound proteins.
Extracts were mixed with equal volumes of lysis buffer (pH 7.5)
and with 4£ sample buffer for SDS-PAGE at a ratio of 1:3.
Samples were then subjected to Western blot analysis, using
rabbit anti-galectin-9 and mouse anti-Tim-3 primary antibod-
ies, as described above. The plate was subjected to analysis with
galectin-9 detection antibody followed by standard ELISA steps
to ensure that no galectin-9 remained in the wells. Signals
obtained were similar to those where PBS was used instead of
the sample conﬁrming that all the protein was extracted.
Detection of galectin-9 and VEGF secretion, soluble forms
of Tim-3 and Tim-3-galectin-9 complexes
Galectin-9 and VEGF levels released into the medium were
analyzed by ELISA (R&D Systems assay kits) according to the
manufacturer’s instructions. Soluble Tim-3 was detected using
similar approach where mouse anti-Tim-3 (mAnti-Tim-3) was
employed as a capture antibody and rabbit anti-Tim-3 (rAnti-
Tim-3)—for detection (Fig. 6C, scheme). HRP-labeled anti-
Rabbit secondary antibody (Abcam) was used to visualize the
reaction. Tim-3-galectin-9 complexes in blood plasma were
detected by ELISA. Mouse anti-Tim-3 (mAnti-Tim-3) was
employed as a capture antibody and biotinylated goat anti-
galectin-9 (gAnti-Galectin-9, R&D Systems) as detection anti-
body. The reaction was visualized using HRP-labeled streptavi-
din (R&D Systems; Fig. 6C, scheme). In all cases plates were
washed using TBST and bound secondary antibodies visualized
by the peroxidase reaction (ortho-phenylenediamine/H2O2).
Characterization of glycolysis and MGO levels
Glycolytic degradation of glucose was analyzed using a colori-
metric assay as described before.20 Brieﬂy, the approach was
based on the ability of cell lysates, used as a multi-enzyme prepa-
ration, to convert glucose into lactate in the absence of oxygen
(this was achieved by employing an anaerobic chamber). Cell
lysates were incubated for 1 h at 37C with 1% glucose solution
within the anaerobic chamber. 2% trichloroacetic acid solution
was then used to precipitate proteins. This was followed by
carbohydrate precipitation using saturated CuSO4 solution in
combination with Ca(OH)2 (at a ﬁnal concentration of
60 mg/mL). Lactate was then converted into acetic aldehyde
using concentrated H2SO4 at 90C for 1 min and cooled the sam-
ples down on ice. We then detected acetaldehyde using the vera-
trole (1,2-dimethoxybenzene) test. MGO was also detected
colorimetrically following biochemical modiﬁcations.24,25 Brieﬂy,
MGO was condensed with reduced glutathione (GSH, 1 mM)
for 10 min at 37C. The complex was then converted into lactate
by Glyoxalases I and II at pH 8.0 (Glyoxalase I converted the
complex in D-lactoyL-glutathione, which was then transformed
into lactate by Glyoxalase II26). The whole process is highlighted
in Fig. S2). Lactate was then measured colorimetrically as
described above.
Statistical analysis
Each experiment was performed at least three times and sta-
tistical analysis was conducted using a 2-tailed Student’s t
test. Statistical probabilities (p) were expressed as p < 0.05,
p < 0.01, and p < 0.001.
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Supplementary Figure 1. qRT-PCR analysis of galectin-9 and Tim-3 mRNA levels in U-
937 cells. Non-treated normal (wild type), galectin-9 knockdown, Tim-3 knockdown and 
transfected with random siRNA U-937 cells, as well as the same cells which underwent 4 h 
treatment with 2 µg/ml anti-Tim-3, were used. Total RNA was isolated and subjected to qRT-
PCR analysis of Tim-3 and galectin-9 mRNA levels as outlined in Materials and Methods. 
Data are mean values ± SEM of eight independent reactions; * – p < 0.05; ** – p < 0.01 vs. 




Supplementary figure 2. Biochemistry of glycolytic degradation of glucose, generation 
of methylglyoxal (MGO) and MGO-dependent formation of advanced glycation end 
(AGE) products. The scheme contains the biochemistry of glycolysis, shows spontaneous 
conversions of dihydroxyacetone phosphate -and possibly glyceraldehyde-3-phosphate- into 
MGO. The scheme highlights (in red) the process of conversion of MGO into lactate (used 
also to design the biochemical assay to detect MGO levels). The Maillard reaction between 
glucose and L-lysine leading to the generation of the Amadori adduct followed by conversion 
into carboxymethyl lysine and then into AGE is presented.  
Additional abbreviations used: HK – hexokinase, PGI – phosphoglucose isomerase, PFK – 
phosphofructokinase, AL – Aldolase, TPI – Triose-phosphate isomerase, GPDH – 
glyceraldehyde-3-phosphate dehydrogenase, PGK – phosphoglycerate kinase, PGM – 
phosphoglycerate mutase, EL – enolase, PK – pyruvate kinase, LDH – lactate dehydrogenase, 
DHAP – dihydroxyacetone phosphate, GA3-P – glyceraldehyde-3-phosphate, 3-PG – 3-
phosphoglycerate, 2-PG – 2-phosphoglycerate, PEP – phosphoenolpyruvate, G-SH – reduced 
glutathione, GLO (I or II) – glyoxalases I and II. 
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Acutemyeloid leukemia (AML) is a severe and often fatal systemicmalignancy. Malignant cells are capable of es-
caping host immune surveillance by inactivating cytotoxic lymphoid cells. In this work we discovered a funda-
mental molecular pathway, which includes ligand-dependent activation of ectopically expressed latrophilin 1
and possibly other G-protein coupled receptors leading to increased translation and exocytosis of the immune
receptor Tim-3 and its ligand galectin-9. This occurs in a protein kinase C and mTOR (mammalian target of
rapamycin)-dependent manner. Tim-3 participates in galectin-9 secretion and is also released in a free soluble
form. Galectin-9 impairs the anti-cancer activity of cytotoxic lymphoid cells including natural killer (NK) cells.
Soluble Tim-3 prevents secretion of interleukin-2 (IL-2) required for the activation of cytotoxic lymphoid cells.
These results were validated in ex vivo experiments using primary samples from AML patients. This pathway
provides reliable targets for both highly speciﬁc diagnosis and immune therapy of AML.









Acutemyeloid leukemia (AML) is a blood/bonemarrow cancer orig-
inating from self-renewing malignant immature myeloid precursors,
which rapidly becomes a systemic malignancy. It is often a fatal disease
becausemalignant cells are capable of suppressing anti-cancer immuni-
ty by impairing the functional activity of natural killer (NK) cells and cy-
totoxic T cells (Golden-Mason et al., 2013;Wang et al., 2007; Khaznadar
et al., 2014). Recent evidence clearly demonstrated an involvement of
the T cell immunoglobulin and mucin domain 3 (Tim-3) - galectin-9
pathway in this immune escape mechanism (Golden-Mason et al.,
2013; Kikushige et al., 2015; Gonçalves Silva et al., 2016). Galectin-9 is
a β-galactoside-binding lectin, which has a tandem structure and
contains two carbohydrate recognition domains (CRDs) fused together
by a peptide (Delacour et al., 2009). Galectin-9 has a speciﬁc receptor
on AML cells known as Tim-3 which also could act as its possible traf-
ﬁcker (galectin-9 as all other galectins lacks a signal sequence required
for transport into the endoplasmic reticulum (ER) and thus requires a
trafﬁcking protein for its secretion (Hughes, 1999; Delacour et al.,
2009)). However, the mechanisms underlying the activation of biosyn-
thesis of the components of the Tim-3-galectin-9 autocrine loop,
galectin-9 secretion and its effects on cytotoxic lymphocytes (NK cells
and T cells) remain poorly understood.
Recently, we discovered that humanAML cells – but not healthy leu-
kocytes – express physiologically active latrophilin 1 (LPHN1;
Sumbayev et al., 2016). LPHN1, an adhesion G-protein-coupled recep-
tor, is highly expressed in neuronal axon terminals and in many secre-
tory cells (Davletov et al., 1998; Silva and Ushkaryov, 2010). In all cells
expressing this receptor, LPHN1 activation by its most potent agonist,
α-latrotoxin (LTX) from black widow spider venom (Ushkaryov,
2002), triggers intracellular Ca2+ signaling and exocytosis of neuro-
transmitters and hormones (Volynski et al., 2003). Similarly, ligand-
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induced activation of LPHN1 in AML cells facilitates exocytosis of cyto-
kines and growth factors (Sumbayev et al., 2016). Production of
LPHN1 in AML cells is controlled by themammalian target of rapamycin
(mTOR) (Sumbayev et al., 2016), a highly conserved serine/threonine
kinase that acts as a central regulator of growth and metabolism in
healthy and malignant human myeloid cells (Yasinska et al., 2014). To
function in cell-cell interactions and cell signaling, LPHN1 can interact
with at least two endogenous ligands, Lasso/teneurin-2 (Silva et al.,
2011) and ﬁbronectin leucine rich transmembrane protein 3 (FLRT3)
(Boucard et al., 2014), although only FLRT3 seems to be expressed in pe-
ripheral tissues. In addition to triggering exocytosis by increasing cyto-
solic Ca2+, LPHN1 can enhance the sensitivity of the release machinery
by activating protein kinase C (Liu et al., 2005), which is also thought to
be involved in galectin-9 secretion (Chabot et al., 2002). Based on these
observations, we hypothesized that activation of LPHN1 by its ligands
can induce secretion of galectin-9, thus protecting AML cells against
NK and cytotoxic T cells. This hypothesis has been studied experimen-
tally in the present study.
Here we report that the Tim-3-galectin-9 autocrine loop is
activated in AML cells through protein kinase C (PKC)/mTOR
pathways. These pathways trigger translation of both Tim-3 and
galectin-9 and induce high levels of galectin-9 secretion as well as
the release of soluble Tim-3. Importantly, this effect was also veriﬁed
in the AML patients studied. Galectin-9 was found to impair AML cell
killing by primary human NK cells. Soluble Tim-3 reduced the ability
of T cells to secrete IL-2, a cytokine, which is required for the
activation of both NK cells and cytotoxic T cells (Dhupkar and
Gordon, 2017). Blood plasmas of AML patients contained
signiﬁcantly lower amounts of IL-2 compared to those of healthy
donors. We conﬁrmed that PKC activation occurred in AML cells in
a LPHN1-dependent manner. The LPHN1 agonist LTX and natural
ligand FLRT3 upregulated the Tim-3-galectin-9 autocrine loop in a
PKC-dependent manner. Based on our ﬁndings, we conclude that
LPHN1/PKC/mTOR/Tim-3-galectin-9 is a biosynthetic and secretory
pathway which is operated by human AML cells resulting in a
decrease of immune surveillance and promotion of disease
progression.
2. Materials and Methods
2.1. Materials
RPMI-1640 medium, fetal bovine serum and supplements and basic
laboratory chemicals were purchased from Sigma (Suffolk, UK).
Maxisorp™microtitre plates were provided either by Nunc (Roskilde,
Denmark) and Oxley Hughes Ltd. (London, UK). Mousemonoclonal an-
tibodies directed against mTOR and β-actin, as well as rabbit polyclonal
antibodies against phospho-S2448 mTOR, galectin-9, HRP-labelled rab-
bit anti-mouse secondary antibody were purchased from Abcam (Cam-
bridge, UK). Mouse monoclonal antibody against FLRT3 was obtained
from Santa Cruz Biotechnology (Heidelberg, Germany). The polyclonal
rabbit anti-peptide antibody (PAL1) against LPHN1 was described pre-
viously (Davydov et al., 2009). LTXwas puriﬁed as previously described
(Ashton et al., 2000). Goat anti-mouse and goat anti-rabbit ﬂuorescence
dye-labelled antibodies were obtained from LI-COR (Lincoln, Nebraska
USA). ELISA-based assay kits for the detection of galectin-9, Tim-3 and
IL-2 were purchased from Bio-Techne (R&D Systems, Abingdon, UK).
Anti-Tim-3 mouse monoclonal antibody, its single chain variant as
well as human Ig-like V-type domain of Tim-3 (amino acid residues
22–124), expressed and puriﬁed from E. coli (Prokhorov et al., 2015)
were used in our work. Secondary antibodies for confocal laser
microscopy and imaging ﬂow cytometry (goat anti-mouse and goat
anti-rabbit Alexa 488, Alexa 555 and Alexa 647) were from Invitrogen
(Carlsbad, USA). All other chemicals purchased were of the highest
grade of purity.
2.2. Cell Lines and Primary Human Cells
THP-1 humanmyeloid leukemiamonocytes, K562 chronicmyeloge-
nous leukemia cells and Jurkat T cells were obtained from the European
Collection of Cell Cultures (Salisbury, UK). Renal clear cell carcinoma
RCC-FG1 cells were obtained from CLS Cell Lines Service (Eppelheim,
Germany). Cells were cultured in RPMI 1640 media supplemented
with 10% fetal bovine serum, penicillin (50 IU/ml) and streptomycin
sulfate (50 μg/ml). LAD2 mast cells were kindly provided by A.
Kirshenbaum and D. Metcalfe (NIH, USA). Cells were cultured in Stem-
Pro-34 serum-free media in the presence of 100 ng/ml SCF
(Kirshenbaum et al., 2003).
Primary human AMLmononuclear blasts (AML-PB001F, newly diag-
nosed/untreated)were purchased fromAllCells (Alameda, CA, USA) and
handled in accordance with the manufacturer's instructions. Primary
human NK cells were puriﬁed from buffy coat blood (prepared from
healthy donors) obtained from the National Health Blood and Transfu-
sion Service (NHSBT, UK) following ethical approval (REC reference:
16-SS-033). Primary CD34-positive HSCs were obtained from Lonza
(Basel, Switzerland).
Femur bones of six-week-old C57 BL16mice (25± 2.5 g, kindly pro-
vided by Dr. Gurprit Lall, School of Pharmacy, University of Kent) were
used for the experiments following approval by the Institutional Animal
Welfare and Ethics Review Body. Animals were handled by authorized
personnel in accordance with the Declaration of Helsinki protocols.
Bone marrow was isolated from femur bone heads as described before
(Swamydas and Lionakis, 2013) and whole extracts (1 mg protein/ml)
were then obtained.
2.3. Primary Human Plasma Samples
Blood plasma of healthy donors was obtained from buffy coat
blood (originated from healthy donors undergoing routine blood
donation) which was purchased from the National Health Blood
and Transfusion Service (NHSBT, UK) following ethical approval
(REC reference: 16-SS-033). Primary human AML plasma samples
were obtained from the sample bank of University Medical Centre
Hamburg-Eppendorf (Ethik-Kommission der Ärztekammer
Hamburg, reference: PV3469).
2.4. Western Blot Analysis
Tim-3, galectin-9, FLRT3, LPHN1 and Gαq were analyzed by
Western blot and compared to β-actin in order to verify equal pro-
tein loading, as previously described (Yasinska et al., 2014). Brieﬂy,
cells were lysed using lysis buffer (50 mM Tris–HCl, 5 mM EDTA,
150 mM NaCl, 0.5% Nonidet-40, 1 mM PMSF, pH 8.0). After centrifu-
gation, the protein content in the supernatants was analyzed. Finally,
samples were added to the same volume of 2× sample buffer
(125 mM Tris–HCl, 2% sodium dodecyl sulfate (SDS), 10% glycerine,
1 mM dithiothreitol (DTT), 0.002% bromophenol blue, pH 6.9) and
boiled for 5 min. Proteins were resolved using SDS–polyacrylamide
gels followed by blotting onto nitrocellulose membranes. Molecular
weights were calibrated in proportion to the running distance of
rainbow markers. For all primary antibodies (see Materials section)
a 1:1000 dilution was used, except those against LPHN1 and FLRT3
(where a 1:500 dilution was used). β-actin staining was used to
conﬁrm equal protein loading as described previously (Yasinska et
al., 2014). LI-COR goat secondary antibodies (dilution 1:2000),
conjugated with ﬂuorescent dyes, were used in accordance with
manufacturer's protocol to visualize target proteins (using a LI-COR
Odyssey imaging system). Western blot data were quantitatively
analyzed using Odyssey software and values were subsequently
normalized against those of β-actin.
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2.5. Characterization of Tim-3 and Galectin-9 in Tissue Culture Medium
Secreted Tim-3 and galectin-9 were characterized in the RPMI-1640
mediumused to culture THP-1 cells. The proteinswere ﬁrst precipitated
onMaxisorp ELISA plates (seeMaterials section). For this purpose ELISA
plateswere coated overnight using single-chain antibody against Tim-3.
Plates were then blocked with 2% BSA. Tissue culture mediumwas then
applied and incubated for 4 h at room temperature, followed by exten-
sivewashingwith TBST buffer. Proteinswere then extracted using 0.2M
glycine-HCl buffer (pH 2.0). Extracts were neutralized using lysis buffer
and subjected toWestern blot analysis usingmouse anti-Tim-3 and rab-
bit anti-galectin-9 antibodies as described before (Gonçalves Silva et al.,
2016) and above.
2.6. Enzyme-linked Immunosorbent Assays (ELISAs)
Galectin-9, sTim-3 and IL-2 were measured by ELISA using R&D Sys-
tems kits according to manufacturer's protocols. In all cases the proce-
dure involves speciﬁc detection of captured target proteins using
biotinylated detection antibody. The interaction was then analyzed
using streptavidin conjugated with horseradish peroxidase (HRP) ac-
cording to the manufacturer's protocol. Tim-3-galectin-9 complex was
also analyzed by ELISA. Single-chain antibody (described above, dilution
1:100)was used to capture the complex and biotinylated goat R&D Sys-
tems antibody against galectin-9 (detection antibody) was used to de-
tect galectin-9 bound to Tim-3. HRP-labelled streptavidin was then
used to perform quantitative analysis according to the R&D Systems
protocol for the galectin-9 assay kit. Phosphorylation of mTORwas ana-
lyzed by ELISA as previously described (Yasinska et al., 2014).
2.7. In Cell Assays and in Cell Westerns
Weemployed a standard LI-COR in-cellWestern (ICW) assay (meth-
anol was used as permiabilization agent) to analyze total Tim-3 and
galectin-9 expressions in the studied cells. The in-cell (ICA, also called
on-cell) assay was employed to characterize Tim-3 and galectin-9 sur-
face presence in the studied cells. We also used this assay to visualize
binding of LAD2 cells toNK cells. IgE-sensitized LAD2 cellswere exposed
for 5 min to 1 μg/ml, carefully washed with sterile PBS and exposed to
LI-COR goat anti-mouse labelled secondary antibody. Following wash-
ing with PBS, cells were scanned using a LI-COR Odyssey imaging sys-
tem (Gonçalves Silva et al., 2016).
2.8. Confocal Microscopy and Imaging Flow Cytometry
THP-1 cells were grown on 12 mm cover glasses in 24-well plates.
Cells were treated (o/n) with PMA and then ﬁxed/permeabilized for
20 min with ice-cold MeOH or MeOH/acetone. Alternatively cells were
ﬁxed in a freshly prepared 2% paraformaldehyde, washed 3 times with
PBS and then permeabilized with 0.1%TX-100. Cover glasses were
blocked for 1 h at RTwith 10% goat serum in PBS. 1 μg/ml anti-Tim-3 an-
tibody and anti-galectin-9 antibody were used as primary antibodies
and incubated o/n at 4 °C. Goat-anti-mouse Alexa Fluor 488 and goat-
anti-rabbit Alexa Fluor 555 were used as secondary antibodies. Cells
were incubated with secondary antibodies for 45 min at RT. The prepa-
rations were examined on Olympus laser scanning confocal microscope
as described (Prokhorov et al., 2015; Fasler-Kan et al., 2010). Images
were collected and analyzed using proprietary image acquisition soft-
ware. Imaging ﬂow cytometry was performed in accordancewith a pre-
viously described protocol (Fasler-Kan et al., 2016). Brieﬂy,
permiabilized cells were stained with mouse anti-Tim-3 and rabbit
anti-galectin-9 antibodies for 1 h at room temperature. Goat anti-
mouse Alexa Fluor 647 and goat-anti-rabbit Alexa Fluor 488 were
used as secondary antibodies. Images were collected and analyzed
using IDEAS analytical software on ImageStream X mark II (Amnis-
EMD-Millipore, USA).
2.9. Synchrotron Radiation Circular Dichroism Spectroscopy
Human recombinant Tim-3, human recombinant galectin-9 and
Tim-3-galectin-9 complex were analyzed using SRCD spectroscopy at
beam line 23, Diamond Light Source (Didcot, UK). SRCD measurements
were performed using 0.2 μg/ml of samples in 10 cm path length cell,
3 mm aperture diameter and 800 μl capacity using Module B with
1 nm increment, 1 s integration time, 1.2 nm bandwidth at 23 °C
(Hussain et al., 2012a, 2012b; Siligardi and Hussain, 2015). The results
obtained were processed using CDApps (Hussain et al., 2015) and
OriginLab™.
2.10. PKCα Activity Assay
The catalytic activity of PKCα was measured as described before
based on its ability to phosphorylate speciﬁc substrate in a reaction buff-
er containing 20mMTris-HCl (pH 7.5), 20 μMATP, 5mMMgCl2 and 200
μM CaCl2 (Micol et al., 1999). Phosphate groups attached to the sub-
strate were detected using colorimetric assay (Abooali et al., 2014).
2.11. Cell Viability Assay
Cell viability was analyzed using the Promega UK Ltd. (Southamp-
ton, UK) assay kit. We used an MTS colorimetric assay for assessing
cell metabolic activity. NAD(P)H-dependent cellular oxidoreductase en-
zymes playing crucial role in human myeloid cell survival (Sumbayev
and Nicholas, 2010), reﬂect the number of viable cells present. Cells
were incubated with 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS)
and then absorbance was measured at 490 nm in accordance with the
manufacturer's protocol.
2.12. Leukemia Cell Protection Assay
K562 and NK cells were cultured separately or as a 1:2 co-culture
(K562:NK) for 16 h, at 37 °C, in the absence or presence of 0.5–
5 ng/ml of galectin-9. The unﬁxed cell cultures were then imaged
under an inverted microscope (TE200, Nikon), using phase-contrast
lighting, a digital camera and the WinFluor image acquisition software
(J. Dempster, University of Strathclyde). Raw images were analyzed
using the ImageJ software (Schindelin et al., 2015), including illumina-
tion correction, background subtraction, overlapping cells separation,
edge artefacts elimination, and particle size optimization (based on
the size difference between K562 and NK cells). The selected areas
were then applied to the raw images for automatic cell counting.
2.13. Statistical Analysis
Each experiment was performed at least three times and statistical
analysis when comparing two events at a time was conducted using a
two-tailed Student's t-test. Multiple comparisons were performed
using ANOVA test. Post-hoc Bonferroni correction was applied. Statisti-
cal probabilities (p) were expressed as * where p b 0.05; **, p b 0.01 and
*** when p b 0.001.
3. Results
3.1. Differential Proteolytic Enzymes are Involved in the Secretion of the
Tim-3 and Galectin-9 Complex in Human AML Cells
We investigated differential proteolytic shedding of free and
galectin-9-bound Tim-3 from the surface of human AML cells as a pos-
sible mechanism for the secretion of these proteins. Firstly, we exam-
ined the medium used to culture THP-1 human AML cells with or
without 16 h exposure to 100 nM phorbol 12-myristate 13-acetate
(PMA) known to activate proteolytic shedding of Tim-3 (Moller-
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Hackbarth et al., 2013). We then immunoprecipitated Tim-3 from the
medium and extracted the precipitate as outlined in the Materials and
Methods. Extracts were subjected to Western blot analysis followed
by speciﬁc detection of galectin-9 and Tim-3. Speciﬁc galectin-9 bands
appeared at around 32 kDa (molecular weight of galectin-9) as well as
52 kDa (Fig. 1A). Interestingly, the 52 kDa band was also detectable by
anti-Tim-3 antibody (Fig. 1A), suggesting that this band corresponds
to the unbroken Tim-3-galectin-9 complex. Furthermore, speciﬁc Tim-
3 bands appeared at around 33 kDa (molecular weight of soluble Tim-
3 – sTim-3) and around 20 kDa. This 20 kDa band is likely to be a
fragment of Tim-3 shed together with galectin-9 being released from
the complex during theWestern blot procedure (Fig. 1A). This suggests
that the Tim-3 protein fragment complexed with galectin-9 might be
shed at different cleavage site(s). Interestingly, the amount of all the
proteins detected was clearly higher in PMA-treated samples.
It has recently been found that Tim-3 can be shed from the cell sur-
face by a disintegrin andmetalloproteinase domain-containing proteins
(ADAM) 10/17 (Moller-Hackbarth et al., 2013). We therefore investi-
gated whether these proteases are associated with release of free Tim-
3 and/or of the galectin-9-Tim-3 complex. We exposed THP-1 cells for
16 h to 100 nM PMA, after which the PMA-containing medium was re-
moved and replaced with the same medium containing 100 μM
GI254023X (ADAM 10 and 17 inhibitor) or 100 μMBB-94, a matrix me-
talloproteinase inhibitor. The cells were incubated for 4 h and levels of
Tim-3 and galectin-9 were then measured in the culture medium by
ELISA. We also measured soluble Tim-3-galectin-9 complex by captur-
ing Tim-3 using a single-chain antibody and then detecting galectin-9
using a biotinylated anti-galectin-9 antibody. We found that PMA
treatment signiﬁcantly upregulated sTim-3 release as well as the release
of galectin-9 (a similar increase was observed in the Tim-3-galectin-9
complex, Fig. 1B). GI254023X and BB-94 decreased PMA-induced sTim-
3 release but did not affect the release of either galectin-9 or the Tim-3-
galectin-9 complex (Fig. 1B), suggesting that this complex is differentially
shed from the cell surface.
3.2. Protein Kinase C is Involved in the Activation of Tim-3 and Galectin-9
co-secretion by AML Cells
We considered the levels of Tim-3 and galectin-9 remaining in
THP-1 cells following 16 h of exposure to speciﬁc PKC activator
PMA. It was found that, despite the levels of released sTim-3,
galectin-9 and Tim-3-galectin-9 complex were increased in PMA-
treated cells, the levels of respective cell-associated proteins
decreased (Fig. 2). Interestingly, a speciﬁc band in the range of
70 kDa detectable by both anti-Tim-3 and anti-galectin-9 antibodies
was present in all the assays (Fig. 2). This molecular weight
corresponds to a sum of those of uncleaved Tim-3 and galectin-9.
This indicates that a complex between full Tim-3 and galectin-9 is
ﬁrst formed before undergoing shedding, which results in a release
of its soluble form corresponding to the 52 kDa species, as described
above. Our observations were conﬁrmed by co-localization assays
using confocal microscopy (Fig. 3). Following 24 h exposure to
100 nM PMA, paraformaldehyde-ﬁxed non-permeabilized and
methanol-permeabilized THP-1 human AML cells were investigated.
We found that both galectin-9 and Tim-3 were present on the cell
surface. In permeabilized cells there was clear evidence of co-localization
Fig. 1. Free and galectin-9-bound Tim-3 is shed differentially from the cell surface. THP-1 cells were exposed for 16 h to 100 nM PMA; medium was then exchanged for fresh PMA-free
medium and cells exposed to the indicated concentrations of GI254023X (ADAM10/17 inhibitor) and BB-94 (matrix metalloproteinase inhibitor). Non treated THP-1 cells were
incubated for 16 h after which medium was changed and cells incubated for further 4 h and used as a control. Western blot characterization of galectin-9 and Tim-3 variants (20 kDa
fragment (Tim-3 (fr)) and 33 kDa (sTim-3)) was performed in medium collected after ﬁnal 4 h of incubation of resting and PMA-pre-treated THP-1 cells as outlined in the Materials
and Methods (A). All the samples were subjected to ELISA-based detection of galectin-9, soluble Tim-3 and Tim-3-galectin-9 complex (B). Images are from one experiment
representative of six which gave similar results. Quantitative data represent mean values ± SEM of six independent experiments; *p b 0.05; **p b 0.01 vs. control.
4 I. Gonçalves Silva et al. / EBioMedicine xxx (2017) xxx–xxx
Please cite this article as: Gonçalves Silva, I., et al., The Tim-3-galectin-9 Secretory Pathway is Involved in the Immune Escape of Human Acute
Myeloid Leukemia Cells, EBioMedicine (2017), http://dx.doi.org/10.1016/j.ebiom.2017.07.018
of both proteins. These ﬁndings were conﬁrmed using imaging ﬂow
cytometry (Supplementary Fig. 1). In non-permeabilized cells we saw
sectors full of either Tim-3 or galectin-9, without substantial co-localiza-
tion. Given that galectin-9 is soluble, it can remain on the cell surface
only if it is bound to its receptor, Tim-3 (Fig. 3). Taken together our
ﬁndings suggest that Tim-3 is either externalized on its own or acts as a
trafﬁcker for galectin-9 (which lacks the signal domain required for
secretion and thus requires a trafﬁcker). Given that PMA, a speciﬁc PKC
activator, signiﬁcantly increases Tim-3 and galectin-9 secretion, it is likely
that PKC is involved in the Tim-3 and galectin-9 co-secretion process.
3.3. Levels of Soluble Tim-3 andGalectin-9 are Highly Increased in the Blood
Plasma of AML Patients: Characterization of the Tim-3-galectin-9 Complex
in Human Blood Plasma
We then sought to conﬁrmourﬁndings in primary samples collected
from AML patients. We analyzed plasma samples from 98 AML patients
versus healthy donors and found that galectin-9 and Tim-3 levels were
strikingly increased in blood plasma of AMLpatients (Fig. 4A, B, E and F).
Five randomly selected plasma samples from the group of studied AML
patients and ﬁve from healthy donors were then subjected to detection
Fig. 2.PMAactivates Tim-3 andgalectin-9production and release aswell as generation of Tim-3-galectin-9 complex. THP-1 cellswere treatedwith 100nMPMA for 16 h.Non-treated THP-
1 cells were used as a control. Cells were then harvested and galectin-9 as well as Tim-3 were analyzed in whole cell extracts by Western blot. Both proteins and Tim-3-galectin-9
complexes were analyzed by ELISA in the medium used to treat the cells. The bar diagram on the top shows the comparative analysis (expressed in % control) of galectin-9 and Tim-3-
galectin-9 complex levels released by non-treated and PMA-treated THP-1 cells. Images are from one experiment representative of three which gave similar results. Quantitative data
are the mean values ± SEM of three independent experiments; *p b 0.05; **p b 0.01; ***p b 0.001 vs. control.
Fig. 3. Co-localization of Tim-3 and galectin-9 in PMA-activated THP-1 cells. Co-localization of Tim-3 and galectin-9 was analyzed in non-permeabilized and permeabilized THP-1 cells
following 24 h of exposure to 100 nM PMA using confocal microscopy (see Materials and Methods for details). Images are from one experiment representative of six which gave
similar results.
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of Tim-3-galectin-9 complex by ELISA as described above. The level of
increase in Tim-3-galectin-9 complex in AML samples was similar to
that of galectin-9 (Fig. 4C and G). We then randomly chose ﬁve plasma
samples from the group of studied AML patients and analyzed Tim-3
and galectin-9 levels by Western blot (Fig. 4D). Prior to loading onto
the SDS-PAGE, samples were sonicated and boiled for 5 min at 95 °C.
We found that sTim-3 and galectin-9 were clearly detectable. We
could also see a clear band (probably representing the soluble form of
the Tim-3-galectin-9 complex) at around 52 kDa (detectable by both
anti-Tim-3 and anti-galectin-9 antibodies). This suggests that the com-
plex released by THP-1 cells (Fig. 1) and the one found in blood plasma
is unlikely to be formed after secretion. If this had been the case, its mo-
lecular weight would have been around 65 kDa (33 kDa for sTim-3 and
32 kDa for galectin-9) rather than 52 kDa. A speciﬁc band was also de-
tectable at around 20 kDa (Fig. 4D). These results are in line with
those obtained for soluble forms of Tim-3, galectin-9 and Tim-3-
galectin-9 complex released by THP-1 cells conﬁrming that sTim-3
and Tim-3 complexed with galectin-9 are likely to be differentially
shed from plasma membranes of AML cells. Interestingly, there is a
clear evidence of a correlation between Tim-3 and galectin-9 levels in
the plasma of both healthy donors and AML patients and these correla-
tion levels were very similar to each other (Fig. 4H and I) suggesting a
co-release of both proteins in both cohorts.
3.4. Tim-3 Binding Alters the Conformation of Galectin-9
In order to assess the biophysical properties of Tim-3, galectin-9 and
the Tim-3-galectin-9 complex we investigated them using synchrotron
radiation circular dichroism (SRCD) spectroscopy at Diamond Light
Source (Beam Line 23, Supplementary Fig. 2). Structural organization
of Tim-3 and galectin-9 as well as their interaction are schematically
presented in the Fig. 5A. Galectin-9 interacts with non-glycosylated
Tim-3 with nanomolar afﬁnity (Kd = 2.8 × 10−8 M); the binding can
be further strengthened by interaction of galectin-9 with glycosylated
Tim-3 (Prokhorov et al., 2015). Indeed, the complex is detectable by
Western blot, which means that interaction between a lectin and
sugar is taking place. SRCD spectroscopy was also performed on
galectin-9 and Tim-3 mixed to a stoichiometry of 1:1 molar ratio (Fig.
5B). Galectin-9 when mixed with Tim-3 showed a CD spectrum signiﬁ-
cantly different from the simulated spectrum indicating that the inter-
action of galectin-9 with Tim-3 causes signiﬁcant conformational
change of the proteins with a clear increase in β-strand component.
Based on the above, one might speculate that Tim-3 binding could
alter the conformation of galectin-9, resulting in increased ability to in-
teract with receptors in target cells. Since galectin-9 is a tandem protein
with two sugar binding domains, one domain could bind Tim-3 (or
other proteins) and leave the other domain open for interaction with
a receptor molecule associated with the plasma membrane of a target
cell (for example membrane associated Tim-3).
3.5. Latrophilin 1, Protein Kinase C andmTOR-Dependent Translation Play a
Crucial Role in Tim-3 and Galectin-9 Production and Secretion
LPHN1mRNAwas found in primary humanCD34-positive stem cells
(Maiga et al., 2016).Wewere able to detect LPHN1 protein in them (at a
slightly highermolecular weight than in THP-1 cells (around 140 kDa)),
while in THP-1 it is detectable at 130 kDa (Supplementary Fig. 3) aswell
as in primary AML cells (Sumbayev et al., 2016). No Tim-3 or galectin-9
protein expression was detectable in primary human CD34-positive
stem cells (Supplementary Fig. 3).
For this experimental set-up we used THP-1 cells and exposed
them to 100 nM PMA or 250 pM α-latrotoxin (LTX, a highly speciﬁc
and potent ligand of LPHN1 (Sumbayev et al., 2016)). We found that
both PMA and LTX downregulated intracellular Tim-3 and galectin-9
levels (though not signiﬁcantly) and signiﬁcantly increased activat-
ing phosphorylation of the mammalian target of rapamycin
(mTOR) at S2448 (Fig. 6A and B). One hour pre-treatment of THP-1
cells with 70 nM Gö6983 (PKCα inhibitor) before exposure to PMA
or LTX led to attenuation of stimulus-induced mTOR activation and
downregulation of intracellular Tim-3 and galectin-9 levels.
Interestingly, in the cells exposed just to Gö6983, phospho-S2448
mTOR and intracellular Tim-3/galectin-9 levels were not different
Fig. 4. Levels of galectin-9 and soluble Tim-3 are highly increased in blood plasma of AML patients. Galectin-9 and Tim-3 were measured by ELISA in blood plasma obtained from healthy
donors and AML patients (A, B, E and F). The levels of Tim-3-galectin-9 complexweremeasured by ELISA in blood plasma of ﬁve randomly picked healthy donors and AML patients (C and
G). Tim-3 and galectin-9were characterized byWestern blot in blood plasma fromﬁve randomly chosen AML patients (D). Correlations between Tim-3 and galectin-9 aswell as between
galectin-9 andTim-3-galectin-9 complexwas then determined (H, I, J and K). Images are fromone experiment representative ofﬁvewhich gave similar results. Quantitativedata represent
mean values ± SEM of three independent experiments; *p b 0.05; **p b 0.01; ***p b 0.001 vs. control.
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from the control. Both PMA and LTX highly upregulated release of
both sTim-3 and galectin-9 from THP-1 cells. Gö6983 completely
attenuated this increase in both cases, but did not change basic levels
of Tim-3 and galectin-9 secretion, which suggests that basic
(background) release of galectin-9 and Tim-3 does not depend on
PKCα (Fig. 6D).
In summary, both PMA and LTX induce production of both Tim-3
and galectin-9 in THP-1 cells. We conﬁrmed that THP-1 cells express
Gαq (Supplementary Fig. 4A) and PMA aswell as LTX induce highly sig-
niﬁcant upregulation of PKCα kinase activity (Supplementary Fig. 4B).
Pre-treatment of THP-1 cells with 10 μM AZD2014 (a highly speciﬁc
mTOR inhibitor) before exposure to PMA or LTX reduced intracellular
Tim-3 and galectin-9 levels as well as release of both proteins (Fig. 6C
and D). This indicates that PMA or LTX-induced translation of both pro-
teins depends on the mTOR pathway. Importantly, the solvents used to
dissolve pharmacological inhibitors had no effect on any of the studied
protein levels or their secretion (data not shown).
These results were validated using primary human AML cells. For
this purpose we exposed primary human AML mononuclear blasts
AML-PB001F for 24 h to LTX followed by detection of secreted
galectin-9 and Tim-3. We found that AML-PB0011F expressed LPHN1
and the secreted levels of both proteins were signiﬁcantly increased in
LTX-treated AML cells (Supplementary Fig. 5) conﬁrming the ﬁndings
obtained in THP-1 cells.
To conﬁrm the physiological role of LPHN1 in galectin-9 release we
exposed THP-1 cells to FLRT3, which is one of physiological ligands of
LPHN1 (Boucard et al., 2014). We found that 10 nM FLRT3 induced sig-
niﬁcant upregulation of galectin-9 and sTim-3 release (Fig. 7A, a scheme
of the experiment is presented in Supplementary Fig. 6A); it also upreg-
ulated PKCα activity in THP-1 cells (Supplementary Fig. 4B). To conﬁrm
Fig. 5. Interaction of Tim-3with galectin-9 leads to major conformational changes increasing solubility of the protein complex. (A) The schematic structural models of Tim-3 extracellular
domain (left) and galectin-9 (right). In the Tim-3 structure, amino acid residues involved in galectin-9-independent binding are highlighted in green. Residues, which are potential targets
for glycosylation, are highlighted in red. In galectin-9, sugarmolecules,which could potentially bind theprotein, located close to the carbohydrate binding sites are shown in green. (B) The
SRCD spectroscopy of Tim-3, galectin-9 and Tim-3-galectin-9 interaction (both simulated and real curves are presented). (For interpretation of the references to color in this ﬁgure legend,
the reader is referred to the web version of this article.)
Fig. 6. LPHN1, PKCα andmTOR pathways are involved in Tim-3 and galectin-9 production and secretion in AML cells. THP-1 cells were exposed to the indicated concentrations of PMA or
LTX for 16 h with or without 1 h pre-treatment with the PKCα inhibitor Gö6983 (A, B, D) or themTOR inhibitor AZD2014 (C, D). Cellular levels of Tim-3 and galectin-9 were analyzed by
Western blot. Released Tim-3 and galectin-9 were detected by ELISA. Images are from one experiment representative of three which gave similar results. Quantitative data are the mean
values ± SEM of three independent experiments; *p b 0.05; **p b 0.01; ***p b 0.001 vs. control. Symbols “a” or “b” are used instead of “*” to indicate differences vs. PMA and LTX-treated
cells, respectively.
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that this effect was physiologically relevant, we exposed THP-1 cells for
16 h to mouse bone marrow (mBM) extracts (10 μg protein/ml, which
contain FLRT3, Fig. 7B, a scheme of the experiment is presented in Sup-
plementary Fig. 6B) obtained as outlined in the Materials and Methods.
Treatments were conducted with or without 1 h pre-treatment with 5
μg/ml FLRT3 neutralizingmouse antibody.We found that mBMextracts
signiﬁcantly upregulated galectin-9 and sTim-3 secretion in THP-1 cells.
FLRT3 neutralizingmouse antibody reduced the effects of mBM extracts
but did not block them (Fig. 7B). This means that BM contains several
activators of galectin-9 secretion in AML cells. Finally, we co-cultured
THP-1 cells with RCC-FG1 renal carcinoma cells (which are highly ad-
herent) in the ratio 1 THP-1:2 RCC-FG1. RCC-FG1 cells express high
levels of FLRT3 and release almost undetectable amounts of galectin-9
(Fig. 7C, a scheme of the experiment is presented in Supplementary
Fig. 6C). Cells were kept together for 16 h in the absence or presence
of 5 μg/ml FLRT3 neutralizing antibody and then galectin-9 and sTim-
3 secretion levels were analyzed. We found that the presence of RCC-
FG1 cells signiﬁcantly increased galectin-9 and sTim-3 release and
FLRT3 neutralization attenuated these effects. The presence of RCC-
FG1 cells signiﬁcantly upregulated PKCα activity, an effect that was
also attenuated by neutralization of the FLRT3 (Supplementary Fig.
4C). These results suggest that FLRT3 stimulates the release of
galectin-9 from AML cells.
3.6. Galectin-9 and sTim-3 Attenuate AML Cell Killing Activity of NK Cells
Recent evidence suggested that galectin-9 (either soluble or cell sur-
face associated) can interact with Tim-3 or possibly other receptors on
Fig. 7. FLRT3, a physiological ligand of LPHN1, induces galectin-9 and Tim-3 secretion. (A) THP-1 cells were exposed for 16 h to 10 nM extracellular domain of human recombinant FLRT3
followedbymeasurement of released Tim-3 and galectin-9 by ELISA. (B) THP-1 cellswere exposed tomouse bonemarrow (mBM) extracts for 16 hwith orwithout 1 h pre-treatmentwith
5 μg/ml anti-FLRT3 antibody. The presence of FLRT3 in mBM extracts was conﬁrmed by Western blot analysis. Secreted Tim-3 and galectin-9 were measured by ELISA. (C, left) RCC-FG1
cells express FLRT3 as conﬁrmed byWestern blotting. (C, right) RCC-FG1 cells were co-culturedwith THP-1 cells at a ratio of 1 THP-1:2 RCC-FG1with orwithout 1 h pre-treatmentwith 5
μg/ml FLRT3 neutralizing antibody. Secreted galectin-9 and Tim-3 were measured by ELISA. Images are from one experiment representative of three which gave similar results.
Quantitative data depict mean values ± SEM of three independent experiments; *p b 0.05; **p b 0.01; ***p b 0.001 vs. control. Symbols “a” or “b” are used instead of “*” to indicate
differences vs. cells treated with mBM extracts or co-cultured with RCC-FG1 cells, respectively.
Fig. 8. LAD2 cells express and externalize Tim-3 and galectin-9. Left panel: surface-based and total Tim-3 and galectin-9 were measured in LAD2 humanmast cell sarcoma cells using LI-
COR in cell assay (ICA, non-permeabilized cells) and in cell Western (ICW, permeabilized cells). Right panel: protein levels of Tim-3 and galectin-9 were measured in resting and IgE-
sensitized LAD2 cells by Western blot. Galectin-9 release was characterized using ELISA. Images are from one experiment representative of three which gave similar results.
Quantitative data show mean values ± SEM of three independent experiments; ***p b 0.001 vs. control.
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cytotoxic lymphoid cells including NK cells and cytotoxic T cells
(Gleason et al., 2012). Itmay be proposed that Tim-3-galectin-9 interac-
tion is involved in the creation of immunological synapses between tar-
get cells and cytotoxic lymphoid cells. To investigate this we used LAD2
humanmast cell sarcoma cells kindly provided by Prof. Metcalfe andDr.
Kirshenbaum (NAID, NIH, USA; Kirshenbaum et al., 2003). These cells
express both Tim-3 and galectin-9 with both proteins located mostly
on the cell surface (Fig. 8) and not rapidly shed. This can thus be used
to visualize the formation of immunological synapses between the
two cell types. They also express high afﬁnity IgE receptors (FcɛRI)
which are not expressed by NK cells and thus can be used to distinguish
between the two cell types.
Resting LAD2 cells do not release detectable amounts of galectin-9
and sensitization with IgE (which was used in order to label the cells
for visualization) does not augment galectin-9 secretion considerably
(Fig. 8). We therefore immobilized primary human NK cells isolated
frombuffy coats of human blood on ELISA plates as outlined inMaterials
and Methods. NK cells express Tim-3 (several glycosylation variants,
Supplementary Fig. 7) but do not produce detectable amounts of
galectin-9 protein. We applied IgE-sensitized LAD2 cells (Sumbayev et
al., 2012) to the NK cells at a ratio of 1:1 with or without 15 min pre-in-
cubationwith galectin-9 neutralizing antibody. Isotype control antibody
was also used instead of galectin-9 antibody to rule out the IgG effect.
LAD2 cells were then ﬂagged using mouse IgM anti-IgE followed by vi-
sualization using anti-mouse LI-COR secondary antibody (which recog-
nizes IgM, seeMaterials andMethods for further details).We found that
LAD2 cells were binding to NK cells and the presence of galectin-9 neu-
tralizing antibody (but not isotype control antibody) abrogated this ef-
fect (Fig. 9, a scheme of the experiment is presented in Supplementary
Fig. 8). These results conﬁrm that galectin-9 produced by LAD2 cells
participates in their interactions with NK cells. Furthermore, abrogation
of the effect by anti-galectin-9 antibodies may indicate that the Tim-3-
galectin-9 interaction is the only pathway through which these cells
could interact. This is most likely a result of IgE sensitization of LAD2
cells which highly increases the presence of galectin-9 on their surface.
We then used K562 chronic myeloid leukemia cells which do not re-
lease detectable amounts of galectin-9 (as conﬁrmed by ELISA). K562
cells were exposed to PMA for 24 h in 96well Maxisorp plates. Medium
was replaced with PMA-free RPMI-1640 medium containing isolated
primary humanNK cells at a ratio of 1 K562:2 NK in the absence or pres-
ence of 5 ng/ml human recombinant galectin-9. Cells were co-incubated
for 16 h and their viability was then assessed using an MTS test. We
found that the presence of NK cells signiﬁcantly reduced the viability
of K562 cells however, the presence of galectin-9 attenuated K562 kill-
ing effect (Fig. 10A). Viability of NK cells was not affected in any of the
cases (Fig. 10A). Interestingly, the cytotoxic attack by NK cells also led
to a dramatic change in the behavior of K562 cells, causing theirmassive
aggregation. Usingphase contrastmicroscopy,we determined the effect
of galectin-9 on cell aggregation in individual or combined K562 andNK
cell cultures. In the absence of galectin-9, there was clear evidence of
K562 cells aggregating in the presence of NK cells (Fig. 10B). Galectin-
9, in a dose-dependent manner, decreased the aggregation of K562
cells by NK cells, such that no K562 cell aggregation was detectable in
the presence of 5 ng/ml galectin-9 (Fig. 10C). Galectin-9 itself had no
visible effect on either of the two cell types alone. Thus, galectin-9 clear-
ly protects myeloid leukemia cells from being killed by NK cells.
We then investigated the interactions between AML THP-1 cells and
primary human NK cells. THP-1 cells were exposed to 100 nM PMA for
16 h. The medium was then replaced with PMA-free medium contain-
ing NK cells at a ratio of 2 NK cells:1 THP-1 cells and left for 6 h in the
absence or presence of 5 μg/ml galectin-9-neutralizing antibody. Tim-
3 and galectin-9 were then measured in the NK cells by Western blot
analysis, and viability of THP-1 cells, activities of granzyme B, caspase-
3 and galectin-9 release were monitored. We found that THP-1 cell via-
bility was reduced when galectin-9 was neutralized (Fig. 11). This was
in line with increased caspase-3 activity and granzyme B activities.
Galectin-9 releasewas not affected (Fig. 11, galectin-9 bound to neutral-
izing antibody is detectable in our system). We conﬁrmed that resting
NK cells did not produce detectable amounts of galectin-9. However,
this protein on its own, and in the form of unbroken Tim-3-galectin-9
complex, was detectable in NK cells co-cultured with THP-1 cells and
was reduced in the presence of galectin-9 neutralizing antibody. This
suggests that THP-1 cells were the source of galectin-9, which was
most likely bound to Tim-3 on the surface of NK cells, preventing the de-
livery of NK cell-derived granzyme B into THP-1 cells and inhibiting the
caspase-3-dependent apoptotic pathway.
Recently, a possible reciprocal link between levels of sTim-3 and IL-
2, a cytokine, which activates cytotoxic activity of NK cells and T cells,
was reported (Geng et al., 2006). We also found that in the plasma of
healthy donors the levels of sTim-3 were signiﬁcantly lower compared
to AML patients (Fig. 4) whereas the levels of IL-2 were signiﬁcantly
higher (Fig. 12A and B). To investigate a possible direct inﬂuence of
sTim-3, we exposed Jurkat T cells (resting Jurkat T cells produce detect-
able amounts of IL-2) to increasing concentrations of Tim-3 for 24 h.We
found a striking sTim-3 concentration-dependent and signiﬁcant reduc-
tion of IL-2 release from Jurkat T cells. This indicates that sTim-3 is capa-
ble of binding a target protein (or a group of target proteins) and
reducing IL-2 production thus preventing induction of NK cell and T
lymphocyte anti-cancer activities.
Taken together, our results demonstrate a pathobiochemical path-
way in AML cells. It is associated with activation of PKCα by LPHN1
(or any other receptors with similar activity) leading to the expression
and exocytosis of sTim-3 and galectin-9, which prevent the activation
of cytotoxic lymphocytes and impair their malignant cell killing activity.
4. Discussion
AML is a malignancy affecting bone marrow and blood and is a se-
vere, and often fatal, systemic disease. AML cells escape host immune
attack involving NK and cytotoxic T cells by impairing their activity
(Golden-Mason et al., 2013; Kikushige et al., 2015; Gonçalves Silva et
al., 2016). However, the biochemical mechanisms underlying the im-
mune escape of malignant white blood cells remain unclear. Recently,
it was shown that AML cells express high levels of the immune receptor
Tim-3 and release galectin-9 which impairs the activity of NK cells and
cytotoxic T cells (Gonçalves Silva et al., 2016). We have also suggested
that Tim-3, as a membrane associated glycoprotein, might act as a traf-
ﬁcker for galectin-9 (Gonçalves Silva et al., 2016). As for all galectins,
Fig. 9.Galectin-9participates in the formation of an “immunological synapse” betweenNK
cells and LAD2cells. Primary humanNK cellswere immobilized on the surface ofMaxisorp
plates. Cells were then co-incubated for 30 min with LAD2 cells with or without 30 min
pre-treatment of LAD2 cells with 5 μg/ml galectin-9 neutralizing antibody (or the same
amount of isotype control antibody). LAD2 cells were then visualized using LI-COR assay
as outlined in Materials and Methods. Images are from one experiment representative of
ﬁve which gave similar results. Quantitative data represent mean values ± SEM of ﬁve
independent experiments; *p b 0.05; **p b 0.01.
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galectin-9 is synthesized on free ribosomes and since it lacks the signal
domain required for secretion it thus needs a trafﬁcker in order to be re-
leased (Delacour et al., 2009). When on the cell surface, Tim-3 is known
to be shed by ADAM 10/17 proteolytic enzymes thus producing sTim-3,
the function of which remains unknown (Moller-Hackbarth et al.,
2013). We found, that Tim-3 could be shed in its free form as well as
in complex with galectin-9; however, differential shedding is taking
place. The Tim-3 fragment in the complex is about 20 kDa molecular
weight, while sTim-3 is around 33 kDa. SRCD analysis of the complex
suggests that the interaction between Tim-3 and galectin-9 proteins
leads to major conformational change, possibly increasing the ability
of galectin-9 to interact with the target proteins. Since galectin-9 is a
tandem protein containing two domains (Delacour et al., 2009), one of
them might be interacting with Tim-3, while the other one could bind
to a target receptor molecule, for example another molecule of Tim-3
associated with the plasma membrane of the target cell (Nagae et al.,
2006). This may explain the high efﬁciency of galectin-9 in triggering
Tim-3 onNK cells, which do not express galectin-9 and thus contain un-
occupied Tim-3 on their surface.
Since we can observe the Tim-3-galectin-9 complex on Western
blots following denaturing SDS-gel electrophoresis (Figs. 1, 2 and 4;
~52 kDa soluble form and ~70 kDa cell-derived form), it is likely that
Fig. 10.Galectin-9 protectsmyeloid leukemia K562 cells frombeing killed by primary humanNK cells. (A) K562 cellswere co-cultured for 16 hwith primary humanNK cells (at a ratio of 1
K562:2 NK) in the absence or presence of 5 ng/ml galectin-9. Viability of K562 and NK cells was thenmeasured using anMTS test. Images are from one experiment representative of three
which gave similar results. Quantitative data represent mean values ± SEM of three independent experiments; ***p b 0.001 vs. control. (B) K562 cells were co-cultured for 16 h with
primary human NK cells (at a K562:NK ratio of 1:2) in the presence of different concentrations of galectin-9 (0–5 ng/ml). Cells were imaged using phase-contrast microscopy. The
images are from one representative experiment of six (n= 6), which gave similar results. Scale bar (the same for all images), 50 μm. (C) The NK cell-induced aggregation of K562 cells
was quantiﬁed as a function of galectin-9 concentration. Left panel: percent of cells found in aggregates in individual cultures and in co-culture. Right panel: the size of cell aggregates
in individual cultures and in co-culture. The data represent the mean values ± SD of six independent experiments; *, p b 0.05; **, p b 0.01; ****, p b 0.0001.
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the binding between proteins is further strengthened by the interaction
of galectin-9 with Tim-3-associated glycosides. Interestingly, the com-
plex is detectable by Western blot with both anti-Tim-3 and anti-
galectin-9 antibodies. However, when these antibodies are sequentially
applied to the same blot, the second antibody fails to detect the respec-
tive protein in the same band (unless the ﬁrst antibody is stripped off),
due to steric hindrance. This effect explains why Tim-3 located on the
cell surface and covered by galectin-9 cannot be co-stained by the anti-
body in confocal microscopy co-localization analysis (Fig. 3). Another
point supporting this conclusion is that there was also clear evidence
of co-localization of Tim-3 and galectin-9 in permiabilized THP-1 cells
upon exposure to PMA (Fig. 3, Supplementary Fig. 1).
Previously it was reported that the release of both Tim-3 and
galectin-9 depends on PKCα and proteolysis (Chabot et al., 2002). Our
Fig. 11. Cell-derived galectin-9 attenuates AML cell killing activity of primary human NK cells. THP-1 cells were co-incubated with primary human NK cells (ratio – 1 THP-1:2 NK) for 6 h
followed by detection of THP-1 cell viability by the MTS test, measurement of activities of granzyme B and caspase 3 in THP-1 cell lysates and released galectin-9 (left panel). Galectin-9
levels from NK cells were determined by Western blot (right panel). Images are from one experiment representative of three which gave similar results. Quantitative data show mean
values ± SEM of three independent experiments; *p b 0.05; **p b 0.01; ***p b 0.001 vs control.
Fig. 12. Soluble Tim-3 attenuates IL-2 release. (A and B) IL-2 levels were measured by ELISA in blood serum of healthy donors and AML patients. (C) Jurkat T cells were exposed to the
increasing concentrations of Tim-3 for 24 h followed by detection of secreted IL-2 by ELISA. Data show mean values ± SEM of three independent experiments; *p b 0.05; **p b 0.01.
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results conﬁrmed these ﬁndings. PMA treatments induced PKCα activa-
tion, which activated exocytosis of Tim-3 and galectin-9 as well as their
mTOR-dependent production in THP-1 AML cells (Fig. 6).
Interestingly, natural and exogenous ligands of LPHN1, a G-protein
coupled neuronal receptor expressed also in CD34-positive human
stem cells (Supplementary Fig. 3) and AML cells but not healthy white
blood cells, activated the PKCα pathway. They also induced both
mTOR-dependent translation of Tim-3 and galectin-9 as well as their
exocytosis. The effect was observed in THP-1 and primary human AML
blasts. PKCα is known to provoke agglomeration of SNARE complex re-
sponsible for exocytosis (Stockli et al., 2011; Morgan et al., 2005). Since
FLRT3, one of natural ligands of LPHN1, is present in bone marrow (Fig.
7) it might explain how LPHN1 causes PKCα activation. Interestingly,
constitutively active PKCα in malignant primary AML cells correlates
with a very poor prognosis and high mortality rate of patients
(Kurinna et al., 2006). This suggests that AML cells constantly release
high levels of Tim-3 and galectin-9. Bone marrow also expresses other
PKCα-activating proteins. When we exposed THP-1 cells to mouse
bone marrow extracts, galectin-9 release was signiﬁcantly higher
compared to resting THP-1 cells. FLRT3 neutralizing antibody signiﬁ-
cantly reduced but did not abolish FLRT3 induced PKCα-dependent
galectin-9 release. This suggests that galectin-9 and Tim-3 are synthe-
sized and exocytozed by AML cells in a PKCα and mTOR-dependent
manner, using available plasma membrane-associated PKCα activating
receptors (for example LPHN1) to induce the whole pathway.
Galectin-9 prevents thedelivery of granzymeB into AML cells (this is
a perforin and mannose-6-phosphate receptor-dependent process
(Supplementary Fig. 9)). Inside AML cells granzyme B performs cleav-
age of the protein Bid into tBid, thus inducing mitochondrial dysfunc-
tion and cytochrome C release followed by caspase 3 activation.
Proteolytic activation of caspase 3, in addition to the classic pathway,
might also be directly catalyzed by granzyme B (Lee et al., 2014). Our re-
sults with galectin-9 conﬁrmed this concept (Fig. 11). Recently it was
reported that galectin-9 induces interferon-gamma (IFN-γ) release
from NK cells (Gleason et al., 2012). IFN-γ interacts with AML cells in-
ducing the activity of indoleamine 2,3-dioxygenase (IDO1), an enzyme
which converts L-tryptophan into formyl-L-kynurenine, which is then
converted into L-kynurenine and released (Corm et al., 2009; Folgiero
Fig. 13.AML cell-based pathobiochemical pathway showing LPHN1-induced classic activation of PKCα, which triggers translation of Tim-3 and galectin-9 aswell as their secretionwhich is
required for immune escape. The interaction of FLRT3 located on the surface of endothelial cells (EC)with LPHN1 leads to the activation of PKCα through the classic Gq/PLC/Ca2+ pathway.
Ligand-bound LPHN1 activates Gq, which in then stimulates PLC. This leads to phosphatidyl-inositol-bisphosphate (PIP2) degradation and production of inositol-trisphospate (IP3) and
diacylglycerol (DAG). IP3 interacts with ER-associated IP3 receptor (IP3R) leading to Ca2+ mobilization. PKCα is activated by DAG and Ca2+ activates mTOR translational pathway
through downregulation of TSC1/TSC2. mTOR controls translation of Tim-3 and galectin-9. PKCα also phosphorylates Munc18 exocytosis regulator protein which provokes formation
of SNARE complexes that tether vesicles to the plasma membrane. This pre-activates the release machinery, and elevated cytosolic Ca2+ lead to exocytosis of free and galectin-9-
complexed Tim-3. Both types of Tim-3 are differentially shed from the cell surface by proteolytic enzymes. Soluble Tim-3 prevents IL-2 secretion required for activation of NK cells and
cytotoxic T cells. Galectin-9 impairs AML cell killing activity of NK cells (and other cytotoxic lymphocytes).
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et al., 2015; Mabuchi et al., 2016). L-kynurenine affects the ability of NK
cells to kill AML cells, an effect which was seen in our experiments and
presented in Supplementary Fig. 9. Soluble Tim-3 was shown to
signiﬁcantly downregulate production of IL-2, a cytokine required for
activation of NK cells and cytotoxic T lymphocytes.
Taken together, our results show that human AML cells possess a se-
cretory pathway which leads to the production and release of sTim-3
and galectin-9. Both proteins prevent the activation of NK cells and im-
pair their AML cell-killing activity. This pathway, which involves the
LPHN1-dependent activation of Tim-3 and galectin-9 production is
summarized in Fig. 13. The described pathway presents both bio-
markers for AML diagnostics and potential targets (both sTim-3 and
galectin-9) for AML immune therapy and thus can be considered as a
fundamental discovery.
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 Supplementary figure 1. Co-localization of galectin-9 and Tim-3 in THP-1 human AML 
cells upon PKC activation. THP-1 cells stimulated with PMA (please see Figure 3 for 
details) were permiabilized and subjected to imaging flow cytometry as outlined in Materials 
and Methods. Images represent six selected single cells.  
 
  
Supplementary figure 2. Beam line 23 at Diamond Light Source synchrotron and 
scheme of SRCD spectroscopy analysis.  
 
  
Supplementary figure 3. Characterisation of expression of LPHN1, Tim-3 and galectin-
9 proteins in CD34 positive human stem cells (HSCs) and THP-1 AML cells (positive 
control). LPHN1, Tim-3 and galectin-9 proteins were detected in CD34-positive HSCs and 
THP-1 cells (positive control) using Western blot analysis. Images are from one experiment 
representative of three which gave similar results.  
 
  
Supplementary figure 4. Expression of Gαq and activity of PKCα in THP-1 human 
AML cells. (A) Gαq expression was analysed by Western blot analysis in resting THP-1 
cells. (B) Activity of PKCα was analysed in resting THP-1 cells as well as those exposed for 
16 h to 100 nM PMA, 250 pM LTX and 10 nM FLRT-3. (C) Activity of PKCα was analysed 
in resting THP-1 cells and those co-cultured with RCC-FG1 cells (ratio 1 THP-1: 2 RCC-
FG1) in the absence or presence of 5 µg/ml FLRT-3 neutralising antibody. Images are from 
one experiment representative of three which gave similar results. Quantitative data are mean 
values ± SEM of three independent experiments; *p < 0.05; **p < 0.01 vs. control. Symbol 
“bb” indicates p<0.01 vs. THP-1/RCC-FG1 co-culture. 
  
Supplementary figure 5. LTX induces on Tim-3 and galectin-9 secretion in primary 
human AML cells. Primary human AML blasts (AML-PB001F) were exposed for 24 h to 
250 pM LTX followed by detection of secreted galectin-9 and Tim-3 levels by ELISA (A) as 
outlined in Materials and Methods. LPHN1 expression in these cells was confirmed by the 
Western blot analysis (B). Images are from one experiment representative of six which gave 
similar results. Quantitative data are mean values ± SEM of six independent experiments; **p 






 Supplementary figure 6. Schemes of the experiments presented in the Figure 7. Sections 




Supplementary figure 7. Expression of Tim-3 and galectin-9 in primary human NK 
cells. Expressions of both proteins were analysed in whole cell extracts by Western blot. 
Human recombinant galectin-9 was used as a positive control. Images are from one 
experiment representative (two donors in each) of three which gave similar results.  
 
  





Supplementary figure 9. Possible biochemical interactions between AML and NK cells. 
LPHN1/Tim-3/galectin-9 pathway (Figure 14) leads to externalisation/release of galectin-9, 
which binds to the NK cell receptor (likely – Tim-3). In response, NK cells release IFN-γ 
which triggers the activation of IDO1 in AML cells. IDO1 converts tryptophan (Trp) into 
formyl-kynurenine (FKU), which is further degraded into L-kynurenine (KU). KU is released 
and is capable of attenuating the ability of NK cells to deliver granzyme B into SAML cells 
in perforin/mannose-6-phosphate receptor (MPR)-dependent manner. If successfully 
delivered, granzyme B catalysed Bid cleavage leading to cytochrome c release from 
mitochondria. This leads to formation of apoptosome and activation of caspase-3. 
Furthermore, granzyme B is capable of performing direct proteolytic activation of caspase-3. 
These effects lead to AML cell apoptosis. However, this process is not taking place due to 
galectin-9-induced impairing of NK cell activity as described above.  
